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IMBALANCE BETWEEN NEUTROPHIL ELASTASE AND ELAFIN PROMOTES
BREAST CANCER GROWTH AND PROGRESSION
Joseph Anthony Caruso, B.S.
Supervisory Professor: Dr. Khandan Keyomarsi, Ph.D.
Abstract: Elafin, an endogenous serine protease inhibitor, is a critical component of
the epithelial barrier against neutrophil elastase (NE) activity. The central hypothesis
examined in this dissertation was that elafin has tumor suppressive properties in breast
cancer. In support of this hypothesis, immunohistochemical (IHC) analysis revealed that
elafin was downregulated in the majority of invasive breast tumors and a subset of preinvasive ductal carcinoma in situ (DCIS) compared to elafin expression in the normal
mammary epithelium. To understand the role of elafin in the mammary epithelium and
the impetus for its downregulation during breast tumorigenesis, primary and
immortalized human mammary epithelial cells (HMECs) were utilized as a model
system. Elafin was highly expressed in G0-arrested HMECs, suggesting a previously
unrecognized role for elafin in growth control. Stable knockdown (KD) of elafin
compromised the ability of HMECs to maintain G0-arrest during long-term growth factor
deprivation. This effect was reversed by re-expression of wild-type elafin but not elafinM25G lacking protease inhibitory function, suggesting a role for deregulated protease
activity. Elafin KD HMECs demonstrated enhanced sensitivity to NE-induced
proliferation. Mechanistically, activation of the ERK signaling pathway downstream of
toll-like receptor 4 (TLR4) was essential to the mitogenic effect of NE in this system.
Compared to HMECs, the majority of breast cancer cell lines lack endogenous elafin
expression. Adenoviral-mediated expression of elafin was utilized to evaluate the tumor
suppressive properties of elafin in breast cancer cell lines. Rb-status was identified as
the critical factor governing the anti-tumor effect of elafin in this system. In breast
cancer cell lines expressing functional Rb, the expression of elafin triggered Rbdependent cell cycle arrest. However, in breast cancer cell lines lacking functional Rb,
elafin expression induced caspase-3 dependent apoptotic cell death. Elafin is a critical
counterbalance against NE-activity. IHC analysis revealed that high levels of NEexpressing tumor-associated neutrophils (TAN) were associated with reduced
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recurrence-free survival, high tumor grade, and triple-receptor negative breast cancer
(TNBC).

ERK-catalyzed

phosphorylation

of

p90RSK

(T359/S363)

and

Rb

phosphorylation (S807/811) were significantly enriched in NE-positive breast tumors,
suggesting that NE-induced ERK signaling and proliferation may be relevant to human
breast cancer. The in vivo role of deregulated NE in breast tumorigenesis was
examined in the C3(1)TAg mouse model of TNBC. Knockout of NE in C3(1)TAg mice
significantly reduced tumor growth and proliferation. Elafin has tumor suppressive
properties in the context of breast cancer and is a critical counterbalance against the
growth promoting effect of NE in vitro and in vivo. Deregulated NE-activity is a viable
therapeutic target in breast cancer.
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Chapter 1: Introduction

Cancer is fundamentally a genetic disease. The accumulation of genetic and
epigenetic alterations drives unrestrained proliferation and the invasive capacity of
tumor cells (1). However, genomic derangement alone is insufficient for unabated tumor
growth and progression. Post-mortem histological examination of adult tissues reveals a
high frequency of occult tumors, held in stasis by a non-permissive microenvironment
(2). Experimental evidence suggests that the ability of tumor cells to recruit and
manipulate non-malignant cell types, including fibroblasts, endothelial cells, and
leukocytes, governs their malignant growth potential (3-6). The interdependency of
tumor cells and the surrounding stromal microenvironment in which they evolve (7)
provides a strong rationale for the therapeutic targeting of essential crosstalk. The
cellular constituents of the tumor microenvironment are not susceptible to the selective
pressures driving resistance in tumor cells; therefore therapeutic modalities targeting
microenvironmental factors may yield durable anti-tumor responses.
Extracellular proteases are powerful modifiers of stromal-epithelial crosstalk.
Deregulated protease activity is implicated in the etiology (8) and progression of cancer
(9). Consequently, endogenous protease inhibitors are critical to the maintenance of
tissue homeostasis, while imbalance in protease-inhibitor stoichiometry is a significant
component of protease deregulation during tumor progression (9, 10). Neutrophil
elastase (NE) is a potent serine protease implicated in the pathogenesis of a wide
variety of inflammatory diseases (11). High levels of NE, largely contributed by activated
neutrophils in the tumor microenvironment, are prognostic of poor survival in human
cancer (12). Elafin is a serine protease inhibitor produced by epithelial cells as a
counterbalance against the deleterious effects of excessive NE activity (13).
Permutations in elafin expression affect the integrity of the anti-protease shield and
dramatically alter the pathogenesis of inflammatory disease (14-20). Elafin is
downregulated in squamous cell carcinomas of the skin, head/neck, and esophagus
(21, 22) as well as tumor-derived cell lines (23-27), suggesting that elafin loss is a
feature of malignant progression.
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The central hypothesis examined in this dissertation was that elafin has tumor
suppressive properties in breast cancer. Based on the canonical function of elafin as an
endogenous NE inhibitor, this hypothesis implicitly questions the tumor-promoting
activity of deregulated NE in breast tumorigenesis. Chapter One is a review of three
major topics relating to the research described in this dissertation: (1) the biology of the
normal mammary gland, breast tumorigenesis, and the clinical management of breast
cancer, (2) the physiological role of NE and the consequences of deregulated NE
activity, and (3) the control of NE activity by elafin. In Chapter Two, the expression of
elafin during breast cancer progression, the normal regulation of elafin in human
mammary epithelial cells (HMECs), and the consequences of disequilibrium between
elafin and NE were examined. In Chapter Three, the tumor suppressive properties of
elafin following expression in breast cancer cell lines were investigated. In Chapter
Four, NE expression in human breast tumors and the role of NE in a mouse model of
breast cancer were explored. Chapter Five discusses the findings reported within this
dissertation, the potential clinical application of the results presented, and the future
directions for this research.
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BREAST CANCER
Epidemiology of Breast Cancer
Breast cancer is the most frequently diagnosed malignancy and a leading cause
of cancer mortality in women worldwide, accounting for 23-percent of female cancer
diagnoses (1,380,000 cases; 2008) and 14-percent of female cancer fatalities (458,000
breast cancer deaths; 2008). Breast cancer disproportionately affects women in
economically developed, westernized nations. The incidence of breast cancer is two- to
three-fold higher in the developed countries of Western Europe and North America
compared to the developing countries of Asia, South America, and Africa (28). Greater
access to advanced mammographic screening technology exaggerates breast cancer
incidence in developed nations and has contributed to the overall increase in breast
cancer incidence observed since the late 1970s (29). However, the statistical anomaly
created by breast cancer screening cannot completely rationalize the distribution and
trends in breast cancer incidence over the last several decades. Lifestyle and
environmental factors remain significantly associated with the increased incidence of
breast cancer and observed geographical disparities. The increasing incidence of
breast cancer within the population presents significant clinical, social, and economic
challenges.
Despite rising incidence, breast cancer mortality has decreased in the United
States and several other developed countries since the early 1990s. In 1991, the agestandardized breast cancer mortality rate in the United States was 32.7/100,000 per
year; fifteen years later it had decreased to 23.4/100,000 per year (30). The overall fiveyear relative survival rate of women diagnosed with breast cancer between 2001 and
2007 was 90.0-percent, up from 75.1-percent for women diagnosed between 1975 and
1977 (31). Breast cancer survivorship has benefited from early detection by widespread
mammographic

screening,

optimization

of

chemotherapeutic

regimens,

the

standardized assessment of prognostic/predictive markers, and the introduction of
targeted therapeutics. However, progress against breast cancer is unevenly distributed
within

the

population.

The

age-standardized

mortality

of

Caucasian

women

(28.3/100,000 per year) is significantly less than that of African American women
(36.4/100,000 per year). Socioeconomic factors, access to screening, treatment
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disparities, and fundamental genetic differences influence the unbalanced burden of
breast cancer mortality (31, 32).
In the United States, one in eight women will be diagnosed and treated for
breast cancer within her lifetime. Despite declining mortality rates over the last several
decades (31), breast cancer remains a significant public health problem especially in
economically developed countries.
Hereditary Susceptibility to Breast Cancer
Those affected by breast cancer or troubled by its prevalence are typically
concerned with causality. However, no single factor can account for an individual’s risk
of developing breast cancer. Epidemiological evidence convincingly demonstrates that
all common cancer types have a familial component (33, 34). Compared to the general
population, the incidence of breast cancer is between two- and three-fold higher in the
first-degree relatives of the cancer stricken (35). The aggregation of breast cancer
within families is largely attributable to heritable factors (36, 37). In women diagnosed
with breast cancer and treated by mastectomy, the rate of breast cancer incidence in
the contralateral breast is two- to three-fold higher than the general population,
suggesting that the majority of breast cancer occurs within genetically predisposed
women. This association is seen regardless of the stage of the original tumor indicating
that incidence of contralateral breast cancer was not a recurrence of the original tumor
(38, 39). The study of cancer incidence in twins provides the most compelling evidence
of a role for genetic factors in breast cancer susceptibility. In the monozygotic twins of
women diagnosed with breast cancer, the incidence of breast cancer is three- to fourfold higher than in dizygotic twins or first-degree female relatives and six- to ten-fold
higher than breast cancer incidence within the general population (35, 37).
Mutations in the highly penetrant breast cancer susceptibility genes, BRCA1 and
BRCA2 (Table 1), are emblematic of hereditary breast cancer. Sub-populations with
high frequencies of BRCA1 and BRCA2 mutations have been described, including
Ashkenazi Jewish (40) and Bahamian (41) women. Women of African and Hispanic
ancestry also have slightly higher frequencies of mutant BRCA1- and BRCA2-related
breast cancers compared to woman of European or Asian descent (42, 43). In addition
to BRCA1 and BRCA2 mutations, highly penetrate mutations in TP53 (Li-Fraumeni
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syndrome), PTEN (Cowden syndrome), and STK11/LKB1 (Peutz-Jegher syndrome) are
association with high breast cancer incidence (Table 1) (44-48). Together BRCA1,
BRCA2, TP53, PTEN, and STK11/LKB1 mutations account for less than 25% of
hereditary susceptibility to breast cancer (35, 49-51).
The majority of hereditary breast cancer susceptibility is believed to be
polygenic, such that the genetic component of breast cancer risk is dependent on the
combinatorial effect of several moderate and low penetrance gene variants. These
alleles are not necessarily rare within the population, as is the case with mutations in
BRCA1, BRCA2, TP53, PTEN, and STK11/LKB1 (49-51). The contribution of individual
loci to cancer susceptibility is typically small, generally less than 1.3-fold, however the
combinatorial effect can be significant.
Low penetrance polymorphisms at breast cancer susceptibility loci cannot be
resolved by traditional genetic linkage studies, which relies on the mendelian
inheritance of a rare disease-causing allele (52). Testing the association of
polymorphisms in large cohorts of breast cancer patients versus controls is a powerful
methodology to detect disease susceptibility loci. Pioneering association studies were
limited by existing technology to the examination of candidate genes implicated in the
etiology of breast cancer (53).
The sequencing of the human genome has cataloged over 10 million single
nucleotide polymorphisms (SNPs) with allele frequencies greater than one-percent (5456). The mapping of haplotypes, sets of SNPs that are statistically associated due to
inheritances as a discrete unit (linkage disequilibrium blocks), allows the selection of a
subset of genetic markers that define the majority of human genetic variability (56).
These advances have facilitated the development of high throughput technologies
capable of simultaneously assessing a great deal of common genetic diversity.
Utilization of these technologies in association studies, referred to as genome-wide
association studies (GWAS), has dramatically enhanced the capacity to detect disease
susceptibility loci within the population. Large-scale genotyping remains an expensive
and logistically challenging undertaking. GWAS generally employs a tiered design,
beginning with a discovery phase that utilizes a relatively small cohort of cases and
controls to identify potential susceptibility loci and followed by a validation phase
utilizing much larger cohorts of case and controls (52).
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High penetrance mutations in BRCA1 and BRCA2 account for a relatively small
percentage of hereditary breast cancer susceptibility. GWAS studies have identified a
significant number of low and moderate penetrance breast cancer susceptibility loci
(Table 1). Individually these loci are associated with very modest increases in breast
cancer susceptibility, however in combination their effect is pronounced. The majority of
loci contributing to breast cancer susceptibility are located in intergenic and intronic
chromosomal regions. The relevance of these regions is often unknown and functional
significance is generally ascribed to the proximal gene based on the assumption that
the majority of these loci fall within cis-regulatory elements (57).
Breast cancer is an extremely heterogeneous disease. Hereditary factors can
influence susceptibility to particular biological subtypes of breast cancer. Women of
African descent demonstrate increased susceptibility to aggressive, triple-receptor
negative breast cancer (TNBC; estrogen receptor [ER] negative, progesterone receptor
[PR] negative, and human epidermal growth factor receptor 2 [HER2] negative),
suggesting the enrichment of TNBC susceptibility loci in this population (32, 58-60).
BRCA1 and BRCA2 mutations are associated with the development of TNBC (61, 62).
Knockout of Brca1 and Trp53 in the mouse mammary gland generates tumors with
features of TNBC (63-65). Polymorphisms at the TERT-CLPTM1L (58), 19p13 (59),
16q12 (66), 5q11 (66), 11p15 (66), and 2q35 (66) loci are associated with the
development of TNBC and some of these loci have been associated with women of
African descent. ER-positive breast cancer susceptibility loci have also been identified
in FGFR2 (67), TNRC9 (67), 8q24 (67), 2q35 (68), 16q12 (68) 9q31.2 (69), 5p12 (70),
10q26 (66), 3q24 (66), and 17q25 (66). The association of susceptibility loci with rare
breast cancer subtypes is more difficult to ascertain due to the inability to generate
adequately powered cohorts (66). Sufficient evidence exists that an individual’s
genotype plays a role in the genesis of specific breast cancer subtypes. Studies in
larger cohorts are likely to identify more subtle associations between genetic variability
and the genesis of breast cancer susceptibility.
Although cancer is a disease of somatically acquired genetic and epigenetic
alterations, the underlying genotype of the individual also influences tumor biology. A
recent study, utilized quantitative trait locus (eQTL: loci that regulate gene expression)
based analysis to evaluate the contribution of germline eQTLs to tumor gene
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expression. Using the cancer genome atlas (TCGA) database, cis-acting eQTLs were
found to be responsible for 1.2% of the absolute variance in gene expression within
breast tumors. Taking into account the effect of somatic genetic and epigenetic factors
within tumors, the authors examined the effect of fifteen known breast cancer
susceptibility loci, hypothesized to exist within cis-acting elements, on gene expression.
Polymorphisms at 9q31, 8p24, and 9q31.2 were significantly associated with the
expression level of ESR1, MYC, and KLF4 respectively (57). This study is notable in its
ability to connect polymorphic loci with a functionally relevant change in gene
expression.
The majority of breast cancer incidence likely occurs within a genetically
susceptible subpopulation of women (36-39). Estimates suggest that about a third of the
loci responsible for heritable breast cancer susceptibility have been identified, including
high penetrance mutations (Table 1) (52, 53, 71-76). With rare exception, the
contribution of individual polymorphisms to the etiology and progression of breast
cancer is unknown. Building a comprehensive understanding of hereditary influences on
breast cancer susceptibility is essential to understanding the etiology of breast cancer
and more importantly identifying women at high risk of developing breast cancer who
could benefit from the application of preventative medicine to this population.
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Symbol

Name

Function

BRCA1 (77)

Breast cancer
one, early onset

DNA repair:
homologous
recombination

BRCA2 (79)

Breast cancer two,
early onset

DNA repair:
homologous
recombination

TP53 (80)

Tumor protein 53

Genome integrity,
DNA damage
response,
apoptosis, cell
cycle control, etc.

PTEN (46)

Phosphatase and
tensin homolog

Control of PI3Ksignaling, which
regulates
proliferation, cell
survival, cell
growth,
metabolism, etc.

STK11 (LKB1)
(83)

Serine-threonine
kinase 11

Apoptosis and cell
cycle regulation

CDH1 (84, 85)

E-cadherin

Cell adhesion

PALB2 (86)

Partner and
localizer of
BRCA2
Ataxia
telangiectasia
mutated

DNA repair,
homologous
recombination
DNA damage
checkpoint, double
stranded breaks,
DNA repair
DNA damage
checkpoint, double

ATM (87, 88)

CHEK2 (71, 89)

Checkpoint kinase
2
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Penetrance

Disease

High penetrance:
mutant alleles
also increase
susceptibility to
ovarian cancer
High penetrance:
mutant alleles
also increase
susceptibility to
ovarian cancer
High penetrance:
mutant alleles
also increase
susceptibility to
leukemia,
sarcomas, brain
tumors etc.
High penetrance:
mutant alleles
increase
susceptibility to
thyroid,
endometrial,
colon, kidney
cancer etc.
High penetrance:
mutant alleles
also increase risk
of
gastrointestinal,
pancreatic,
ovarian, uterine,
lung cancer, etc.
Moderate
penetrance:
mutant alleles
also increase risk
of colorectal and
gastric cancer

50-65% of women with
deleterious mutation
develop breast cancer
by age 70 (78).
40-57% of women with
deleterious mutation
develop breast cancer
by age 70 (78).
TP53 mutations cause
Li-Fraumeni
syndrome. 49% of
women with
deleterious mutation
develop breast cancer
by age 60 (81).
PTEN mutations
cause Cowden
Syndrome. 81% of
women with
deleterious mutation
develop breast cancer
by age 70 (82)
STK11 mutations
cause Peutz-Jeghers
syndrome. 32-54% of
women with
deleterious mutation
develop breast cancer
by age 60

Moderate
penetrance

Associated with the
development of lobular
carcinoma of the
breast. 40-54% of
women with
deleterious mutation
develop breast cancer
by age 70.
PALB2 mutations
cause Fanconi anemia

Moderate
penetrance

ATM mutations cause
ataxia telangiectasia

Moderate
penetrance

1100delC

BRIP1 (90)
RAD51C (76, 90)
XRCC2 (91)

FGFR2 (74)

TNRC9 (putative
gene affected by
1612.1 variants)
(68, 74, 92)
MAP3K1
(putative gene
affected by
5q11.2 variants)
(74)
LSP1 (putative
gene affected by
11p15.5 variants)
(74)

BRCA1 interacting
protein c terminal
helicase 1
RAD51 homolog C
X-ray repair
complementing
defective repair in
chinese hamster
cells 2
Fibroblast growth
factor receptor 2

Moderate
penetrance
Moderate
penetrance

Low penetrance

Trinucleotiderepeat-containing
9

DNA repair, gene
transcription,
poorly defined

Low penetrance

Mitogen-activated
protein kinase
kinase kinase one

Mitogenic
signaling,
component of the
ERK signaling
pathway
F-actin binding
protein, expressed
by lymphocytes,
neutrophils, and
macrophages,
may have a role in
adhesion and
motility of these
cell types
Untranslated
mRNA, regulated
insulin-like growth
factor two

Low penetrance

Lymphocytespecific protein
one

RAD51-like 1

DNA repair:
homologous
recombination

Caspase 8

Apoptosis

9

BRIP1 mutations
causes Fanconiaanemia
RAD51C mutations
cause Fanconiaanemia like phenotype

Moderate
penetrance

Receptor tyrosine
kinase involved in
mitogenic
signaling, and
differentiation

H19 (74)

RAD51L1
(RAD51B)
(putative gene
affected by
14q24.1 variants)
(93)
CASP8 (53, 94)

stranded breaks,
DNA repair
DNA Repair:
homologous
recombination
DNA Repair:
homologous
recombination
DNA Repair:
homologous
recombination

Breast cancer
associated variants
cluster within intron
two among punitive
transcription factor
binding sites.

Low penetrance

Cluster in intron 10

Low penetrance:
significance may
be associated
with linkage to
LSP1 variants
Low penetrance

Long non-coding RNA,
maternally imprinted.

Low penetrance

D302H
Shown to reduce
breast cancer
susceptibility.

ESR1 (putative
gene affected by
6q25.1 variants)
(69, 95)

Estrogen receptor
alpha

Hormone
signaling,
mammary gland
development, and
breast cancer
Transcriptional
regulation of cell
proliferation,
metabolism etc.
Transcriptional
regulation, stem
cell marker

Low penetrance

MYC (putative
gene affected by
8q24.21
variants)(96)
KLF4 (putative
gene affected by
9q31.2
variants)(96)
TERT (putative
gene affected by
5p15 variants)
(58)

V-Myc
myelocytomatosis
viral oncogene
homolog
Kruppel-like factor
4
Telomerase
reverse
transcriptase

Maintenance of
telomere repeats

Low penetrance

TGFβ1(94)

Transforming
Growth Factor
Beta 1

Low penetrance

PTHLH (putative
gene affected by
12p11 variants)
(97)
NRIP1 (putative
gene affected by
21q21 variants)
(69, 97)
COX11 (putative
gene affected by
17q23.2 variants)
(98)

Parathyroid
hormone-like
hormone isoform 1

Pleiotropic
cytokine with proand anti- tumor
properties
Mammary gland
and bone
development

Low penetrance

SLC4A7/ NEK10
(putative genes
affected by 3p24
variants) (98)

Solute carrier
family 4, sodium
bicarbonate
cotransporter,
member 7

Transcriptional
repressor of
nuclear receptors
including ER
Mitochondrial
respiration,
catalyzes electron
transfer from
cytochrome c to
oxygen
SLC4A7:
extracellular pH

Nuclear receptorinteracting protein
1
Cytochrome c
oxidase assembly
homolog 11

NEK10: mitosis?

Never-in mitosis
related kinase 10
Table 1: Breast Cancer Susceptibility Genes.
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Low penetrance

Low penetrance

Low penetrance

Low penetrance

Low penetrance

Intron 4 polymorphism
identified in women of
African descent.
Variant alleles
associated with
increased risk of
developing ERnegative breast cancer
L10P

Non-Heritable Breast Cancer Risk Factors
Non-heritable, environmental and physiological factors can also significantly
affect the risk of breast cancer development. The mammary epithelium undergoes
frequent and repeated remodeling events in the context of the female reproductive cycle
and pregnancy (99). Despite the evolution of robust tumor suppressor pathways,
dynamic tissues, such as the mammary gland, are inherently sensitive to
transformation. Many environmental and physiological factors influence an individual
susceptibility to breast cancer, including gender, age, estrogen exposure, childbearing,
and lifestyle. The interplay between these factors and the underlying genetic
susceptibility in the development of breast cancer is poorly defined.
Gender and Age
Breast cancer is 100-times more common in women than in men. Age is the
greatest risk factors influencing breast cancer development in women. In European and
North American countries, the cumulative incidence of breast cancer in women is 2.7percent by 55 years of age, nearly doubling to 5-percent by 65 years of age, and
increasing to 7.7 percent by 75 years of age (100). Following tumor initiation, the
accrual

of

an

adequate

mutational

spectrum

capable

of

facilitating

tumor

growth/progression can take years or decades. The somatic mutation rate is believed to
be the major factor limiting carcinogenesis. Under-recognized age-related changes in
tissue architecture and the composition of the ECM may also play an important role in
susceptibility to cancer by generating a microenvironment permissive of malignant cell
expansion (101). Chronic low-grade inflammation and cytokine production are also
associated with advanced age and significantly enhance the development of breast
cancer (102). Rising life expectancy and aging populations in the United States,
Western Europe, and elsewhere in the developed world will continue to increase the
absolute incidence of breast cancer.
Estrogen Exposure
High-fidelity control of hormone levels is essential to the coordination of
proliferation, differentiation, and apoptosis, processes that facilitate remodeling of the
glandular architecture. Factors influencing hormone signaling are particularly important
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determinants of breast cancer risk. Estrogen promotes growth and development of the
mammary gland and also plays a central role in the etiology of breast cancer. The
cumulative lifetime exposure of a woman to estrogen is consistently associated with the
likelihood of breast cancer development (103). Early menarche (<12 years versus >16
years) and late menopause (>55 years versus <45 years) are significant breast cancer
risk factors (104, 105). High levels of serum estrogen in post-menopausal women are
associated with increased breast cancer incidence (106, 107). The pharmacological use
of estrogen as a component of hormone replacement therapy (100) and to a lesser
extent in contraceptives (108-110) increases breast cancer risk. Estrogen analogs
increase the prevalence of breast cancer in heavily exposed populations. Estrogenic
activity is a common property of industrial byproducts, herbicides, pesticides, and other
synthetic products (111-114).
Childbearing
Pregnancy is associated with drastic changes in hormone signaling that can
have confounding affects on breast cancer incidence. In the short term, high levels of
serum estrogen can promote the progression of small pre-existing tumors and expand
the pool of susceptible stem/progenitor cells, increasing breast cancer incidence in the
years directly following pregnancy (104). In experimental models, pregnancy and
lactation can induce changes in stromal ECM composition enhancing the invasive and
metastatic capacity of breast tumor cells (115, 116) However, early-pregnancy (<20
versus >30) and multiple pregnancies greatly reduces long-term chances of developing
breast cancer (104). Pregnancy is associated with high, sustained levels of circulating
progesterone, inducing differentiation of mammary stem and progenitor cells, which is
thought to underlie the long-term protective effect of pregnancy. Experimentally,
carcinogen transformed mammary epithelial cells fail to form tumors in the stromal fat
pad of uniparous rats, but readily form tumors in virgin rats. The factors responsible for
the enhanced tumor suppressive properties of the post-partum mammary stroma are
uncharacterized (117). Changes in the stroma and the stem/progenitor cell population
within the mammary gland likely underlie long-term reductions in breast cancer risk
following pregnancy. Lactation and prolonged breast-feeding are also known to reduce
the risk of breast cancer, however the mechanism is undefined (118).
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Obesity and the Western Lifestyle
Characterized especially by dietary overconsumption and a lack of physical
activity, the western lifestyle encompasses a wide range of behavioral patterns and
lifestyle choices known to promote several tumor types. Western women tend to give
birth at relatively older ages and to fewer children, forgoing the protective benefit of
early and repeated childbearing (119). A high fat diet and lack of physical activity are
significant risk factors for breast cancer, especially in post-menopausal women (120).
Resultant high body mass index (BMI) is strongly associated with breast cancer
incidence (121-123). In post-menopausal women, the synthesis of estrogen is catalyzed
in peripheral adipose tissue by the aromatase enzyme (CYP19). Dietary fat intervention
studies demonstrate that reducing the percentage of calories consumed as fat
significantly decreases circulating estrogen levels and breast cancer incidence,
suggesting that increased estrogen signaling partially underlies breast cancer risk due
to obesity (122, 124). In obese individuals, sub-clinical chronic inflammation is
commonly observed in the visceral and subcutaneous adipose tissue. Dead adipocytes
elicit an inflammatory response resulting in the recruitment of macrophages, which
produce pro-inflammatory mediators known to promote tumor development and
progression (125-128). In animal models, obesity induces significant inflammation of the
mammary gland characterized by activation of the NF-κB pathway, elevated proinflammatory cytokine production, and enhanced aromatase expression (129). Alcohol
consumption increases estrogen levels and breast cancer risk in a dose-dependent
fashion (130). Perturbed hormonal homeostasis may be a significant mechanism by
which the western lifestyle influences breast cancer incidence.
The western lifestyle may partially account for regional disparities in breast
cancer incidence. Breast cancer incidence is more than three times higher in the United
States than in Asian countries, including China, Japan, and the Philippines. Following
migration to the United States, the incidence of breast cancer in Asian women from
these countries shifts precipitously towards that of other Americans, reaching
significance after only a decade; even when controlling for regional differences in heath
care and surveillance. After two generations of residence in the United States, the
relative risk of breast cancer is indistinguishable when comparing the descendants of
Asian immigrants to other groups living in the United States (131). Increased breast
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cancer incidence in recent immigrants and the overall trend of rising incidence among
women in rapidly developing countries have been largely attributed to the
westernization of these populations (132).
Breast cancer risk factors either increase the somatic mutation rate within the
mammary epithelium and/or facilitate the aberrant growth and progression of breast
cancer to clinical relevance. A comprehensive understanding of the environmental and
hereditary factors influencing breast cancer susceptibility does not exist. The
mechanisms underlying the effect of known risk breast cancer factors is largely absent
or conjecture. Building a multivariate risk model for breast cancer could increase the
efficiency of breast cancer screening programs and guide cancer-preventative
strategies.
The Mammary Gland
The mammary gland is the defining characteristic of the class, Mammalia;
evolutionarily designed, as an epidermal appendage, to provide for the rapid growth,
development, and immunological defense of live-born offspring (133). The mammary
gland is architecturally defined by ductal branching, a distinction that applies to several
organs, including the kidney, salivary gland, vascular system, and lung. Most organs
are patterned embryonically and maintain their basic structure throughout adulthood.
Uniquely, the mammary gland experiences the majority of its growth and development
after puberty and is subject to continual remodeling throughout the reproductive lifespan
of the individual (134). Many of the same properties that make the mammary gland
functional and responsive to the nutritional needs of offspring, also make it susceptible
to tumorigenesis.
The labyrinthine molecular networks coordinating cell fate decisions, the
proliferation of stem/progenitor cells, the initiation of context dependent differentiation
programs, and maintenance of tissue homeostasis within the mammary gland are only
partially understood. Essential paradigms of signaling are persistently observed,
including the importance of stromal-epithelial interaction in the normal development and
function of the mammary gland. Many of the developmental processes and molecular
circuitry that shape the adult mammary gland, also play a role in promoting or inhibiting
breast tumorigenesis and progression.
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Murine Mammary Gland as a Model System
The availability of human breast tissue at discrete developmental stages is
limited. The relatively few studies of human mammary gland development are restricted
to histology, ultrastructure, and immunohistochemistry (135). In vitro culture systems
have been developed that recapitulate some aspects of human mammary gland biology
(136). However, mammary gland development and function is dependent on
simultaneous interactions between a broad array of cell types and ECM elements,
limiting the utility of in vitro systems. Therefore, the mouse has become the
predominate model of mammary gland development. The transplantability of the adult
mouse mammary gland makes it an ideal system for the examining the interaction
between stromal and epithelial elements.
Despite 65-75 million years of divergent evolution, eighty-percent of human
genes have direct orthologs within the mouse genome (137). Since their introduction in
1980s, transgenic (138, 139) and knockout (140-142) mouse models have significantly
contributed to our understanding of the genetic and biological basis of mammary gland
development and tumorigenesis. However, significant morphological, functional, and
developmental differences exist between the mouse and human mammary gland,
complicating the interpolation of observations made in the mouse to human physiology
and disease (135, 143).
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Figure 1: Critical Elements of the Signaling Network Regulating the Development of the Mouse
Mammary Gland

The development of a ductal system capable of producing and delivering milk to
offspring at parturition is a highly regulated process. The embryonic mouse mammary
gland is formed by the invagination of epidermal cells from circular placodes into the
dermal mesenchyme. Mammary cell fate decisions within the placode are dependent on
Wnt and Fgf signaling as well as the Tbx3 transcription factor. Reciprocal paracrine
exchange with the developing mesenchyme directs the development of the mammary
bud; essential factors include Pthrp, hedgehog, and Wnt signaling as well as the
Msx1/Msx2 transcription factors. At puberty, estrogen and GH drive branching
morphogenesis through paracrine signaling intermediates including Egf, amphiregulin,
and Igf1. Progesterone, prolactin, and placental lactogens drive lobuloalveolar
differentiation through a series of paracrine intermediates, including Wnt-4, Stat5a, and
Rankl. Upon parturition, high levels of prolactin and declining levels of progesterone,
estrogen, and placental lactogens stimulate milk production. Oxytocin stimulates
contraction of myoepithelial cells, triggering lactation. Following weaning, Lif-induced
Stat3 synergizes with C/ebpδ to induce pro-apoptotic signaling and drive involution of
the redundant epithelium.
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Embryonic Mammary Gland Development
The initial stage of mammary gland development, as defined in the mouse, is
the formation of bilateral milk lines; a multilayered epithelial ridge within the single
layered embryonic epidermis. Nascent mammary epithelial cells then migrate to circular
placodes, later forming the nipples, at regular intervals along the milk line (135, 144).
Wnt/β-catenin signaling (145), fibroblast growth factor (Fgf) signaling (146), and the
Tbx3 transcription factor (147, 148) are critical components of the molecular network
directing early cell fate decisions at the mammary placode (Figure 1). Induction of
Wnt/β-catenin signaling is among the earliest events at the mammary placode.
Overexpression of the secreted Wnt inhibitor, Dickkopf 1, in the epidermis of mice
abrogates mammary placode formation (145). Similarly, Fgf10, Fgfr2, and Tbx3
knockout mice cannot form embryonic placodes (146-148). Wnt/β-catenin (149, 150),
Fgf (74, 151, 152), and Tbx3 (152, 153) pathways are commonly deregulated in breast
cancer through overexpression, amplification, and in the case of some FGF-receptors,
somatic mutation. Hyperactivity of these pathways been shown to enhance
stem/progenitor cell populations and facilitate breast tumorigenesis in animal model
(149, 150, 153).
The mammary bud is formed by the invagination of cells from the epidermal
placode into the underlying dermal mesenchyme. The development of the mammary
bud is dependent on reciprocal, paracrine exchange with the mammary mesenchyme
(99, 154). The influence of mesenchymal signals on glandular epithelial development is
very significant, such that transplantation of embryonic mammary epithelial cells into
salivary gland mesenchyme results in the generation of salivary gland-like structures
(155). The embryonic mammary mesenchyme even has the capacity to induce
differentiation of mammary carcinoma cells (6). The importance of cellular context to
mammary epithelial cells has also been demonstrated in vitro using three-dimensional
culture on reconstituted basement membrane. Three-dimensional culture systems are
capable of inducing functional differentiation of mammary epithelial cells and
normalizing tumor cells, largely through epigenetic reprogramming (136, 156).
Several factors have been shown to drive mammary bud development, including
Wnt/β-catenin signaling (157), parathyroid hormone related peptide (Pthrp) (158, 159),
hedgehog signaling (160-162), and the Msx1/Msx2 transcription factors (163, 164)
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(Figure 1). Pthrp signaling exemplifies paradigmatic stromal-epithelial crosstalk during
mammary gland development. The mammary epithelial bud expresses Pthrp, while
mesenchymal cells express the Pthrp receptor (Pth1r). Pthrp/Pth1r signaling drives the
specialization of mesenchymal cells, the formation of the nipple, and suppresses hair
follicle formation around the nipple. Pthrp has no direct effect on the developing
mammary

epithelium.

Instead,

Pthrp

stimulates

the

expression

of

secreted

mesenchymal factors essential to epithelial growth and differentiation, including bone
morphogenetic protein 4 (Bmp4), neuregulin 3, and Fgf10. Pthrp knockout mice are
incapable of maintaining the mammary bud (158, 159, 164, 165).
The hedgehog pathway also plays a prominent role in the development of the
mammary bud. Similar to Pthrp, hedgehog ligands are exclusively expressed by the
mammary epithelium. Haploinsufficiency of the Patched-1 hedgehog receptor (Ptc-1) is
sufficient to disrupt early mammary gland development; evidenced by ductal
hyperplasia and dysplasia. Transplantation of Ptc-1 +/- epithelium into a Ptc-1 +/+
stromal compartment completely reverses the phenotype, further evidencing the
importance of stromal signaling during mammary epithelial development through
paracrine feedback (161, 162). The hedgehog transcriptional affecter, Gli2, is
exclusively expressed within the mammary mesenchyme. Knockout of Gli2 completely
inhibits formation of the epithelial bud, corroborating the importance of stromal
hedgehog signaling (160).
Embryonic mammary gland development is heavily dependent on reciprocal
paracrine exchange between the epithelial and stromal compartments. The wnt,
hedgehog, and Pthrp pathways are commonly deregulated in breast cancer and have
pleiotropic roles in the tumor initiation and progression (166-172).
Post-Pubertal Mammary Gland Development
Relatively little is known about the molecular mechanisms governing embryonic
ductal outgrowth and formation of the rudimentary mammary ductal tree evident at birth.
Although embryonic mammary epithelial cells express hormone receptors in the
presence of maternal hormones, knockout of hormone receptor fails to diminish the
embryonic ductal outgrowth, indicating that embryonic ductal morphogenesis is
hormone independent (144). The ductal tree remains virtually growth arrested
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(undergoing only isometric growth) from birth until circulating ovarian hormones trigger
profound expansion at puberty.
The importance of steroid and peptide hormones in the regulation of adolescent
mammary gland development is well known. In rats, ovariectomy prevents ductal
outgrowth of the mammary gland; administration of estrogen rescues this deficiency
(173). Hypophysectomized (pituitary gland removal) rats require growth hormone (GH)
and estrogen supplementation for mammary gland development (174). Estrogen
receptor alpha (ERα) knockout mice and GH receptor knockout mice are incapable of
ductal morphogenesis (175-178). Knockout of the estrogen receptor beta (ERβ),
progesterone receptor (PR), and prolactin receptor do not significantly affect branching
morphogenesis (178).
ERα is primarily expressed in the epithelial compartment of the mammary gland,
displaying a heterogeneous distribution (179, 180). Despite the role of estrogen in the
proliferation of the mammary gland, ERα expressing epithelial cells rarely proliferate
due to TGF-β blockade (181). Transplantation of ERα -/- mammary epithelial cells into
an ERα +/+ stroma does not rescue the ability of these cells to undergo branching
morphogenesis (182). Conditional ERα knockout within the mammary epithelium is
sufficient to abrogate ductal morphogenesis (175). Therefore, only epithelial ERα
activity is required for mammary gland development. ERα-/- mammary epithelial cells,
transplanted with ERα +/+ cells, are capable of proliferation and contribute to ductal
elongation, evidencing a predominately paracrine mechanism of mammary gland
development upon estrogen stimulation (182).
Amphiregulin is strongly induced by estrogen signaling in the mammary gland
and is required for ductal morphogenesis (Figure 1). The protease ADAM17 is required
for amphiregulin shedding and is also essential for ductal morphogenesis (183).
Knockout and transplantation studies demonstrate that the epidermal growth factor
receptor (EGFR), for which amphiregulin is a ligand, is active in the stromal
compartment and required for ductal morphogenesis. Exogenous EGFR-ligands rescue
ductal branching in ovariectomized mice (184). Downstream factors expressed in
response

to

EGFR

activation

in

the

stromal

compartment,

include

matrix

metalloproteinase 2 (MMP-2) and FGFs. Knockout of MMP2 or conditional knockout of
FGFR2 within the mammary epithelium impairs branching morphogenesis (185, 186).
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The available evidence suggests that a paracrine feedback loop exists between ERαinduced, epithelial amphiregulin and stromal EGFR-induced paracrine factors (183,
187).
In contrast to ERα, the GH receptor (GHR) is expressed in the mammary
stroma. Knockout of GHR in the mammary epithelium does not impair mammary gland
development, however complete knockout of the GH signaling in both the epithelial and
stromal compartments completely abolishes ductal outgrowth (188-191). GH drives the
expression of insulin-like growth factor 1 (IGF-1) in stromal cells (Figure 1). Complete
knockout of IGF-1 or knockout of its receptor in the mammary epithelium prevents
ductal morphogenesis. Administration of IGF-1 to hypophysectomized rats or GHRknockout mice restores growth of the mammary ductal tree, however administration of
GH and estrogen to IGF-1 knockout mice does not rescue ductal morphogenesis (174,
190, 192).
Hormone signaling is essential to the development and function of the mammary
gland. Estrogen and GH play a central role in the ductal elongation and morphogenesis.
The human mammary gland undergoes constant remodeling during the reproductive
lifespan of an individual. Hormone levels fluctuate during the menstrual cycle.
Depending on the stage of the menstrual cycle, between four- and twenty-percent of
luminal mammary epithelium expresses the ERα (180, 193). High estrogen levels drive
mammary epithelial proliferation during the menstrual cycle. The proliferative fraction of
mammary epithelial cells reaches 35% during the luteal phase, evidencing the scale of
cyclic epithelial turnover. As estrogen levels decline, equivalent levels of apoptotic cell
death counterbalanced the increased cellularity of the mammary gland (194, 195). The
high levels of proliferation stimulated by estrogen underlie breast cancer risk associated
with the lifetime exposure to estrogen.
In addition to its critical role in normal mammary gland development, estrogen is
essential to tumor growth and progression. Three-quarters of breast tumors express
ERα and are largely dependent on estrogenic stimulation for growth and progression.
Tumors lacking ERα may also arise from estrogen responsive lesions in the breast
(196, 197).
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Mammary Gland Architecture
The mouse mammary ductal tree grows from terminal end buds (TEBs), multilayered, club-shaped structures situated at the tips of the immature ducts. TEBs contain
mammary stem/progenitor cells, which differentiate into two, morphologically unique cell
layers, an outer layer of cap cells and interior body cells. Proliferation within the TEBs
forces invasion into the mammary stroma and ductal elongation. The mammary tree
fans out through the stroma by bifurcation of the TEBs and lateral side branching from
ducts. Branching continues until the TEBs reach the peripheral extent of the mammary
fat pad, at which point TEBs arrest and disappear largely due to the TGF-β signaling
(198, 199). Apoptosis clears the cells within the duct forming a central lumen, a process
dependent on upregulation of the pro-apoptotic regulator, Bim (200). Mature mammary
ducts are bi-layered tubes; a single layer of columnar epithelial cells line a central lumen
(luminal cells), supported by a layer of contractile myoepithelial cells (basal cells) (201).
The cap cells of the TEB become the basal layer of the duct and body cells become the
luminal layer.
The human mammary gland develops similarly as a branched network of ducts
and has a comparable epithelial composition. The most significant morphological
difference is the presence of lobules at the end of each duct, resembling an aggregate
of grapes on a stem. This function unit of the human mammary gland is referred to as
the terminal ductal lobular units (TDLU). Lobules within the TDLU consist of spherical
alveoli are separated by connective tissue (Figure 2). The alveoli within the TDLU
become the milk producing units of the mammary gland during lactation.
The epithelium of the TDLU is responsive to ovarian hormone stimulation and
contains a pool of proliferative mammary stem/progenitor cells. These properties are
retained during the reproductive lifespan of the individual, facilitating the structural
remodeling of the mammary epithelium during the reproductive cycle and pregnancy.
Consequently, the TDLU is the major site of breast tumorigenesis. The mouse
equivalent of the TDLU is the lobuloalveolar unit. In contrast to the TDLU, lobuloalveolar
units form at the terminus of regularly space tertiary side branches, which sprout from
the mature ducts in response to cyclic exposure to ovarian hormones (143, 202).
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Figure 2: Terminal Ductal Lobular Unit

The function unit of the adult human mammary gland is TDLU, which is composed of
the terminal duct and the lobule. The lobule is tightly bound collection of alveoli, which
are hollow spheroids connected to the terminal duct. A single layer of epithelial cells
lines the lumen of the alveoli and ducts. A layer of contractile myoepithelial cells and a
layer of basement membrane surround the luminal epithelial layer. During lactation,
functional differentiation of the alveoli produces the constituents of milk. Contraction of
the myoepithelial layer forces the milk through the ducts and out the nipple. The
epithelium of the TDLU is responsive to ovarian hormone stimulation and contains a
pool of proliferative mammary stem/progenitor cells, making it the preferential site of
breast tumorigenesis.
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The Mammary Stroma
The mammary parenchyma exists within a complex stromal compartment. The
mammary stroma consists of ECM and various cell types, including adipocytes,
fibroblasts, endothelial cells, myofibroblasts, and immune/inflammatory cells (203). The
mammary stroma is not simply a structural unit. Stromal derived signals are essential to
the growth, differentiation, and maintenance of the mammary gland. Transplantation of
mammary epithelial cells between mouse strains demonstrates that strain-specific
differences

in

branching

patterns

are

dependent

on

stromal

factors

(204).

Mammographically dense breast tissue is a significant risk factor for human breast
cancer development, suggesting that breast composition may influence tumorigenesis.
(105, 205, 206).
Mechanical properties associated with ECM density and signaling molecules
secreted by stromal cells significantly influence mammary epithelial cell behavior. A
critical difference between the mouse and human mammary glands is the composition
of the stromal compartment. Within the human breast, the mammary epithelium is
embedded within a thick layer of highly collagenous connective tissue, separating it
from the adipose tissue within the breast. Comparatively small amounts of fibrous
connective tissue separate the mouse mammary epithelium from the adipose tissue
(143, 202). Experimentally, the mammary fat pad of immunocompromised mice must be
pre-injected with human fibroblasts and ECM to generate a stromal microenvironment
conducive to the transplantation of human mammary epithelial tissue (207).
The mammary epithelium is surrounded by a layer of basement membrane
(BM). Physical connection between mammary epithelial cells and BM components is
critical for the control of apical-basal polarity, epithelial architecture, proliferation, and
differentiation (208-210). Critical components of the mammary BM include collagen type
IV, laminin 1, 5, 10, and 11, fibronectin, and heparin sulfate proteoglycans. The
composition and thickness of the BM varies relative to the mammary duct (211). The
composition and distribution of the BM significantly influences elongation, branching,
and lumen clearance (101, 212). Transmembrane proteoglycans, integrins and nonintegrin receptors expressed by the mammary epithelium detect the BM composition,
dictating response. The cellular constituents of the mammary gland express several
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dimeric integrin receptors capable of specifically detecting ECM elements, including
collagen (α1β1 and α2β1), laminin (α3β1 and α6β4), and fibronectin (α5β1 and α5β3).
Knockout of α2-integrin reduces ductal branching, (213), collagen receptor discoidin
domain receptor 1 (DDR1) knockout mice are incapable of ductal elongation (208), and
β1-integrin knockout disrupts alveologenesis (214-216). These results demonstrate the
essential role of interactions between the BM and epithelium to the development and
function of the mammary gland.
Inflammatory signaling networks and effectors of the inflammatory processes
are

important

components

of

mammary

gland

elongation

and

development.

Macrophages are recruited by the developing TEB, contributing angiogenic factors,
proteases, cytokines, and growth factors. Colony-stimulating factor 1 (CSF-1) knockout
mice are deficient in mature macrophages and demonstrate impaired branching
morphogenesis (217). MMPs are critical to stromal remodeling and are known to
dramatically affect invasion, elongation, and branching patterns. MMP-3 and MMP-2 are
of particular importance in branching morphogenesis; MMP-2 knockout mice are
incapable of invasion at TEBs, while MMP-3 knockout mice are deficient in lateral side
branching (186). MMPs have a critical role in invasion and metastasis in breast cancer.
Overexpression of MMPs, results in disruption of normal mammary gland development,
hyperplasia, and in some cases is sufficient to initiate tumorigenesis (8, 218-221).
The composition of the mammary stroma is essential to the growth,
differentiation, and function of the mammary gland (99, 154). Tumor progression is
highly dependent on the ability of the tumor epithelium to recruit and manipulate nonmalignant stromal cell types, including fibroblasts, endothelial cells, and leukocytes (36).
Pregnancy, Lactation, and Involution
During pregnancy, the mammary gland undergoes a dramatic increase in size
and structural complexity, facilitating lactation at parturition. The fundamental
component of the lactating mammary gland is the alveolus, a hollow spheroid with a
central lumen. A single layer of secretory epithelial cells lines the alveoli lumen, which is
surrounded by myoepithelial cells (222). Progesterone and prolactin drive lobuloalveolar
differentiation. Progesterone receptor (PR) knockout mice demonstrate impaired
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alveolar development (223, 224). PR (existing as two isoforms PR-A and PR-B) is
expressed in both the stromal and epithelial compartments. In chimeric mammary
glands, PR-/- epithelial cells are able to contribute to alveologenesis in the presence of
PR+/+ epithelial cells, evidencing a paracrine mechanism of action. Essential
downstream secreted factors include Wnt-4 and Rankl (receptor activated by NF-κB
ligand) (Figure 1) (224, 225). Overexpression of Rankl rescues lobuloalveloar
development in PR-knockout mice (226, 227). Prolactin receptor (PLR) knockout mice
are similarly deficient in lobuloalveolar differentiation and lactation (228). Following
prolactin stimulation, PLR and Jak2 associate resulting in the activation of Stat5a
(Figure 1). Knockout of Stat5a displays the same defect in lobuloaveolar differentiation
seen in prolactin knockout mice (229-231). Stat5a and PLR are both capable of
enhancing Rankl transcription. Rankl knockout, Rankl knockout, or IκB knockin mice
demonstrate failure of lobuloaveolar proliferation and differentiation, evidencing a role
for the NF-κB pathway in growth and differentiation of the secretory epithelium (232).
Rankl is frequently deregulated during breast cancer progression and plays a critical
role in metastasis to the bone (233-235).
At parturition, functional differentiation of the secretory epithelium and lactation
occurs in response to declining estrogen and progesterone levels, loss of placental
lactogens, and high levels of prolactin. During lactation, the secretory epithelium
produces the constituents of milk, secreting them into the alveoli lumen. Stimulated by
oxytocin, myoepithelial cells contract, forcing the milk through progressively larger
ducts, and eventually the nipple (Figure 1) (222, 236, 237).
Following weaning, the milk-producing epithelium involutes through extensive
apoptosis returning the mammary ductal tree to its original size and complexity (238).
Involution of the mammary epithelium is dependent on Stat3, induced by leukemia
inhibitory factor (LIF) (239). Knockout of Stat3 inhibits apoptosis of the secretory
mammary epithelium following forced weaning (240, 241). Stat3 induces the expression
of c/ebpδ, synergy between these two transcription factors potently induces proapoptotic gene expression (Figure 1), including Bak, Igfbp5, and death receptor ligands
(tnfα, FasL, Trail, and Tweak) (242-244). Stat3 activation also inhibits Akt survival
signals by upregulating PI(3)Kinase regulatory subunits p55 α and p50 α (245). As the
redundant mammary epithelial undergoes apoptosis, the activation of inflammatory
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pathways leads to expression of MMPs and serine proteases. Protease activation
enhances apoptosis through the removal of matrix attachment and is necessary for
mammary gland remodeling. Apoptotic cells are cleared by recruited immune cells and
adipoctyes replace the epithelium (246).
The mammary gland is capable of repeated cycles of alveologenesis, lactation,
and involution following subsequent pregnancies, facilitated by stem and progenitor cell
maintained within the TDLU (247). Ultimately, at the conclusion of the reproductive
lifespan of the individual, menopause, the levels of ovarian hormones decline and the
functional elements of the mammary gland atrophy. In mammals, significant efficiency
in energy utilization is derived from tightly coupling mammary gland development and
function with reproduction (154, 248, 249).
The high levels of proliferation throughout the reproductive lifespan and the
essential role of stem/progenitor cells in mammary gland remodeling are believed to
sensitize the mammary gland to tumorigenesis. The majority of breast tumors occur in
post-menopausal women. Sustained estrogen stimulation due to the extra-ovarian
synthesis of estrogen is critical to the development of breast tumors in post-menopausal
women (120).
Breast Tumor Histopathology
Histological examination of breast tumors reveals a great deal of heterogeneity.
Greater than 90% of breast cancers are carcinomas, however several sarcomas are
known to occur within the breast. Invasive ductal carcinoma (IDC) of the breast, arising
from the terminal duct, is the most common form of breast cancer, accounting for 6580% of cases. Ductal carcinoma in situ (DCIS), a non-invasive accumulation of
neoplastic cells within the duct, is generally accepted to be a precursor of invasive
breast cancer (250, 251). Invasive lobular carcinoma (ILC) of the breast, arising from
the lobules, accounts for approximately 8-14% of breast tumors, while 3-6% of breast
tumors display mixed lobular/ductal histology. Despite significant molecular difference
between IDC and ILC, clinical outcomes are similar in multivariate analysis. Loss of ecadherin expression appears to be a critical factor in the development of ILC. Lobular
carcinoma in situ (LCIS) is not a necessarily a precursor lesion, however it is predictive
of subsequent development of breast cancer (either IDC or ILC) (252, 253). Several
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additional subtypes of breast cancer commonly observed based on histological
features. Tubular carcinoma (4%), invasive cribriform carcinoma, and mucionous
carcinoma (2%) generally have a good relative prognosis. Medullary carcinoma (2%)
has an intermediate prognosis. Metaplastic carcinoma (<1%), signet-ring carcinoma
(<1%), inflammatory carcinoma (<1%), and lipid rich carcinoma (<1%) have a relatively
poor prognosis. The molecular characteristics and origins of the rare histological
subtypes are currently not well understood and the majority of research attention is
directed at IDC given its prevalence.
Mammary Stem and Progenitor Cells
The regenerative capacity of the mammary gland is contingent on a stem and
progenitor cell population capable of continuously replenishing the mammary
epithelium. Mammary stem and progenitor cells are a prominent topic of research
investigation not only because of their role in mammary morphogenesis and tissue
homeostasis, but also because they provide a rich set of targets for transformation.
Murine Mammary Stem and Progenitor Cells
The existence of stem cells in the mouse mammary gland was established by
pioneering studies in which normal mammary gland fragments or disassociated
mammary epithelial cells were transplanted into the cleared mammary fat pad of
syngeneic mice (254). A complete and functional mammary gland can be generated
using mammary epithelial cells from any portion of the donor ductal tree, regardless of
donor age or parity (255, 256). Reconstitution of the mammary gland following serial
transplantation evidences a capacity for self-renewal, a critical property of stem cells.
However, unlike neoplastic tissue, the regenerative capacity of normal mammary
epithelial cells in serial transplantation studies is limited (between five and seven
iterations) (257, 258). Transplantation of retrovirally labeled mammary epithelial cells
demonstrated that a single cell can repopulate the entire mammary ductal tree
indicating multipotency (the ability to differentiate into multiple cell types), another
critical characteristic of stem cells (259). Serial transplantation of cells at limiting
dilutions and examination of mammary repopulating efficiency is the gold standard
methodology for verifying stem cell properties and establishing their frequency (260,
261).
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Long-term label retaining cells can be identified by bromodeoxyuridine (BrdU) or
3

H-thymidine pulse and chase experiments, suggestive of infrequent and asymmetric

divisions, providing additional evidence of a stem cell population with the adult
mammary gland (261, 262). Ultrastructure and histological studies identified several
populations of undifferentiated cell types within the mouse mammary glands, which
have been hypothesized to be stem and progenitor cells (255).
Isolation of stem cell populations is difficult due to their rarity and failure to
maintain their phenotype in culture. Using cell surface markers and fluorescenceassisted cell sorting several impressive studies have overcome the barriers to
mammary stem cell purification from disassociated mouse mammary glands. The
authors of one study were able to generate a functional mammary gland at limiting
dilution with cells expressing CD24 (heat stable antigen) and high levels of CD49f (α6integrin) (260). Similarly, another group was able to reconstitute the mammary gland
using a single cell expressing CD24 and high levels of CD29 (β1-integrin) (261). In both
studies, serial transplantation into the cleared mammary fat pad of secondary recipient
mice reconstituted the mammary gland, demonstrating the hallmark capacity for selfrenewal. The ability of the reconstituted mammary glands to form milk producing
lobuloalveolar units during pregnancy confirms the ability of the identified mammary
stem cells to differentiate into the critical lineages comprising the mammary gland (260).
Bi-potent and lineage restricted progenitors have been identified in the mouse
mammary gland suggesting a hierarchical organization of mammary stem and
progenitor cells. Committed luminal progenitors can be purified based on high
expression of CD61 (β3-integrin), low levels of CD133 (prominin-1), and low levels of
Sca-1. Differentiation into mature luminal cells is accompanied by loss of CD61,
increased CD133, and increased Sca-1 (263-265). The number of intermediates, their
nature, and the relationships between them are not fully understood. Characterization of
individual progenitor cells is challenging. Cell surface markers are an imperfect means
to consistently segregate pure populations of progenitors. Specific cell surface markers
have not been identified for myoepithelial progenitor. Plasticity likely exist within the
mammary stem and progenitor cell hierarchy further complicating their purification and
characterization ex vivo.
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Lineage Tracing of Murine Stem and Progenitor Cells
Lineage tracing is an important tool for the examination of stem and progenitor
cell hierarchy in vivo. Using the K14 promoter to drive YFP expression, a mutipotent
progenitor can be identified in the embryonic mouse mammary gland. However,
postnatal lineage tracing using inducible K14-YFP reporter mice find a K14 expressing,
lineage restricted subpopulation of progenitor cells capable of generating cells of the
myoepitelial, but not luminal lineage cells. Inducible-YFP expression under the K5 and
Lgr5 promoters, confirms the existence of unipotent myoepithelial progenitor cells in the
mature mouse mammary gland. Using inducible-K8-YFP reporter mice, a subpopulation
of progenitor cells were identified that can give rise to the luminal lineage alone. These
results argue that in the adult mammary gland, luminal and myoepithelial lineages are
derived independently from distinct lineage-restricted progenitor cell populations.
Interestingly, transplantation of the unipotent myoepithelilal (but not luminal) progenitor
alone into a cleared mammary fat pad forces them to become multipotent and
reconstitute both the luminal and myoepithelilal compartments. Transplantation of
myoepithelilal progenitors with luminal progenitors maintains their unipotent nature
(247). This indicates that plasticity exists between the myoepithelial progenitor and
mammary stem cell populations and possibly explains the discordant results of lineage
tracing and transplantation experiments.
Lineage-tracing using WAP-Cre and Rosa26LacZ reporter mice has also been
used to identify a long-lived sub-population of parity-identified mammary epithelial cells
(PI-MECs) (266). PI-MECs proliferate during pregnancy and give rise to the alveolar
structures (267). PI-MECs express high levels of CD49 (268), suggesting that they are
a component of the population shown to repopulate the mammary gland (260).
Mouse mammary stem and progenitors cells are arranges in a hierarchical
manner (Figure 3). The relationship between individual stem and progenitor cells
identified by lineage tracing and cell surface markers is unclear. The number of
intermediates and organization of the hierarchy is unknown.
Human Mammary Stem and Progenitor Cells
Similar to mice, the human mammary gland also contains a population of stem
cells (Figure 3). Examination of X-chromosome inactivation patterns in the normal,
human mammary gland suggests that entire ducts and lobules, containing both luminal
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epithelial and myoepithelial components, are clonally derived from a single cell (269).
Immunohistochemistry and FACS analysis of stem cell markers identifies putitive stem
cells in the human mammary gland (265, 270-274). Low levels of epithelial cell
adhesion molecule (Ep-CAM) and high levels of CD49f identifies a subpopulation of
human mammary epithelial cells capable of generating mammary gland-like structures
in severely immunocompromised mice. These experiments require “humanization” of
the stromal microenvironment, achieved by pre-injection of either the cleared mammary
fat pad or highly vascularized renal capsule with ECM components and irradiated
fibroblasts. The resulting mammary structures contained both ductal and lobular
structures composed of myoepithelial and luminal lineage cells. Serial transplantation
demonstrates that these cells are capable of self-renewal (65, 275, 276). However, this
system is limited by inefficiency.
Subpopulations of bipotent and lineage restricted progenitor cells have been
identified in human breast tissue using in vitro clonogenic assays, evidencing a
hierarchical organization of mammary epithelial precursors (271, 277, 278). Stem and
progenitor cells are resistant to anoikis and can be propagated under non-adherent
conditions, resulting in floating multicellular structures termed mammospheres. Serial
passaging of mammospheres is an accepted surrogate test of self-renewal (260, 265,
270-274, 279). Disassociated mammospheres plated at clonal densities in adherent
monolayer culture can give rise to colonies containing myoepithelial cells (markers
include: K5, K14, and α-smooth muscle actin), luminal epithelial cells (markers include:
K8, K18, K19, MUC-1, ER, and PR), or both cell types.
Using these assays the mammary precursor population isolated based on
expression of EpCAM and CD49f can be further subdivided into a uncommitted/bipotent population (Muc-1-, CD24-, CD133-, Thy1+, and CD10+) and luminal-restricted
population (Muc-1+, CD24+, CD133+, Thy1-, and CD10-) (65, 274, 275, 279-281). Bipotent progenitor cells within the human mammary gland can also be identified by
double positivity for myoepithelial K14 and luminal K19 (274). Specific markers of
myoepithelial-restricted precursors have not been identified, however myoepithelialrestricted colony forming cells have been identified in vitro (281, 282)
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Figure 3: Simplified Mammary Stem and Progenitor Cell Hierarchy

Mouse and human stem and progenitor cells are organized in a hierarchical manner. In
this simplified diagram, a multipotent stem cell gives rise to a bipotent progenitor, which
in turn generates two lineage restricted progenitor populations, luminal-restricted and
myoepithelial-restricted. Through a series of intermediates these progenitors give rise to
the differentiated populations making up the mammary gland. The number of
intermediates and the relationship between them are unknown.
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Stem and Progenitor Cell Niche
In the mammary gland stem and progenitor cells exist within a specific
microenvironmental niche and are not randomly distributed throughout the bulk of the
epithelium. In the developing mouse mammary gland, stem and progenitor cells reside
within the TEB, however in the mature mammary gland these cells are located within
specialized regions of the duct as observed by immunohistochemical analysis of stem
cells markers and the spatial arrangement of lobule structures during pregnancy (267,
283, 284). Microdissection of the human mammary organoids from reduction
mammoplasty and validation of stem cell properties in vitro revealed the stem cell niche
is in the terminal duct (274).
Self-renewal and the ability to differentiate into multiple cells types are
advantageous traits for tumor cells. Cell extrinsic control of stem cell activity may have
evolved to prevent unrestrained, cell autonomous self-renewal and carcinogenesis
(285). In the absence of self-renewal signals from the niche, stem cells differentiate
making it difficult to study the factors influencing mammary stem cell biology in vitro.
Regulation of Stem and Progenitor Cells
Although the existence of stem and progenitor cells is well accepted, the
molecular mechanisms underlying their maintenance and differentiation remains
unclear. Paracrine signaling downstream of hormone receptors and microenvironmental
factors are critical to the maintenance and differentiation of normal mammary stem and
progenitor cells.
Mammary stems cells can be enriched based on the expression of integrins,
particularly α6-(CD49f) and β1-(CD29). Heterodimeric integrin complexes, such as
α6/β1, directly anchor cells to the ECM and are critical to communication with the
stromal microenvironment. Deletion of β1-integrin in the basal compartment (using K5Cre) eliminates the mammary repopulating capacity in serial transplantation
experiments. The mammary glands of these mice also display abnormal ductal
branching, atypical polarity, and disequilibrium between the myoepithelial and luminal
lineages. β1-integrin mediated interactions with the ECM are critical to maintenance and
cell fate decisions in mammary stem cells (286).
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Ovarian hormone exposure and reproductive history profoundly influence breast
cancer risk. Although mammary stem and progenitor cells are generally ER and PR
negative (only a subset, 6-10%, of luminal progenitors express hormone receptors)
hormone dynamics dramatically affect the frequency and activity of these cell
populations (154). Ovariectomy dramatically reduces the number of stem/progenitor
cells, while treatment with estrogen and progesterone restore their numbers (287).
Pregnancy enhances the stem/progenitor pool ten-fold (288). The downstream effectors
of ERα and PR, amphiregulin, Wnt-4, and Rankl, are critical paracrine factors affecting
mammary stem and progenitor cell dynamics (287, 289, 290) Fluctuations in the
frequency and activity of stem and progenitor cells in the context of reproductive cycle
and pregnancy likely underlies the complicated relationship between breast cancer risk
and ovarian hormone exposure (105). The estrogen receptor target gene, Gata3, plays
a specific role in the evolution of the luminal lineage. Conditional knockout of Gata3 in
the mouse mammary gland results in expansion of the luminal progenitor population
and defective differentiation. Overexpression of Gata3 in mammary stem cells forces
differentiation into alveolar luminal cells (264). GATA3 is an important marker and is
essential to the development of luminal breast cancer (291).
Transcriptional profiling of human mammary bi-potent progenitors and luminal
restricted progenitors suggests that the NOTCH, WNT, and NF-κB pathways are of
particular importance in the regulation of stem/progenitor cell function. The NOTCH
signaling pathway is critical to stem cell maintenance and the specification of cell fate in
diverse tissues. NOTCH receptor 4 was highly expressed in the bi-potent progenitor
population, while NOTCH receptor 3 was enriched in the luminal progenitor populations,
suggesting a role for differential NOTCH signaling in regulating the stem cell hierarchy
(280). Disruption of Cbf-1/Rbpκ, a critical component of the Notch transcriptional
complex, alters the cellular composition of the mouse mammary gland during
pregnancy (292). Downregulation of Notch signaling in mammary stem cells results in
expansion of the stem and progenitor cell pool, suggesting that Notch is required for cell
fate decisions and the regulation of the stem and progenitor cell pool within the
mammary gland. In progenitor cells, constitutive activation of Notch-1 results in
preferential selection of luminal cell fate resulting in the accumulation of luminal
progenitors, hyperplasia, and tumorigenesis (293-295). In breast cancer patients,
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NOTCH1 and JAG1 overexpression have been observed and are prognostic of poor
outcome (296).
The Wnt/β-catenin pathway is critical to mammary stem cell self-renewal. Wnt
ligands expand the pool of mammary progenitors, however they fail to significantly alter
cell fate (297). Overexpression of Wnt ligands in the mammary gland is associated with
a six-fold increase in the mammary stem cell population (261). Overexpression of MMP3 enhances the mammary stem cell population and induces hyperplasia by binding the
non-canonical wnt, Wnt5b, which is known to inhibit the canonical Wnt/β-catenin
pathway (298).

MMP-3 knockout mice demonstrate a marked decrease in the

mammary stem cell activity (298). Wnt/β-catenin is commonly deregulated in breast
cancer (299-302). The hedgehog pathway also appears to regulate the stem cell
population

within

the

mammary

gland; expression

of constitutively

activated

smoothened was shown to increase the pool of stem and progenitor cells (303).
The factors governing the maintenance, proliferation, and differentiation of
mammary stem and progenitor cell is poorly understood. Stem and progenitor cell
populations are long-lived, compared to fully differentiated cell types. Proliferation of
mammary stem and progenitor cell population in the context of mammary gland
remodeling exposes them to the accumulation of transforming mutations over the
lifespan of the individual. Mammary stem and progenitor cells are likely cellular targets
of oncogenesis in breast cancer.
Cancer Stem Cells
According the cancer stem cell hypothesis, breast tumors are organized in a
hierarchical manner, similar to normal breast tissue. In this model, only a small
subpopulation of tumor cells, termed cancer stem cells, drive tumor growth,
progression, recurrence, and therapeutic resistance. Cancer stem cells have been
hypothesized to originate from normal tissue stem cells that have acquired a limitless
proliferative capacity. Alternatively, a more differentiated cell acquires the cancer stem
cell phenotype.
High levels of CD44 and low levels of CD24 enrich for breast cancer stem cells
capable of recapitulating tumors in immunocompromised mice following serial
transplantation at limiting dilutions (304). Gene expression analysis of cells isolated
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using these markers identifies a gene signature highly enriched in stem cell
regulators/markers identified in other organ systems and prognostic of poor patient
outcome in breast cancer (305, 306). High activity of aldehyde dehydrogenase (ALDH)
and the ability to form mammospheres in a non-adherent culture system are similarly
capable of identifying cancer stem cells. Furthermore, ALDH1 expression is prognostic
of poor patient outcome (307). Many genes and pathways associated with stem cell
function, such as Wnt, NOTCH, NF-κB, hormone receptor signaling, are deregulated in
tumors.
Breast Cancer Progression
Post-mortem histological examination of adult tissues reveals a high frequency
of tumors that fail to progress to clinical relevance despite the expression of strong
oncogenes (2). Occult tumors are observed in the breast tissue of approximately 40% of
young and middle-aged women (20-54 years of age) (308). The high relative frequency
of microscopic tumors compared to actual clinical diagnoses suggests the existence of
robust tumor suppressive mechanisms limiting tumor growth and progression.
Understanding the barriers to tumor growth/progression and the mechanisms utilized by
tumors to circumvent them are essential to the development of novel therapeutic
strategies and predictive/prognostic markers.
Oncogenes and Tumor Suppressors
Tumorigenesis is driven by genetic and epigenetic alterations. In 1982, several
groups simultaneously reported the discovery of activated and transforming ras, the first
oncogene

(309-311).

Oncogenes

are

normal cellular

genes

constitutively or

inappropriately activated by chromosomal translocation, gene amplification, or mutation.
In 1986, loss of heterozygosity at the retinoblastoma susceptibility locus led to the
identification of the first tumor suppressor gene, Rb (312). Tumor suppressors are
genes rendered insufficiently active or inactive by deletion, insertion, mutation, or
epigenetic silencing. Except in rare cases where haploinsufficiency provides a selective
advantage during tumorigenesis (i.e. PTEN), tumor suppressors generally require loss
of both alleles (313, 314).
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Multiple safeguards have evolved in mammals to impede tumorigenesis. To
circumvent these safeguards, the activation of multiple oncogenes and/or loss of
multiple tumor suppressors are typically required for transformation (315, 316). Tumor
initiation occurs within a single cell. Stem and progenitor cell are believed to be
preferential targets of transformation within the mammary epithelium.
Clonal Selection Model of Tumor Progression
Following initiation, the accumulation of additional somatic mutations is essential
to tumor growth and progression. Cancer develops over many years following the
initiating

event,

reflecting

the

time

required

for

accumulation

of

mutations.

Tumorigenesis is theorized to be an evolutionary process, driven by the selection and
expansion of tumor clones with advantageous traits from a heterogeneous population.
The identification of cancer stem cells suggests that only a small subset of cells are
responsible for tumor growth and progression giving rise to a phenotypically diverse
population of non-tumorigenic progeny cells through an aberrant differentiation
program. Given that the differentiated progeny of the cancer stem cells are incapable of
contributing to disease progression the clonal selection may occur exclusively among
the cancer stem cells. Alternatively, plasticity between the cancer stem cell
compartment and more differentiated progeny making up the bulk of the tumor may
allow clonal selection and expansion across the broader tumor cell landscape to
influence the disease progression.
Histopathological examination of tumor progression has defined a model in
which several intermediate stages exist between initiation and a malignant tumor. In
some tumor types, the acquisition of specific mutational events coincides transition
between histologically defined stages. For example, colon cancer progression is
characterized by the sequential accumulation of genetic alterations: APC/β-catenin
mutation results in crypt dysplasia, the activation of K-RAS drives progression to an
intermediate adenoma, the activation of DCC/SMAD4/SMAD2 coincides with transition
to a late adenoma, and finally the loss of p53 occurs at the transition to invasive colon
carcinoma (317). Breast cancer, on the other hand, demonstrates much greater
heterogeneity in tumor progression and as a result very few recurrent genetic
alterations have been identified in breast cancer (85, 318, 319).
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Ductal Carcinoma In Situ
Strong molecular, epidemiological, and histopathological evidence suggests that
DCIS is antecedent to the majority of invasive breast carcinomas. Pre-malignant
atypical ductal hyperplasia (ADH) is the precursor to DCIS (320). Both ADH and DCIS
are characterized by the proliferation and accumulation of neoplastic cells within the
lumen of mammary ducts. ADH lesions are smaller and lack some histological features
of DCIS, but are contiguous with low grade.
DCIS is a genetically advanced lesion, demonstrating a high degree of
cytogenetic abnormalities (321). Many of the genetic alterations evident in invasive
carcinoma are already established in pre-invasive DCIS (322-324). Comparison of
DCIS and adjacent invasive carcinoma finds significant continuity between many
molecular markers, including amplification of HER-2, ERα, cyclin D1, and Myc and
mutations of PI3KCA and p53 (325). The intrinsic subtypes of breast cancer can be
identified in pre-malignant breast tissue, suggesting the existence of distinct avenues of
breast cancer progression (326). Gene expression profiling of large cohorts of DCIS
and invasive breast tumors cannot resolve stage-specific differences in gene
expression (318, 327-329). Based on the available evidence, specific genetic events
are unlikely to facilitate the progression of DCIS to invasive carcinoma. The majority of
mutational events driving tumor progression are likely acquired prior to DCIS.
Metastatic Breast Cancer
The underlying cause of death among breast cancer patients is the metastatic
spread of tumors to distant organ sites, especially the bone, lungs, brain, and liver. The
five-year relative survival rate of women diagnosed with localized breast cancer is 98.6
percent, decreasing to 83.3 percent for patients with regional spread, and 23.3 percent
for patients with distant metastasis (31). Metastatic breast cancer can develop at any
time, years or even decades after the original diagnosis and remains virtually
untreatable using current therapies (330). Following surgical excision of the primary
breast tumor, 20-30% of breast cancer patients will experience a metastatic recurrence
over a 15-year period (331).
No reproducible genetic events can differentiate metastatic lesions from the
primary tumor. Gene expression signatures predicting the development of metastatic
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disease can be derived from early stage breast cancer patients (332, 333). Circulating
tumor cells can be detected in a subset of these patients. Metastases can be generated
from these genetically ‘primitive’ clones of the primary tumor (334-336). These results
indicate

that

metastatic

propensity

is

likely

programed

early

during

breast

tumorigenesis, by many of the same genetic and epigenetic events that drive
proliferation and clonal expansion (337). Multistep progression models predict that
alteration in metastasis genes late in tumorigenesis triggers dissemination. These
models provide the rationale for mammographic screening and early intervention in
breast cancer. However, the available data suggests that the manifestation of breast
cancer as a metastatic lesion is unlikely to be a result of additional mutational events
late in tumorigenesis (332-336).
Role of the Microenvironment in Breast Cancer Progression
Accumulating evidence suggests that the normal microenvironment has tumor
suppressive properties. Injection of fully malignant mammary carcinoma cells into the
embryonic mammary mesenchyme can suppress tumor formation and induce
differentiation (6). Malignant teratocarcinoma cells injected into a normal developing
mouse blastocyst give rise to phenotypically normal chimeric mice (5). Similarly,
chicken embryos infected with Rous Sarcoma Virus (RSV) develop normally despite
constitutive expression of the v-src oncogene. Dissociation of the embryo alleviates
restraints on transformed growth (4). Tumor formation in RSV-infected chickens
requires wounding, suggesting a role for an altered microenvironment in tumor
progression (3). Even genotoxic agents target the normal microenvironment in animal
models of carcinogenesis. The cleared mammary fat pad of carcinogen-exposed rats
enhances the tumorigenicity of transplanted mammary epithelial cells exposed to
carcinogens in vitro. By comparison, the mammary fat pad of un-exposed rats
suppressed the tumorigenic potential of identically in vitro transformed mammary
epithelial cells instead resulting in the formation of a normal mammary ductal tree (338).
The focus on mutational events within the tumor epithelium as the primary
drivers of tumor progression has largely obscured the importance of the stromal
microenvironment. The ability of tumor cells to recruit and manipulate non-malignant
cell types, including fibroblasts, endothelial cells, pericytes, adipocytes, mesenchymal
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cells, and leukocytes, governs their malignant growth potential. In mouse models,
injection of tumor cells into different anatomical sites, with varying stromal compositions,
dramatically affects proliferation, invasion, metastasis, and therapeutic sensitivity (339343). Depletion of specific non-malignant cell types or contributed factors can
profoundly effect tumor progression (344-347). Many microenvironmental changes are
permanent, breast tumor-derived stromal fibroblast maintain their abnormal phenotype
in culture (348). Epigenetic reprogramming of stromal cell types has been shown to
account for the alterations in gene expression (349). Genetic alterations have been also
noted within the stromal compartment (350-352).
Critical modes of communication between tumor cells and the stromal
microenvironment include, the composition of the ECM, cell-to-cell contact, and
paracrine signaling molecules. Comparison of distinct cell types within the normal
breast, DCIS, and invasive breast cancer, reveals significant changes in stromalepithelial crosstalk during breast tumor progression (353). Gene expression analysis of
the breast tumor stroma identifies a robust prognostic signature, evidencing the
importance of stromal signaling especially in metastatic proclivity (7). In breast cancer
xenograft models, the gene signature of cells migrating to the bone, lung, or brain is
heavily populated by secreted or cell surface proteins, including cytokines/chemokines,
MMPs, and cell adhesion molecules (354-356).
Changes in the interaction between tumor cells and the microenvironment are
critical to the transition from pre-invasive DCIS to invasive breast cancer. The
disappearance of myoepithelial cells as a continuous entity surrounding the duct is the
critical histological distinctions of invasive disease (357, 358). Abnormalities in
myoepithelial cells results in the expression of MMPs resulting in the degradation of the
basement membrane (353, 357).
Deregulated interaction between the tumor epithelium and the tumor stromal are
essential to tumor progression. Breast cancer progression cannot be defined by solely
focusing on genetic changes within the tumor epithelium. The identification of
microenvironmental factors that promote breast cancer progression is essential to the
design of novel therapeutic strategies and continued progress against breast cancer
mortality.
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Inflammation and Breast Cancer Progression
Inflammation and the presence of leukocytes in the tumor microenvironment are
regarded as essential components of malignant progression. Tumors resemble “wounds
that do not heal” (359). In many tumor types, chronic inflammatory stress due to viral or
bacterial infection, autoimmune disease, or environmental irritants promotes the
development and progression of tumors. Helicobacter pylori infection dramatically
increases risk of developing gastric cancer (360). Autoimmune inflammatory bowel
disease greatly enhances colon cancer development (361). Prostatitis increases the risk
of developing prostate cancer (362). Asbestos and silica particles induce chronic
inflammation essential to the development of mesothelioma (363). Long-term usage of
non-steroidal anti-inflammatory drugs decreases the overall burden of cancer (364366). Systemic markers of inflammation are prognostic of poor overall and disease-free
survival in breast cancer patients (367).
Many factors contribute to the inflammatory tumor microenvironment. Tumor
cells secrete cytokines, chemokine, and toll-like receptor ligands downstream of
oncogenes, such as RAS and MYC (368-371) and in response to stress conditions,
including hypoxia, necrosis, chemotherapy, and ionizing radiation (372-374). Tumor
associated fibroblast significantly contribute to the inflammatory microenvironment.
Gene expression characteristic of activated fibroblasts defines a wound healing
signature that is prognostic of poor survival and the development of metastasis (375).
Co-injection of tumor cells with activated fibroblast is routinely used to enhance the
establishment of xenograft tumors (376).
The inflammatory mileu surrounding the developing tumor results in the
recruitment of leukocytes. Both innate and adaptive immune cells are evident in the
tumor stroma including macrophages, dendritic cells, neutrophils, myeloid derived
suppressor cells, mast cells, natural killer cells, T-lymphocytes, and B-Lymphocytes.
Leukocytes can participate in either a tumor-promoting inflammatory response
(demonstrated for all except natural killer cells (377)) or an anti-tumor immune
response. The pro/anti-tumor properties of leukocytes are largely programmed by
secreted factors and heterotypic interactions within the tumor microenvironment. In
malignant tumors the balance is largely tilted in favor of a tumor-promoting inflammatory
response. Many mechanisms play a role in immunosuppression within tumors including
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the cytokine, TGF-β1 (378). Targeting immunosuppressive receptors expressed by Tcells, PD-1 and CTLA-4, is a promising therapeutic strategy and highlights important
efforts to reactivate anti-tumor immunity (379-382).
Tumor-associated macrophages (TAMs) are among the most abundant immune
cells within the tumor microenvironment. TAMs are essential to angiogenesis, invasion,
and metastasis contributing cytokines, proteases, and growth factors to the tumor
microenvironment. Within breast tumors, TAMs frequently localize near the vasculature.
In this context, TAMs facilitate angiogenenic reprograming through secretion of VEGF
and invasion by establishing chemotactic gradients of EGF (383-386). Gene expression
signatures associated with poor patient outcome often include genes that are
specifically expressed by macrophages (387). High levels of TAMs are associated with
poor patient prognosis in breast and other tumor types (388-392). The expression of
cytokines and chemokines, such as CCL2 and CSF-1, are essential to the recruit and
activation of macrophages, correlated with poor patient prognosis (393-395). Depletion
of macrophages in transgenic and xenograft models of breast tumorigenesis
demonstrate reduced growth, invasion, angiogenesis, and metastasis (344, 396-399).
Macrophages are differentiated in multiple phenotypes M1 macrophages
activated by IFNγ and microbial components are pro-inflammatory, express major
histocompatibility complex molecules and likely function in anti-tumor immunity. The
majority of TAMs are believed to be of the M2-phenotype, alternatively activated by IL4, IL-10, and IL-13. M2-macrophages normally participate in the wound healing through
the secretion of growth factors and angiogenic factors. In some models, tumor
progression is dependent on a switch from the M1 to M2 phenotype (400). TAMs
express high levels of pro-inflammatory cytokines reminiscent of the M1 phenotype
suggesting that they do not fall into typical classifications. TGFβ is a critical factor in
suppressing the role of TAMs in anti-tumor immunity and in the generation of a tumor
promoting phenotype (401-403). Subsets of T-lymphocytes known to promote breast
cancer in animal models and correlated with poor prognosis in breast cancer,
progression enhance metastatic progression by stimulating the activity of TAMs through
production of IL-4 and (404). TAMs stimulated by CSF-1 induces the expression of
hypoxia-associated iNOS and arginase-1 which suppress the proliferation and
activation of cytotoxic T-cells (405, 406).
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Tumor-associated neutrophils (TAN) are also recruited by tumor cell-derived
chemokines, especially IL-8 (368, 407). High levels of circulating neutrophils, induced
by tumor-derived GM-CSF and other cytokines, are prognostic of poor survival in
melanoma and renal carcinoma patients (408, 409). Relatively few studies have
examined the prognostic significance of TAN. In renal cell carcinoma, TAN are
prognostic of short recurrence-free survival (RFS). In the presence of TAN, patients
demonstrated a five-year RFS of 53%, however in the absence of TAN patients had a
five-year RFS of 87%. In multivariate analysis, TAN were shown to be an independent
prognostic marker of disease-specific survival (DSS) and overall survival (OS) (410). In
human gliomas, high numbers of TAN correlate with high tumor grade (411). High levels
of neutrophils in the bronchoalveolar lavage fluid from patients with bronchioloalveolar
carcinoma were associated with high levels of IL-8, NE, and poor DSS (407). Although
not commonly observed in pancreatic tumors, TAN were shown to be associated with
the

relatively

aggressive

micropapillary

and

undifferentiated

subtypes

(412).

Lymphocyte to neutrophil ratio is a prognostic factor in colorectal cancer and non-small
cell lung cancer (413, 414).
Depletion of neutrophils or disruption of neutrophil chemotaxis inhibits tumor
growth, angiogenesis, and metastasis in mouse models of tumor progression (415-417)
The majority of studies in humans and animal models show that TAN augment tumor
progression through the secretion of growth factors, cytokines, ROS, and proteases
(345, 418-421). TAN can be polarized by TGF-β blockade to assume an anti-tumor
phenotype, however little evidence exists of a role for TAN in anti-tumor immunity in the
absence of therapeutic manipulation (422, 423).
Breast Cancer Subtypes
Breast cancer is a collection of diseases sharing a common anatomical site but
radical differences in incidence, morphology, genetics, therapeutic response, and
outcome. Clinically, breast tumors are generally segregated into three groups, estrogen
receptor (ER)-positive, HER2-amplified, and triple-negative breast cancer (TNBC: ER-,
PR-, and HER2-negative); these distinctions are largely based on outcome and
response to available targeted therapeutics. Gene expression profiling, using DNA
microarray or RNA sequencing technologies, has the capacity to rapidly measure global
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mRNA transcription. Comparative study of large cohorts of tumors by gene expression
profiling has greatly enhanced our understanding of breast cancer biology and
heterogeneity. These studies consistently highlight the importance of differences in
hormone receptors, HER2, and proliferation in breast cancer classification (332, 333,
424-426)
Pioneering work by Perou and colleagues was among the first to use these high
throughput technologies to classify breast tumors and remains the most influential.
Their analysis first compared gene expression between breast tumors to define an
intrinsic gene set, genes demonstrating the greatest differences in expression across
the tumor spectrum. Using this intrinsic gene set the tumors were then subjected to
hierarchical clustering, grouping tumors by similarities in gene expression. From this
type of analysis five, reproducible intrinsic subtypes of breast cancer are widely
considered: luminal A, luminal B, basal, HER2-enriched, and normal-like (291, 427).
Recent publications also recognize a claudin-low subtype of breast cancer (428).
Analysis of breast tumors using DNA copy number array, DNA sequencing
technologies, global DNA methylation analysis, microRNA sequencing, and proteomic
analysis can reproducibly group tumors into these subtypes (85). Each molecular
subtype displays dramatic differences in incidence, patient outcome, and characteristic
gene expression (Table 1) (425, 429-431). The intrinsic subtypes of breast cancer can
be identified in DCIS evidencing distinct pathways of tumor progression (319).
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Table 2: The Intrinsic Subtypes of Breast Cancer.
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Luminal Subtypes of Breast Cancer
In general, the luminal subtypes are defined by expression of ER-complex
components and target genes, including ESR1, GATA3, FOXA1, XBP1, and MYB. The
luminal subtypes also highly express transcripts characteristics of the luminal lineage
within the normal breast, such as cytokeratins 8/18. Luminal-subtype tumors are
predominately ER-positive by immunohistochemistry (Lum A: 87% and Lum B 82%),
however can contain TNBC (Lum A: 7% and Lum B 1%) and HER2-positive patients
(Lum A: 2% and Lum B 15%). Segregation into luminal A and B is largely based on the
differential expression of proliferation genes, which tend to be highly expressed in
luminal B tumors relative to luminal A tumors. In ER-positive tumors, markers of
proliferation (i.e. Ki67) can distinguish between Luminal A and Luminal B tumors (432,
433). Luminal B tumors also tend to express lower relative levels of ER-target genes. A
subset of luminal B tumors demonstrates HER2 amplification.
The luminal A subtype is the largest tumor cohort (40-60% of the total) and
demonstrates the greatest heterogeneity in gene expression. Luminal A tumors are
characterized by low histological grade and have a relatively good prognosis. Luminal B
subtype tumors are generally of higher histological grade and have an intermediate
prognosis compared to all other subtypes. Luminal A patients have a 15-year relapse
rate of 27.8% compared to 42.9% for luminal B patients. Following relapse, luminal A
patients had a longer median survival of 2.2 years compared to 1.6 years for luminal B
patients (425, 429-431).
HER2-Enriched Subtype of Breast Cancer
The HER2-enriched subtype generally demonstrates a high degree of 17q12
amplification (71%) resulting in the overexpression of HER2 and adjacent genes. The
majority of HER2-enriched subtype tumors, when evaluated by immunohistochemistry
are HER2-positive and ER-negative (68%), but can contain ER-positive (20%) and
TNBC tumors (9%). HER2 amplicon associated gene expression is an important
component of the segregation of this subtype by transcriptomic analysis. Tumors in the
HER-2 enriched subtype display overexpression of receptor tyrosine kinases, including
FGFR4 and EGFR, and do not express luminal cluster genes (i.e. GATA3 and ESR1).
The HER2-enriched subtype is largely defined by tumors of high histological grade, high
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proliferation index, and is frequently metastatic. Historically, HER-2 enriched tumors
have a poor prognosis (52.4% relapse, 0.7 year median survival following relapse),
however HER-2 directed therapies have increased survivorship in both metastatic and
non-metastatic tumors.
Basal-like Subtype of Breast Cancer
Basal-like tumors generally lack gene expression associated with the ER, PR,
and HER2 (80%), however can contain ER-positive (10%) and HER2-positive tumors
(1%). Basal-like tumors express markers of the basal/myoepithelial cell lineage in the
normal breast, including cytokeratins 5/17, P-cadherin, caveolin 1, nestin, CD44, and
EGFR. Evaluation of basal cytokeratins and EGFR can refine the ability to identify
basal-like tumors by IHC (434). Basal-like tumors are often large at diagnosis, have a
high histological grade, high proliferation index, and a high frequency of lymph node
involvement (425, 429-431). Basal-like tumors have a poor prognosis, 43.1% relapse
with a 0.5 year median survival following relapse. A significant portion of hereditary
BRCA1 and BRCA2 related tumors cluster within the basal subtype. Several studies
have identified BRCA1 and BRCA2 downregulation, through either promoter
methylation or transcriptional inactivation, in sporadic cases of basal-like breast cancer
(61, 62). Conditional knockout of Brca1 and Trp53 in the mouse mammary gland
generates tumors with distinctly basal-like features (63-65).
Additional Subtypes of Breast Cancer
Normal-like tumors cluster with normal breast tissue, have not been extensively
characterized. The normal-like subtype may be an artifact of normal tissue
contamination and is generally ignored (431).
Since the original description of the intrinsic subtypes of breast cancer, several
additional subtypes have been described, including the interferon subtype characterized
by high levels of interferon gene expression and the molecular apocrine subtype
characterized by androgen receptor signaling. Notable is the claudin-low subtype.
These tumors cluster closely with the basal-like tumors, however they characteristically
express very low levels of intracellular adhesion molecules including claudin-3,4,7,
ocludin, and e-cadherin. These tumors are of high histological grade and low
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proliferation index. Claudin-low tumors are enriched for mesenchymal and cancer stem
cell properties and highly express genes characteristic of immune cell infiltration (428).
Claudin low patients have a very poor prognosis.
A recent study identified six-subtypes of TNBC through k-means and consensus
clustering of gene expression profiles. Two basal-like tumor subtypes, basal-like 1,
basal-like 2, were characterized by high expression of genes associated with cell
proliferation and the DNA damage response making them extremely responsive to
chemotherapy. An immunomodulatory subtype was identified by the presence of
immune cell signaling. A mesenchymal and mesenchymal stem-like were defined by
cell signaling characteristic of epithelial to mesenchymal transition and cancer stem
cells. Finally a luminal androgen receptor (AR) subtype was identified expressing
luminal cytokeratins, but lacking ER-signaling in favor of an AR gene signature (435).
Although the intrinsic subtypes of breast cancer are prominently considered, a
great deal of heterogeneity exists beyond the luminal A, luminal B, HER-2 enriched, and
basal-like distinction. The ability to classify tumor heterogeneity through molecular
profiling may allow cancer oncologists to identify effective therapeutic approaches to
similar tumors. The analysis of breast tumors by multiple profiling platforms and using
new bioinformatics techniques should continue to reveal sub-classifications of breast
cancer, predict outcomes, and guide clinical management.
Recurrent Genetic Abnormalities Associated with Breast Cancer Subtypes
Breast tumors are genetically heterogeneous, however some recurrent
abnormalities cluster within the intrinsic subtypes of breast cancer. Luminal A tumors
(Figure 4) demonstrate the lowest overall mutation rate and generally have diploid
genomes. Luminal B tumors (Figure 5) have an intermediate mutational rate and
aneuploidy genomes. Recurrent mutations in the luminal subgroups include: PIK3CA
(Lum A: 49%, Lum B: 32%), GATA3 (Lum A: 14%, Lum B: 15%), MAP3K1 (Lum A:
13%, Lum B: 5%), and MAP2K4 (Lum A: 7%, Lum B: 2%). Mutations in p53 are more
common in luminal B tumors (Lum A: 12%, Lum B:32%), overall the majority of luminal
B tumors have some kind of inactivating events within the p53 pathway. Accordingly,
luminal A tumors express higher levels of p53 target genes GADD45 and CDKN1A. The
Rb-pathway inactivation is also higher in luminal B tumors. Common oncogenic events

47

in luminal B tumors include cyclin D1 (58%) and CDK4 (25%) amplification (compared
to luminal A tumors cyclin D1 amp: 29% and CDK4 amp. 14%). Inactivating mutations
in RB1 are also more common in luminal B tumors. Overall, differences in the clinical
behavior of luminal A and B tumors can partially be explained by differences in Rb and
p53 inactivation.
HER2-enriched (Figure 6) and Basal-like (Figure 7) tumors demonstrate
significantly higher mutational rates compared to luminal tumors and often have
aneuploid genomes. Overall, TP53 mutations are highly enriched in basal-like and
HER2 tumors (Basal:84%, HER2:75%). RB1 mutation/loss is a frequent event in basallike tumors (20%) as is cyclin E amplification (9%); interestingly cyclin D1 amplification
is rare in the basal like subtype compared to luminal tumors and HER2 enriched tumors
(cyclin D1 amp. 38%, CDK4 amp. 24%). PIK3CA mutations are less frequent in basallike tumors compared to luminal and HER2 enriched subtypes (Basal: 7%, HER2: 42%).
However, basal like tumors display the highest Akt activity due in part to frequent
PTEN/INPP4B loss and amplification of PIK3CA (49%). Basal-like tumors also display
amplification of genes within the ERK signaling pathway, including KRAS, BRAF, and
EGFR.
The spectrum of genetic alterations plays an important role in breast cancer
heterogeneity. However, alterations are often shared between subtypes. Unique
mutational spectra does not account for the vast differences in gene expression that
drive the segregation of tumors into the intrinsic subtypes.
Cell of Origin and Breast Cancer Subtypes
Differences in gene expression that segregate the distinct subtypes of breast
cancer are believed to arise from different cells of origin. Analysis of histological and
molecular profiles of breast tumors does not necessarily predict the normal cell of origin.
BRCA1 mutation carriers are particularly susceptible to basal-like breast cancer;
therefore the assumption was that BRCA1 mutation leads to the transformation of basal
progenitor cells. Inactivation of BRCA1 and p53 in basal and luminal progenitor cells
demonstrates that luminal progenitors are the target of BRCA1 loss and the genesis of
basal like breast cancer (65). The cell of origin responsible for the genesis of the other
breast cancer subtypes have not been convincingly demonstrated.
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Figure 4: Common Genetic Alterations in Luminal A Breast Tumors.

Amplifications, deletions, and mutations in recurrently altered genes within the luminal A
subtype of breast cancer. Alterations were measure by exome sequencing and array
comparative genomic hybridization (CGH) by TCGA. The data was visualized as
presented here using the web-based cBioPortal for cancer genomics
(www.cbioportal.org).
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Figure 5: Common Genetic Alterations in Luminal B Breast Tumors.

Amplifications, deletions, and mutations in recurrently altered genes within the luminal B
subtype of breast cancer. Alterations were measure by exome sequencing and array
comparative genomic hybridization (CGH) by TCGA. The data was visualized as
presented here using the web-based cBioPortal for cancer genomics
(www.cbioportal.org).
.
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Figure 6: Common Genetic Alterations in HER2-Enriched Breast Tumors.

Amplifications, deletions, and mutations in recurrently altered genes within the HER2enriched subtype of breast cancer. Alterations were measure by exome sequencing and
array comparative genomic hybridization (CGH) by TCGA. The data was visualized as
presented here using the web-based cBioPortal for cancer genomics
(www.cbioportal.org).
.
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Figure 7: Common Genetic Alterations in Basal-Like Breast Tumors .

Amplifications, deletions, and mutations in recurrently altered genes within the basallike subtype of breast cancer. Alterations were measure by exome sequencing and
array comparative genomic hybridization (CGH) by TCGA. The data was visualized as
presented here using the web-based cBioPortal for cancer genomics
(www.cbioportal.org).
.
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Clinical Management of Breast Cancer
Breast cancer remains a serious public health concern. In the United States, one in
eight women will be diagnosed and treated for breast cancer within her lifetime.
Declining mortality rates over the last several decades reflects progression in the
clinical management of the disease (31). Prior to the mid-1970s breast cancer treatment
had seen little change since the introduction of the radical mastectomy by William
Halsted in 1882. Over the last several decades increased breast cancer survivorship
has come from advances in screening/diagnostic imaging, surgical resection, evaluation
of prognostic/predictive markers, radiotherapy, systemic chemotherapy, and targeted
therapeutics.
Mammography
Mammographic screening has contributed to the decline in breast cancer
mortality, however the effect is often overstated. Overall, the number of women who
present with advance breast cancer has decreased only eight-percent due to screening
mammography (436). The success of early detection is predicated on the linear
progression of breast cancer from initiation to metastatic disease. However, metastatic
proclivity may be pre-programed early during tumorigenesis, resulting in early
dissemination of tumor cells. Mammography overwhelmingly detects slow-growing
primary tumors, a significant proportion of which are unlikely to progress within the
lifespan of an individual (437). The molecular mechanisms governing the tumor
proliferation rate and metastasis are linked, therefore the tumors with the greatest
proliferation rate may also be the most likely to metastasize and least likely to be
detected by mammography (438, 439). Increased sensitivity and access to
mammographic screening has contemporaneously led to the detection of a larger
proportion of pre-invasive DCIS (440). DCIS currently accounts for 20% of all breast
cancer diagnoses (440). Examined retrospectively, breast cancer screening results in
over-diagnosis in 31% of patients. Prior to the widespread use of mammography DCIS
was a very rare diagnosis (436). The development of complimentary screening
methodologies is necessary to accurately define patient risk of disease progression and
guide therapeutic intervention.
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Breast Cancer Diagnosis and Assessment of Clinicopathological Parameters
Diagnostic imaging and core needle biopsy are performed to determine the
presence of malignancy. Following diagnosis, breast cancer treatment is based on
stage and histopathological parameters. Tumor stage, the most important prognostic
parameter, is based on evaluation of tumor size, the number/proximity of involved
lymph nodes, and the presence or absence of distant metastasis. Guidelines for the
evaluation of tumor stage are set by the American Joint Committee on Cancer (AJCC).
Tumor stage is significantly associated with patient outcome and is a critical tool utilized
by oncologists to make treatment decisions (Table 2).
In the absence of metastasis pathological features of the tumor, including
histological grade, hormone receptor (ER and PR), HER2 status, and the presence of
lymphovascular invasion are heavily considered in making treatment decisions.
Platforms including the PAM-50 Breast Cancer intrinsic classifier, the MammaPrint test,
and the Oncotype DX are now being used to supplement traditional clinicopathological
assessment. However, the adoption of these diagnostic platforms is limited by their
substantial cost, lack of standardization, and incomplete clinical trials comparing
outcomes of patients treated according to the established risk groups.
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Stage
0
I

Five-year Overall
Survival (441)
93%
88%

IIA

81%

IIB

74%

IIIA

67%

IIIB
IIIC

41%
49%

IV

15%

Description
Carcinoma in situ
1A: The tumor is less than 20 mm in the greatest
dimension with no evidence of axillary lymph node
metastasis.
1B: The tumor is greater than 20 mm with
micrometastasis (<2mm) to a single axillary node.
The tumor is either between 20 and 50 mm or less
than 20 mm with 1-3 positive lymph nodes.
The tumor is either greater than 50mm or between 20
and 50mm with 1-3 positive node.
The tumor is either less than 50 mm and has 4-9
positive nodes or a tumor is greater than 50 mm and
has 1-3 positive nodes,
The tumor extends to the chest wall or the skin.
A tumor of any size with more than 10 positive
nodes.
Stage IV infers distant metastasis.

Table 3: Breast Cancer Staging and Survival.

Tumor stage is the most important prognostic parameter available to clinicians. Tumor
stage is based on the size of the tumor, the frequency of lymph node metastasis, and
the presence of distant metastasis.
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Surgery
Breast conserving surgery (BCS), lumpectomy followed by radiation therapy is
the gold standard. Large, randomized clinical trials have consistently failed to find a
difference in local reoccurrence rates and overall survival between BCS and modified
radical mastectomy (442-446). The morbidity associated with axillary lymph node
dissection can also be avoided if biopsy of the sentinel lymph node, the node directly
receiving drainage from the tumor, is negative for metastasis. Randomized clinical trials
demonstrate no difference in the outcome of patients who undergo sentinel lymph node
biopsy to determine if complete axillary lymph node dissection was necessary
compared to complete dissection regardless of sentinel lymph node positivity (447,
448). These studies have been practice changing such that complete node dissection
will now be performed only in those patients with sentinel lymph node involvement.
Radiotherapy
Radiotherapy, a necessary component of breast conserving surgery, is
administered to the entire breast to prevent local recurrence. Typically, external-beam
radiation therapy is used to apply a total dose of 50 Gy to the breast over a five-week
period in 2-Gy fractions. Radiation therapy reduces five-year local recurrence from 26%
to 7% in the conserved breast and decreases 15-year breast cancer mortality to 30.9%
compared to 35.9% for women who did not receive radiation therapy (442). An
additional dose of 16 Gy directed at the tumor bed reduces the risk of recurrence even
further from 7.3% to 4.3% at five years (449).
Chemotherapy
Systemic chemotherapy is frequently used to palliate the symptoms of patients
with advanced breast cancer and to reduce the risk of recurrence in patients with
operable breast cancer. The median survival of metastatic breast cancer patients is 1824 months. Treatment with systemic chemotherapy achieve complete responses in
16.6% of patients of which only 3.1% will remain in remission after 5-years (450).
Chemotherapeutics are generally administered in combination to increase therapeutic
efficacy. In randomized clinical trials, many combinations have been tested for efficacy
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and tolerability. In advance breast cancer patients, these studies generally observe
greater response rates with combination therapy compared to mono-therapy, however
with increase toxicity.
For breast cancer patients the risk of recurrence spans decades following
diagnosis and treatment. Following breast conserving surgery, 10-20% of patients will
experience recurrence of those 9-25% are metastatic or locally advance (451-453).
Adjuvant chemotherapy, administered after surgical resection, reduces the risk of
developing distant metastasis by eliminating pockets of tumor cells within the body.
However, the clinicopathological parameters used to determine risk are incomplete and
fail to adequately stratify individual risk resulting in the indiscriminate application of
adjuvant chemotherapy. As many as 80% of treated patients would never actually form
metastases and needlessly suffer the morbidity associated with systemic chemotherapy
(454).
Neoadjuvant chemotherapy, administered prior to surgical resection, was
originally used in patients with locally advanced disease to enhance operability, but is
now more widely used in the treatment of operable breast tumors. A pathological
complete response is achieved in 20-30% of patients treated with neoadjuvant
chemotherapy. The response of breast tumors to chemotherapy is highly variable. A
pathological complete response is achieved in 28-32% of TNBC and HER-2-enriched
subtype patients, partially due to their high proliferation rate. In contrast, luminal tumors
respond poorly to neoadjuvant chemotherapy, a pathological complete response is
achieved in only 6.7% of luminal A patients and 11.2% of luminal B (HER2-negative)
(455). Neoadjuvant therapy has the added advantage of allowing oncologists to
evaluate the efficacy of the drugs being administered by diagnostic imaging, allowing
them to modify the dose or the drugs being applied if ineffective.
The

earliest

adjuvant

chemotherapy

trials

utilized

a

combination

of

cyclophosphamide, methotrexate, and 5-flourouracil (CMF) to successfully increase
disease specific and overall survival compared to surgery alone in a cohort of lymph
node positive breast cancer patients (456). CMF was eventually supplanted by
combination regimens containing anthracyclines, especially doxorubicin and epirubicin.
In a randomized clinical trial, anthracycline regimens demonstrated an 11% reduction in
the risk of recurrence compared to CMF, however others studies are inconclusive on
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the benefits of anthracyclines in combination therapy (331, 457, 458). Overall metaanalysis of clinical trial using both the CMF and anthracycline based adjuvant
chemotherapy regimes demonstrates a reduction in recurrence rate of 35% in women
younger than 50 and 20% in women older that 50. Adjuvant chemotherapy increases
10-year survival 7% (71% to 78%) in node negative patients and 11% (42% to 53%) in
node positive patients (458). The addition of taxanes, docetaxel and paclitaxel, has
further boosted the efficacy of anthracycline based adjuvant chemotherapy, increasing
disease free survival 14% over five years (459).
Large randomized trials testing adjuvant versus neoadjuvant chemotherapy fail
to find a significant difference in disease-free or overall survival compared to adjuvant
chemotherapy. However, neoadjuvant therapy does increase the percentage (7-12%) of
patient eligible for breast conserving surgery without an increase in locoregional
recurrence (460-462). Neoadjuvant therapy has had an important impact on
translational research and clinical trial design, allowing novel therapies and therapeutic
combinations to be tested on a smaller number of patients and with shorter follow-up
compared to traditional adjuvant trails. Neoadjuvant trials are evaluated based on tumor
response and permit collection of tumor tissue before/during treatment by serial biopsy
and after surgical resection in patients not undergoing a pathological complete
response. These trials are important to the development of predictive markers and
optimization of therapy.
Targeted Therapeutics
Traditional chemotherapy is non-specific, targeting proliferating populations of
tumor and normal cells, and is therefore associated with significant toxic side effects.
Breast cancer was among the first tumor types to benefit from targeted therapeutics.
The link between breast cancer and the endocrine system was established in 1896
when it was observed that ovariectomy induced tumor regression in a subset of breast
cancer patients. In 1952, adrenalectomy was found to produce a similar response in
breast tumors. These early studies failed to identify the biological basis of these
observations. Identification of the role of the estrogen in breast cancer and the
introduction of therapeutics specifically inhibiting ER signaling has significantly
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enhanced survivorship in the subsets of breast cancer patients expressing ER (331,
437, 463-467).
Selective

estrogen

receptor

modulators

(SERMs),

such

as

tamoxifen,

structurally resemble estrogen; however upon binding to the ER inhibit its liganddependent functions. In metastatic breast cancer patients (pre-menopausal) the efficacy
of tamoxifen is identical to bilateral ovariectomy (468). The tamoxifen response rate of
ER-positive metastatic breast cancer is 30%, for both pre- and post-menopausal
women (469). Long-term, administration of tamoxifen to ER-positive patients as
adjuvant therapy cuts the recurrence rate in half and reduces mortality by a third over a
15-year period (331). Treatment of DCIS patients with tamoxifen significantly reduces
disease progression and prevents breast cancer in a cohort of high-risk patients (466,
470). In some tissues tamoxifen acts as a partial agonist of ER, increasing the risk of
developing endometrial cancer or a thromboembolic event (471, 472).
Aromatase inhibitors, including anastrozole, letrozole, and exemestane, have
been developed as alternatives to tamoxifen. Aromatase inhibitors interfere with the
enzymatic conversion of androgens to estrogen and are therefore only effective in the
treatment of post-menopausal women. In ER-positive metastatic breast cancer,
aromatase inhibitors prolonged survival in women who fail to respond to tamoxifen
(473-476). As first line therapy for metastatic breast cancer, aromatase inhibitors
demonstrate greater clinical efficacy than tamoxifen alone (477, 478). In a large
randomized, double-blinded study, anastrozole was compared to tamoxifen as adjuvant
therapy in post-menopausal women. Anastrozole demonstrated greater clinical efficacy
in the prevention of breast cancer recurrence (479-481). Fulvestrant, an antagonist that
results in the downregulation of the ER and the PR, is another alternative to tamoxifen
in the treatment of breast cancer. Fulvestrant demonstrates equivalent efficacy to
anastrozole in patients resistant to tamoxifen (482)
The receptor tyrosine receptor HER2 is amplified in approximately 30% of breast
tumors. HER2 amplification is associated with aggressive disease and a poor survival.
Introduction of the HER2-directed chimeric monoclonal antibody, trastuzumab, has
dramatically improved the outcome of women with HER2-amplified breast tumors (both
ER+ and ER-). Trastuzumab decreases the recurrence rate by 50% and reducing
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mortality by a third (464). The dual (HER2/EGFR) kinase inhibitor, lapatinib, significantly
extends survival in advanced, trastuzumab-resistant breast cancer patients (483).
By age 70, 50-65% of women with deleterious mutations in BRCA1 and 40-57%
of women with deleterious mutations in BRCA1 develop breast cancer (78). In sporadic
cases of basal-like breast cancer, BRCA1 and BRCA2 are downregulated by either
promoter methylation or transcriptional inactivation (61, 62). BRCA1 and BRCA2 are
critical components of DNA double strand break repair. Poly(ADP-ribose) polymerase 1
(PARP1) is an essential to DNA single strand break repair. Failure of DNA single strand
break repair results in double strand breaks during DNA replication. Therefore, PARP1
inhibitors result in the accumulation of double strand breaks. In tumors with complete
BRCA1 and BRCA2 loss double stranded breaks cannot be efficiently repaired resulting
in cell death. Cell death induced by the combination of two inactivating events is refered
to as synthetic lethality(484-487).
The success of treating breast cancer using targeted therapies is unprecedented
among the major forms of cancer. Therapeutic resistance remains a problem in a
subset of patients treated with targeted therapies therapy. The promise of targeted
therapies is high efficacy coupled with relatively mild side affects. In order to be
successful, targeted therapies must be tailored to the patient population that will receive
the greatest benefit, using predictive markers. Future advances in the clinical
application of DNA sequencing technologies promises to tightly couple the mutational
spectrum with appropriate therapeutic modalities. Significant hurdles to the application
of personalized medicine exist. Distinguishing causal/driving mutations in the cancer
genes from random, passenger mutations can be challenging.
Unmet Clinical Needs
Currently, about one-third of women diagnosed with invasive breast cancer will
die from the disease. Major areas of unmet clinical need include: 1) the identification of
susceptible populations who could benefit from increased surveillance and the
application of cancer prevention strategies, 2) highly sensitive and specific diagnostic
technologies capable of discerning tumors with a high likelihood of progressing, 3)
prognostic biomarkers capable of identifying early stage breast cancer patients at high
risk of recurrence and metastasis, 4) predictive biomarkers of therapeutic response
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especially capable of guiding the application of targeted therapeutics, 4) therapeutic
modalities or biological technologies capable of targeting essential nodes in growth
sustaining pathways, metastatic dissemination, and recurrence, and 5) overcome
therapeutic resistance.
Summary
Breast cancer is the most frequently diagnosed malignancy and the leading
cause of cancer mortality in women worldwide (28). Epidemiological studies
demonstrate a major role for hereditary factors in breast cancer susceptibility (36-39).
Environmental and physiological factors are also significantly associated with an
individual’s risk of developing breast cancer, including age, lifetime estrogen exposure,
reproductive history, and obesity (100, 103, 104, 121-123).
The development and function of the mammary gland requires extensive
remodeling throughout the reproductive lifespan of an individual. Dynamic tissues are
inherently sensitive to tumorigenesis. Frequent proliferative episodes expose relatively
long-lived mammary stem and progenitor cells to transformation and tumor initiation
(261). Gene expression analysis reveals that breast cancer is a heterogeneous disease
that can be separated into several subtypes, including luminal A, luminal B, HER2enriched and basal-like. The intrinsic subtypes of breast cancer demonstrate distinct
etiology, progression, and clinical behaviors (291, 427, 429). Sources of breast cancer
heterogeneity include cell of origin and the nature of the genetic and epigenetic
alterations within the individual tumor (65).
The stromal microenvironment is essential the normal development and function
of the mammary gland. Extrinsic control of the cell proliferation and stem cell properties
is an important barrier to breast tumorigenesis (6). Changes in the extracellular matrix
and non-malignant cell types within the stromal microenvironment are essential to
malignant progression (2-7). Until relatively recently, mainstream breast cancer
research efforts have concentrated on the relationships between tumor genetics, cancer
cell signaling pathways, and cellular properties of the tumor epithelium. From these
efforts, therapeutic targeting pathways essential to tumor growth and progression have
been developed. Therapeutic targeting of estrogen signaling and HER2 have
dramatically increased the survivability of subsets of breast cancer patients (331, 464,
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468, 469). Advances in breast cancer screen, diagnosis, surgery, and the administration
of chemotherapy have also been critical to the declining mortality of breast cancer
patients (30).
Given the tumor suppressive effects of the normal mammary stroma (6) and the
importance of an altered stromal microenvironment to breast tumor progression (2-7),
essential microenvironmental factors may represent promising therapeutic anti-cancer
targets. A critical advantage of targeting the tumor microenvironment are not
susceptible is the lack of selective pressures driving therapeutic resistance in tumor
cells. In this dissertation, disequilibrium between NE secreted by activated-neutrophils
in the tumor microenvironment and its epithelial-secreted inhibitor elafin is explored.
The data presented suggests that deregulated NE-activity is an important factor in
tumor growth and a therapeutic target in breast cancer.
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NEUTROPHIL ELASTASE
Serine Proteases
More than two-percent of the human genome encodes proteases and 18% of
sequences deposited in the SwissProt database have been annotated as undergoing
proteolysis. Overall, there are 611 proteases in the human genome and 388 nonfunctional homologs that have lost residues critical to proteolytic activity (488). The
sheer abundance of proteases, attest to their importance in biology. Proteases have
evolved to function under a variety of physiological conditions; variables include pH and
oxidation state. Early biochemical work on proteases, concentrated on defining their
catalytic mechanism. These studies identified five distinct proteases classes, aspartic,
cysteine, metallo, serine, and threonine. Glutamic proteases have also been identified
but are not found in mammals (489, 490).
Serine proteases, characterized by a reactive serine residue at their catalytic
core, are one of the largest and most divergent groups of mammalian proteases (489).
Classically viewed as unrefined agents of protein catabolism, many serine proteases
are now understood to be highly preferential in their choice of substrates. Pioneering
work on the activation of trypsinogen and the mechanism of blood clotting revealed that
limited proteolysis can result in altered activity and function (491-493). Proteolytic
processing has the ability to rapidly and profoundly alter diverse cellular and
physiological processes through irreversible post-translational modification of protein
structure and consequently molecular function. Accordingly, serine protease activity is
tightly regulated under normal physiological conditions by redundant mechanisms;
including endogenous inhibitors, compartmentalization, and expression as zymogens.
Inappropriate serine protease activity plays an important role in the etiology and/or
pathogenesis of many disease states, including cancer.
Neutrophil Elastase
Neutrophil elastase (NE) belongs to the chymotrypsin superfamily of serine
proteases. NE has two catalytically active homologs, proteinase 3 (PR3) and cathepsin
G (CG), created by duplication of an ancestral protease gene. Azurocidin shares
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significant sequence and structural homology with NE, PR3, and CG, but lacks protease
activity (494). NE, PR3, and CG are collectively referred to as neutrophil serine
proteases (NSPs), due to their predominate expression in the neutrophil lineage. NE
and CG are also expressed in mast cells and monocytes, but at comparatively low
levels (495). NE is transcribed from the ELA2 gene on chromosome 19p13.3, which is
adjacent to the PR3 gene, PRTN3. CG is transcribed from the CTSG gene residing on
chromosome 14q11.2. NSPs share a similar gene structure, consisting of five exons
and four introns (494, 496).
Neutrophil Elastase Synthesis
NE is normally synthesized in the bone marrow during myeloid-differentiation
and packaged into the azurophilic granules of neutrophils, along with PR3 and CG
(497). Neutrophils contain four types of granules, azurophilic granules (primary),
specific granules (secondary), gelatinase granules (tertiary), and secretory granules.
Neutrophil granules are generated sequentially during differentiation. NSPs are
abundantly expressed during the promyelocytic phase of neutrophil differentiation
corresponding with the generation of azurophilic granules. Conserved PU.1, C/EBP,
and c-Myb binding sites within the promoter sequence of NSPs drive their expression in
promyelocytes (498). In addition to NSP, high concentrations of myeloperoxidase,
azurocidin, bacterial permeability increasing protein, and defensin are contained within
the azurophilic granules. The generation of azurophilic granules is limited to the
promyelocyte. As promyelocytes differentiate into myelocytes, the NSP expression is
downregulated. NSPs are not detected in specific granules, which are packaged in
myelocytes (499). The intracellular concentration of NE in neutrophils is in excess 5 mM
(500)
Neutrophil Elastase Activation
NSPs are synthesized in an inactive “pre-pro” form containing a signal sequence
and a pro-dipeptide (Ser14-Glu15). Prior to being packaged into the azurophilic
granules, pre-pro NE is rapidly processed into its active form first by a signal peptidase
and then by a cysteine protease, dipeptidyl peptidase I (DPPI or cathepsin C). NE is
also processed at the C-terminus by an unidentified protease. C-terminal processing of
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NE does not affect protease activity; instead it creates a docking site for adaptor protein
3 (AP3), responsible for protein shuttling NE between the golgi and granule (501).
Cleavage of the N-terminal pro-dipeptide of NE by DPPI is a crucial step in NE
activation. Following removal of the pro-dipeptide, the free amino group of isoluecine
16 forms a salt bridge with the carboxylate side-chain of aspartate 194 opening the
active site to substrates (502-504). Loss of function mutations in DPPI results in the loss
of NSP activity, underlying the rare genetic disease Papillon-Lefevre syndrome (PLS).
Patients with PLS suffer from periodontal disease, palmoplantar keratosis, and high
susceptibility to systemic infection (505).
Neutrophil Elastase Structure and Function
Active NE prefers to cleave next to small, hydrophobic amino acids (P1
according to the Schechter and Berger notation), especially valine, isoleucine, and
alanine. The substrate specificity of NE overlaps with related NSPs (esp. PR3, 60%nucleotide similarity). However, the distribution of charged amino acids surrounding
their active sites endows each NSP with specificity in substrate recognition (506). NE is
a neutral serine protease, demonstrating the highest degree of activity at pH 7.0.
As with all members of the chymotrypsin superfamily, NE cleaves peptide bonds
using a charge relay system composed of three essential residues, histidine, aspartate,
and serine, collectively referred to as the catalytic triad. The residues of the catalytic
triad are similarly dispersed throughout the peptide sequence of chymotrypsin-like
proteases (i.e. histidine 57, aspartate 102, and serine 195), however they are brought
into close physical proximity by the three-dimensional structure of the protease.
The three dimensional structure of NE consists of two highly similar β-barrels
(six anti-parallel β-sheets) connected by a linker segment and a C-terminal α-helix. Four
disulfide bonds play a critical role in stabilizing the three-dimensional structure of NE.
The catalytic residues are located at the junction of the β-barrels. The active site of the
NE runs along the β-barrels perpendicular to the catalytic amino acids (507). A
substrate binds to the active site of NE with the sissle bond in close proximity to the
reactive serine. The –OH group on the serine acts as a nucleophile, attacking the
carbonyl carbon of the sissle bond and forming a covalent bond with the substrate. The
nitrogen on the histidine residue accepts the -H from the serine –OH and electrons from
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the oxygen of the carbonyl carbon, forming a tetrahedral intermediate. Electrons from
the peptide bond between the carbonyl and amino groups of the substrate then attack
the hydrogen of the histidine, the bond is broken and the N-terminal portion of the
peptide is released. The electrons residing on the nitrogen of the histidine reconstitute
the bond, forming an acyl-enzyme intermediate. A molecule of water is used to replace
the N-terminus of the cleaved peptide, again through nucleophilic attack of the carbonyl
carbon, resulting in the formation of another tetrahedral intermediate. Then the
electrons from the bond between the serine and carbonyl carbon attacks the hydrogen
on the histidine followed by double bonding of the carbonyl carbon to the oxygen,
resolving the tetrahedral intermediate, releasing the C-terminal portion of the cleaved
peptide, and resetting the active site of the protease (508).
A list of biologically relevant NE substrates is presented in Table 3.
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Neutrophil Elastase Substrates
Extracellular Receptors
NE Substrate
IL-2Rα(509)
TNFRII (TNFRSF1B)(510)
CXCR1(511)
CD2(512)
CD4(512)
CD8(512)
CD14(513)
CD40(514)
CD43 (siaiophorin)(515)
CD80(514)
CD86(514)
Urokinase Receptor (CD87)(516)
Complement Receptor 1(517)
Granulocyte colony stimulating factor
receptor (G-CSFR)(518)
Proteinase-activated receptor-1
(PAR1)(519, 520)
Proteinase-activated receptor-2 (PAR2)
(519, 521, 522)
Proteinase-activated receptor-3
(PAR3)(523)

Biological Significance
Inhibition, Impairment of T-cells
Reduced TNFα binding and inhibition of
response
Inhibition of IL-8 signal transduction,
impaired activation of neutrophils
Inhibition, Impairment of T-cell activation
Inhibition, Impairment of T-cell activation
Inhibition, Impairment of T-cell activation
Inhibition of Toll-like Receptor 4
responsiveness to bacterial LPS
Inhibition, Impairment of Dendritic Cells
Enhanced T-cell adhesion
Inhibition, Impairment of Dendritic Cells
Inhibition, Impairment of Dendritic Cells
Inhibition, Inability to bind urokinase
Inhibition, Insensitivity to complement 3b
Inhibition, negatively impacts
granulopoiesis
Inhibition, prevents thrombin induced
activation
Activation of the ERK signaling pathway
Inhibition, prevents thrombin induced
activation

Cytokines, Chemokines, Growth Factors, and Immune Modulators
NE Substrate
Chemokine (C-C motif) ligand 15
(CCL15)(524)
Complement 3(525, 526)
Complement 5(527)
Granulocyte colony stimulating factor (GCSF)(518)
Tumor Necrosis Factor alpha (TNFα)(528530)
Vascular endothelial growth factor
(VEGF)(531)
IL-1β(532)
IL-2(533)

Biological Significance
Activation/liberation of circulating CCL15,
monocyte activation
Cleavage of C3bi into isoforms similar to
C3c and C3d
Cleavage of C5a into isoform similar to
C5b
Inhibition, negatively impacts
granulopoiesis
Conflicting results, may degrade or
activate TNFα
Altered affinity for VEGF receptors,
stimulates Akt activation and chemotaxis
Activation of Pro- IL-1β
Inhibition, Impairment of T-cells migration
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IL-8(534)
IL-18(535)
Macrophage inflammatory protein-1α
(CCL3)(536)
Stromal cell-derived factor-1 (SDF-1 or
CXCL12) (537)
Proepithelin/Progranulin (538, 539)

and adhesion
Inhibition, reduced activation of NF-κB
Inhibition of IFNγ expression
Generation of isoforms with reduced
chemotactic capabilities
Inhibition, reduced chemotactic
capabilities
Degraded, causing enhanced activation of
pro-inflammatory signaling

Transcription Factors and Modulators of Intracellular Signaling
NE Substrate
Cut-like homeobox 1 (CUX1)(540)
Cyclin E(541)
Insulin Receptor Substrate 1 (IRS-1)(542)
PML-RARα(543)
NF-κB p65(544)
Notch 2 N-terminal Like (NOTCH2NL or
N2N)(545)
STAT3 α-isoform(546)

Biological Significance
Generation of a hyperactive p110 isoform
Generation of isoforms, hyperactive in
their ability to activate CDK2
Degraded, enhanced PI3K-AKT activation
Cleavage required for initiation of acute
promyelocytic leukemia in mouse model
Diminished NF-κB activation
Inhibition of Notch2 signaling
Generation of STAT3 γ-isoform

Adhesion Molecules and ECM Components
NE Substrate
E-cadherin(547)
Collagen(548)
Cadherin-5 (Vascular-Endothelial
Cadherin)(549)
Intercellular adhesion molecule 1 (ICAM1)(550)
Laminins(551, 552)
Fibronectin(552, 553)
P-selectin glycoprotein ligand-1 (554)
Aggrecan(555)
Elastin(556)

Biological Significance
Reduced intracellular adhesion
Degradation, alteration of ECM
composition
Reduced adhesion of endothelial cells,
permissive of neutrophil transmigration
Reduced recruitment and transmigration of
immune cells
Generation of bio-active peptides with
chemotactic properties
Generation of bio-active peptides
Reduced recruitment and transmigration of
immune cells
Disruption of proteoglycan structures
Degradation, alteration of ECM
composition

Proteases and Protease Inhibitors
NE Substrate
Matrix metalloproteinase-2(557)

Biological Significance
Activation of protease activity
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Matrix metalloproteinase-3(558)
Matrix metalloproteinase-9 (559)
Merpin α(560)
Elafin(561)
C1-inactivator(562)
Tissue inhibitor of matrix
metalloproteinase-1 (TIMP-1)(559, 563)
Cystatin C(564)
α2-plasmin inhibitor(562)
Secretory leukocyte peptidase inhibitor
(SLPI)(565)

Activation of protease activity
Activation of protease activity
Activation of protease activity
Inability to bind the ECM and loss of
protease inhibitor capability
Loss of protease inhibitor capability
Loss of protease inhibitor capability
Loss of protease inhibitor capability
Loss of protease inhibitor capability
Inability to bind the ECM and loss of
protease inhibitor capability

Blood Clotting
NE Substrate
Von Willebrand factor (vWf)(566)
Platelet integrin (αIIβ3, ITGA2B) (567)
Coagulation factor IX(568)
Coagulation factor V(569)
Heparin cofactor II (570)
Tissue factor pathway inhibitor(571)
Kininogens(572)
Antithrombin-III(573)

Biological Significance
Release of vWf from endothelial cells
Enhanced integrin function, platelet
aggregation
Activation
Increased association with factor Xa
Inability to inhibit thrombin
Reduced ability to inhibit factor VIIa/tissue
factor
Generation of bioactive kinins, enhanced
vasodilatation and smooth muscle
contraction
Inactivation, inability to inhibit thrombin

Regulation of Blood Pressure
NE Substrate
Angiotensin-1(574)
Angiotensin-2(574)
Angiotensinogen(574)

Biological Significance
Local vasodilatation
Local vasodilatation
Local vasodilatation

Lipid Metabolism
NE Substrate
Apolipoprotein A-II(575)
Apolipoprotein(a)(576)

Biological Significance
?
?

Insulin Signaling
NE Substrate
Insulin β-chain(577)

Biological Significance
?
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Insulin-like growth factor binding protein 3
(IGFBP3)(578)

Alteration of IGF binding

Other
NE Substrate
IgG heavy chain(579)
Actin(580)
Pulmonary surfactant-associated protein
D(581)
Ribonuclease L(582)

Biological Significance
Immune dysfunction
?
Impaired anti-microbial and immune
functions
?

Table 4: Experimentally Confirmed NE Substrates and the Biological Significance of their
Modification.
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Role of NE in Neutrophils in Inflammation and Immunity
Circulating neutrophils normally have a half-life of only a few hours, however
they are constantly renewed from stem cells in the bone marrow and are the most
abundant leukocyte in the bloodstream (comprising 60% of circulating leukocytes in a
healthy individual) at a concentration of 1.5 to 5 x109 cells/liter (506). Neutrophils are a
critical component of the innate immune system. Neutropenia, an abnormally low
number of neutrophils in the systemic circulation, dramatically increases susceptibility to
bacterial infections and can lead to life threatening sepsis, evidencing the importance of
neutrophils immunity. Neutropenia is a common side effect in patients undergoing
cancer chemotherapy and can increase susceptibility to developing systemic infection.
Rare genetic diseases, cyclic neutropenia and severe congenital neutropenia commonly
harbor mutations to the ELA2 gene, and less frequently in genes involved in the normal
trafficking of NE, or genes involved in the transcription of NE. The mutant forms of NE
mislocalize and accumulate within neutrophils, however the mechanism by which
mislocalized NE results in neutropenia has not yet been defined (501).
In healthy individuals, neutrophils are the first inflammatory cell type to leave the
vasculature following infection or wounding. Neutrophil chemotaxis requires the release
of chemotactic cues, such as IL-8, complement 5a, leukotriene B4, and N-formylmethionyl-leucyl-phenylalanine (fMLP), from the inflammatory site. Neutrophils contain
four types of granules, azurophilic granules (primary), specific granules (secondary),
gelatinase granules (tertiary), and secretory granules. These granules contain a wide
rande of antimicrobial factors, protease, and ROS. Also contained within neutrophil
granules are number of membrane bound receptors including CD11b/CD18 and fMLP
receptor, which are essential to neutrophil activation and chemotaxis. The intracellular
mobilization of granules is essential to the activation and immune functionality of
neutrophils.(583, 584).
The major physiological function of NE is the intracellular destruction of
pathogens, following phagocytosis at sites of infection. Once engulfed by a neutrophil,
pathogens are sequestered in a membrane bound vesicle, know as the phagosome.
Fusion of the phagosome with a lysosome creates the phagolysosome, triggering the
exposure of the pathogen to massive quantities of reactive oxygen species (ROS)
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generated by membrane-bound NADPH oxidase. The phagolysosome containing the
pathogen then fuses with neutrophil granules releasing NSPs and antimicrobial
compounds, which synergies with ROS in the intracellular destruction of pathogens.
Consistent with its important role in innate immunity, NE knockout mice deficient in
intracellular killing of gram-negative bacteria and are susceptible to infection (500).
Role of Extracellular NE
Non-resolving inflammation and the presence of inflammatory cells in the tumor
microenvironment are regarded as essential components of tumor progression (9, 10).
Activated neutrophils also secrete NE into the microenvironment through limited
exocytosis of azurophilic granules (585). Neutrophils degranulate, releasing NE, in
response to a variety of chemokines, cytokines, and bacterial derived chemotactic
peptides, including IL-8, TNF-α, C5a, fMLP, and LPS (586) A portion of highly cationic
NE associates with the neutrophil cell surface through electrostatic interactions with
negatively charged proteoglycans (587, 588). Neutrophils are the first responders of the
immune system and secreted NE is an important component of the early anti-microbial
and inflammatory responses. In this context, NE is essential to the formation of
neutrophil extracellular traps NETs, complexes formed by the extracellular association
of NSPs, antimicrobial peptides, chromatin DNA, and histones. The high concentration
of NSPs associates with NETs allows for extracellular killing of microbes and digestion
of virulence factors. NE also participates in extracellular ECM remodeling, cleaves cell
adhesion molecules, and alters inflammatory/growth factor signaling networks,
contributing to the immune response, resolution of infection, and wound healing (589).
Extracellular NE and Cell Signaling
NE promotes activation of toll-like receptor 4 (TLR4), inducing NF-κB
activation mediated by MyD88/IRAK/TRAF-6, and ultimately the expression of
inflammatory cytokines such as IL-8 (590). The epidermal growth factor receptor
(EGFR) may also play a role in the NE-induced activation of pro-inflammatory signaling.
Following cleavage by NE the MMP, meprin α, is activated leading to the activation of
pro-TGFα, which in turn results in activation of EGFR (560). Immunoprecipitation
studies found an association between TLR4 and EGFR following NE simulation and is
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essential to NE-induced IL-8 expression (560). NE can also activate the EGFR through
the liberation of latent growth factors trapped by the ECM or adhered to the cell
membrane (506). Proteinase activated receptor 2 (PAR2) belongs to a family of Gcoupled protein receptors that are activated following cleavage of their N-terminal
extracellular domains. Several proteases cleave PAR-2, including NE, which activates
ERK signaling (521). NE also cleaves PAR-1, inhibiting its activation by thrombin (520)
The chemokine stromal cell-derived factor1α (SDF-1α or CXCL12) and its receptor
CXCR4 play a critical role in the trafficking of lymphocytes. Cleavage of SDF-1α and
CXCR4 by NE inhibits their activation (591). Progranulin (or pro-epithelin), suppresses
inflammation by modulating neutrophil activation and preventing the release of NSPs
and reactive oxygen species (ROS). NE and PR3 were found to cleave progranulin in
vitro. In mice deficient in both PR3 and NE, demonstrate a blunted inflammatory
response and progranulin accumulation following inflammation induced by immune
complexes (538).
Imbalance between NE and its Inhibitors in Inflammatory Disease
Following physiological inflammation, serine protease inhibitors rapidly quench
NE activity, inflammation resolves, and tissue homeostasis is restored (506). However,
in disease states characterized by chronic or excessive inflammation and neutrophil
accumulation, such as emphysema, chronic obstructive pulmonary disease (COPD),
(11) and inflammatory bowel disease (IBD) (15), an imbalance between NE and its
inhibitors results in symptomatic tissue destruction, perpetuates inflammation, and is
critical to disease pathogenesis (11). Deregulated NE activity has been implicated in a
variety of inflammatory disease states. NE dramatically alters the immune response by
proteolytically altering or degrading a wide rand of cytokine, chemokines, angiogenic
factors, growth factors, complemtent, and cell surface receptors.
In animal models, pharmacological inhibition of NE reduced granulocyte
accumulation and microvascular dysfunction following ischemia-reperfusion of skeletal
muscle (592), prevents the progression of acute lung injury following endotoxin
inhalation (593), and decreased the severity of collagen-induced arthritis (594). DPPI
knockout mice, deficient in the activation of NSPs, are also protected from experimental
arthritis, demonstrating a local decrease in inflammatory makers (595). NE knockout
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mice are protected from development of the autoimmune disease, bullous pemphigoid
characterized by subdermal blistering (596). Chronic inflammation and the recruitment
of neutrophils to the adipose tissue and liver play an integral role in insulin resistance.
NE knockout in obese mice fed a high fat diet reduced inflammation, improved glucose
tolerance, and enhanced insulin sensitivity compared to wild-type littermates (597).
Taken together these studies suggest a prominent role for NE in the pathogenesis of
chronic inflammatory disease.
COPD is characterized by limited airflow within the lungs and progressive loss of
the lung epithelium. The airways of healthy individuals is sterile, however in patients
suffering from COPD bacteria are able to colonize the lung and stimulate massive
neutrophil infiltration. COPD is a significant and growing cause of morbidity and
mortality within the population. NE is believed to be critical to the degradation of the
ECM and destruction of the lung parenchyma. Treatment of COPD patients with NEinhibitors has been hypothesized to improve lung function. NE inhibitors, such as
AZD9668, have been developed for the treatment of COPD. Limited phase one and two
studies have shown that AZD9668 is well tolerated, however it did not significantly
enhance lung function (598).
Role of Neutrophil Elastase in Tumorigenesis
In the tumor microenvironment the majority of NE is contributed by activated
neutrophils. In breast cancer patients, high levels of NE are prognostic of poor overall,
metastasis-free, and disease-specific survival, and are predictive of resistance to
therapy, suggesting a possible role for neutrophils and NE in tumor progression (12,
599-601). High levels of NE are also found in the tumors of patients with bladder
cancer, lung cancer, and pancreatic cancer (12, 601-605).

A recent study

demonstrates that NE knockout in the loxP-Stop-loxP K-rasG12D mouse model of lung
cancer severely limits tumor growth and proliferation, providing direct in vivo evidence
of a role for NE in tumorigenesis (542). Sivelestat, a pharmacological inhibitor of NE,
was able to reduce the proliferation, motility, and chemotaxis of the pancreatic cancer
cell line Capan-1 in vitro (603). In a mouse xenograft model of non-small cell lung
cancer using the EBC-1 and PC-1 cell lines, sivelestat attenuates proliferation and
metastasis (606). Sivelestat also inhibited spontaneous metastasis of EBC-1 xenograft
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tumors (607). Beige mice are deficient in NE (608). A mutant strain of NE-deficient mice
was created by crossing beige mice with SKH 1 hairless mice. Following ultraviolet
irradiation, NE-proficient mice developed 10 tumors per mouse after 20-weeks, while
NE-deficient mice developed only 0.4 tumors per mouse over the same period. In the
same system, benzopyrene exposure resulted in the formation of 7 tumors per control
mouse and only 0.2 tumors per NE-deficient mouse. Pharmacological inhibitors of NE,
2,4,6-trinitrochlorobenzene and oxazolone were able to attenuate the development of
skin tumors following ultraviolet irradiation (609). NE knockout in the loxP-Stop-loxP KrasG12D mouse model of lung cancer was able to severely limits tumor growth and
progression compared to NE-proficient mice (542).
Extracellular NE
The conventionally understood role of NE in tumor progression is largely
extrapolated from the contributions of extracellular NE to chronic inflammatory disease,
particularly emphasizing the importance of NE in tumor cell invasion and metastasis
through ECM degradation and the cleavage of adhesion proteins (610, 611). NE has
the ability to cleave the majority of ECM element and is known to activate a number of
other tissue degrading proteases including MMP-2, MMP-3, and MMP-9 (559) (612,
613). NE also cleaves adhesion molecules including E-cadherin (550, 614, 615).
Intracellular NE
Several recent studies demonstrate a novel functional context for NE in
directly altering intracellular signaling. In these studies, the ability of cancer cells to
endocytose NE from the microenvironment (542, 585, 616) or inappropriately express
intracellular NE (541, 617) promotes proliferation and tumor progression through
specific intracellular proteolytic events. The intracellular cleavage of cyclin E by NE
generates low-molecular weight cyclin E isoforms (LMW-E) known to hyper-activate
cyclin-dependent kinase 2 (CDK2) (541, 618, 619). LMW-E is prognostic of poor overall,
metastasis-free, and disease-specific survival in breast cancer patients (620), induces
genomic instability and cellular transformation in vitro (621, 622), and can drive mouse
mammary tumorigenesis in a CDK2-dependant fashion (623, 624).
Intracellular NE also acts through degradation of Insulin Receptor Substrate-1
(IRS-1). Reduced levels of IRS-1 increase phosphatidylinositol 3-kinase (PI3K) activity

75

through enhanced association with the platelet-derived growth factor receptor (PDGFR),
ultimately promoting Akt activation. In human lung adenocarcinoma, NE and IRS-1
expression are inversely correlated, suggesting that NE-mediated degradation of IRS-1
is relevant to human lung cancer progression (542). Through the proteolysis of a
repertoire of extracellular and intracellular substrates, NE plays a critical role in
deregulation of many processes and pathways known to promote tumor progression.
NE has been implicated in the pathogenesis of acute promyelocytic leukemia
(APL). A significant portion of APL patients harbors a fusion protein consisting of the
promyelocytic leukemia gene and the retinoic acid receptor alpha (PML-RARα). NE
cleaves the fusion protein PML-RARα in both mouse and human APL and is required
for disease progression in mouse models of the disease (543).
In acute myeloid leukemia (AML), the p200 form of transcription factor CUX-1
(CCAAT Displacement Protein) is cleaved by NE into a shorter p110 form, which is
hyperactive in its ability to stimulate promoter activity. CUX-1 (p110) is known to
increase gene transcription associated with proliferation, motility, and invasion. CUX1(p110) is overexpressed in breast cancer. Mammary specific overexpression of CUX
(p110) drives tumor formation and lung metastasis; indicating that the cleavage of CUX1 by NE may be important in breast cancer (540, 625).
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ELAFIN
Discovery of Elafin
Early reports describe a low-molecular weight inhibitor of elastase-like activity in
the bronchial mucus of human subjects. Failure to detect this protease inhibitor in the
serum of these subjects suggested to the authors that it was produced locally in the
lung, a critical distinction from previously identified elastase inhibitors (626, 627).
Subsequent studies identified a serine protease inhibitor, termed elafin, in skin lesions
associated with the autoimmune disease psoriasis. These reports revealed that elafin is
a highly specific and potent inhibitor of porcine pancreatic elastase (PPE), NE, and PR3
activity (13, 628) with significant sequence similarity to previously identified secretory
leukocyte protease inhibitor (SLPI) (629). Nearly concurrent identification by several
groups and expression as multiple isoforms has resulted in multiple designations,
including skin-derived antileukoprotease (SKALP) and elastase specific inhibitor (ESI),
however elafin is the consensus nomenclature used in this dissertation (630).
Elafin Structure
Elafin is expressed from the gene PI3 located on the chromosomal region 20q13
in close proximity to several structurally related genes (631). The PI3 gene is composed
of three exons separated by two introns. Following translation elafin is 117 amino acids
in length. The N-terminal signal peptide is cleaved in the endoplasmic reticulum
reducing the length of elafin to 85 amino acids (approximately 9 kDa). Following
cleavage of the signal peptide, elafin is secreted via the canonical secretion pathway.
Elafin contains two critical domains: 1) a N-terminal transglutaminase linking
domain, referred to as the cementonin, and 2) a C-terminal globular domain stabilized
by four-disulfide bonds. This four disulfide bond structural motif first observed whey
acidic protein (WAP) an abundant component of milk in rodent and is therefore refered
to as a WAP domain (630). The cementonin domain consists of Gly-Gln-Asp-Pro-ValLys repeats that serves as a substrate for the enzyme transglutaminase, which
catalyzes the covalent cross-linking of elafin to ECM components. Some non-canonical
functions of elafin, such as the ability to bind LPS, have been shown to be dependent

77

on the cementonin-domain (632). The N-terminal region of elafin could not be resolved
by crystallography because of its disordered conformation. Circular dichroism and
nuclear magnetic resonance (NMR) analyses reveal that in the presence of membrane
lipids the disordered N-terminal region adopts a α-helical secondary structure (633).
The C-terminal WAP-domain contains the protease inhibitory loop. The WAP-domain of
elafin can be released from the cementonin domain by proteolytic cleavage, generating
a 57-amino acid form of elafin (approximately 6 kDa). Removal of the cementonin
domain does not effect the protease inhibitor activity of elafin, however in the absence
of the cementonin domain elafin can no longer bind the ECM (561).
Physical Interaction between Elastase and Elafin
Elafin non-covalently binds to the catalytic cleft of the target protease blocking
access of substrates. This mechanism of action differs from serpins, such as α1antitrypsin. Serpins bind to the target protease and form a covalent linkage,
permanently disabling the active site. The crystal structure of the C-terminal globular
domain of full-length elafin in complex with PPE has been resolved (634), as well as the
NMR structure of elafin alone (635). The conformation of elafin consists of a central βsheet stabilized by three disulfide bonds. The protease inhibitory loop is connected to
the central β-sheet by two external peptide chains and is stabilized by the fourth
disulfide bond. The protease inhibitor region is located between amino acids Leu20(P5)
and Leu26(P2’). The side chains of the residues making up the inhibitory loop of elafin
forms four hydrogen bonds and with the PPE active site, Ser214(S5)-Arg217(S2’).
Extensive van der Waals interactions are also formed between the protease inhibitor
domain of elafin (P5-P2’) and the active site of PPE (S5-S5’). The sissle peptide bond is
between Ala24(P1) and Met25(P1’). The Ala24 carbonyl group projects into the
oxyanion hole created by nitrogen atoms of Gly193 and Ser195 of PPE, disfavoring
catalysis. A secondary site of interaction between elafin Ser48, Cys49, and Ala52 and
PPE Asp97 and Val99, further stabilizes the interaction between protease and inhibitor
through hydrogen bonding and van der Waals interaction (634, 635).
Oxidation of Ala24(P1) or Met25(P1’) reduces the ability of elafin to inhibit PPE,
further evidencing the importance of these residues (634, 635). Replacing the
Met25(P1’) with either a lysine or glycine residue attenuates the ability of elafin to inhibit
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NE and PR3, the glycine substitution is completely ineffective at inhibiting NE (636).
The WAP-domain of PI3 and the C-terminal WAP-domain of SLPI (two WAP domains)
share significant sequence similarity and are believed to have share a common
ancestor, however the protease inhibitory domain of SLPI has the ability to inhibit
trypsin, chymotrypsin, NE, and cathepsin G, but not PR3. The P1 residue appears to
govern specificity; the P1 residue of elafin, Ala24, is too small to interact with the S1
pocket of chymotrypsin. Comparatively, the P1 residue of SLPI, Leu72, is large enough
to inhibit chymotrypsin activity (634, 635).
Evolution of WAP-Domain Containing Genes
Fourteen human WAP-domain containing genes are spread over a 683 kb
stretch of chromosome 20q13. The clustering of WAP-domain containing genes
suggests repeated duplication during evolution. Several WAP-domain containing
proteins are encode by genes outside of the 20q13 cluster including WFIKKN,
WFIKKN2, and ps20. Some of the WAP-domain containing proteins are known to have
protease inhibitory function, including elafin, SLPI, human epididymis gene product 4
(HE4), and eppin, however the majority fail to display anti-protease activity or are
uncharacterized (637). Aside from the cysteine residue required for disulfide bonding,
very little sequence conservation is observed between WAP-domain containing
proteins. Significant functional diversity may exists between WAP-domain containing
proteins, for example the porcine sodium-potassium ATPase inhibitor-2 (SPAI-2) has
the ability to inhibit an intestinal NA+/K+ ATPase (638).
The spectrum of WAP containing proteins is extremely variable between
species. Elafin is a relevant example; there is no rodent homolog of human elafin,
however there are six-elafin homologs in the porcine genome (639). WAP-domain
containing genes have been subject to dynamic change over a relatively short period of
evolutionary time. Comparison of the human and chimpanzee genomes identifies the
WAP-locus is one of sixteen regions dense in rapidly evolving genes. One reason for
this may be that the genes encoding the semen proteins, semenogelin 1 (SEMG1) and
semenogelin 2 (SEMG2), are found within the WAP-domain containing gene locus. In
primates with polyandrous mating systems the SEMG proteins form a copulatory plug,
however in primates with monoandrous mating systems the SEMG contributes to the
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viscosity of the semen but does not form a plug. The high rate of SEMG evolution is
correlated with differences post-copulatory sperm competition (due to the evolution of
monoandrous and polyandrous mating systems) and semen coagulation (640, 641).
Exon shuffling between an ancestral WAP-domain containing gene and a
SEMG-like gene is responsible for the chimeric structure (cementonin and globular
domain) of trappin family members, such as elafin. The first and third exons of elafin
share sequence homology with SEMG proteins, while the central exon containing a
WAP domain. Trappins and SEMG proteins are collectively referred to as rapidly
evolving substrates for transglutaminase (REST) (642). Elafin is the only trappin in
humans, sequence similarity with SLPI is restricted to the WAP domain (630).
The Role of Elafin in Immunity and Inflammation
Elafin Expression
Systemic

serine

protease

inhibitors,

such

as

α1-antitrypsin

and

α1-

antichymotrypsin, are expressed by the liver and distributed throughout the body by the
circulatory system. A germline mutation in the SERPINA1 gene (α1-antitrypsin) results
in the accumulation of α1-antitrypsin in the liver and deficiency within the circulation,
resulting in severe COPD, emphysema, liver cirrhosis, and several other inflammatory
diseases (643, 644). Systemic serine protease inhibitors provide baseline control of
deregulated protease activity. Elafin and other “alarm-proteases” are expressed at high
concentration by epithelial cells, providing local anti-protease coverage where systemic
inhibitors may be inadequate (645, 646). Epithelial cells express elafin either
constitutively or in response to inflammatory cytokines, such as IL-1β and TNF-α (13,
647). The p38 MAPK, c-JUN, and NF-κB pathways drive elafin expression downstream
of inflammatory cytokines (646, 648, 649). The inducible expression of elafin is
especially evident in the epidermis. The normal epidermis does not express elafin,
except for the keratinizing cells surrounding the sweat duct and hair follicles. However,
under inflammatory conditions, associated with the hyperproliferative disease psoriasis
or wounding, elafin is highly expressed in the epidermal layer. Elafin expression in the
inflamed epidermis is correlated with the amplitude of neutrophil influx (650-653).
Larynx, lung, kidney, liver, and urthera are all elafin negative under non-inflammatory
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conditions (647). Compared to the related serine protease inhibitor SLPI, elafin
demonstrates much greater cytokine-mediated induction, suggesting that elafin has an
especially important anti-protease role following inflammatory stimulus (645).
Constitutive elafin expression has also been observed in mucosal tissues, for
example the tongue, tonsils, gingiva, epiglottis, esophagus, vagina, and pharynx all
express elafin. In addition to a protease inhibitory role, elafin also boast anti-microbial
and immune functions, which likely underlie its constitutive expression at mucosal
surfaces (647). Interestingly, the fetal tissues including the epidermis express high
levels of elafin, which are downregulated at birth (647). Elafin expression by
macrophages and γδ T-cells has also been reported in response to bacterial ligands
(654). An inflammatory-like reaction is characteristic of tissue remodeling and other
normal homeostatic processes. In the human endometrium, elafin is highly upregulated
during menstruation correlating with the influx of inflammatory leukocytes and
upregulation of inflammatory signaling, suggesting a role for elafin in tissue remodeling
and homeostasis (655).
Protease Independent Functions (Non-Canonical)
Elafin plays a significant role in the immune and inflammatory responses. The
bactericidal effect of elafin is largely due to its highly cationic charge, which allows elafin
to disrupt bacterial membranes. Elafin also possess the ability to bind LPS and
modulate the activity of the toll like receptor (TLR) pathway. Adenoviral overexpression
of elafin reduces neutrophil infiltration and cytokine/chemokine levels in mice treated
with lipopolysaccharide (LPS) (656, 657). Elafin also mediates anti-microbial immunity
through interactions with the innate and adaptive immune response. Elafin can
opsonize bacteria, activate antigen-presenting cells, and act as a neutrophil chemoattractant (632, 633). The antibacterial capacity of elafin against both gram-positive and
gram-negative strains has been demonstrated in vitro and in vivo (20, 632, 658) Elafin
has anti-fungal activity that could be disrupted by high salt and heparin implicating its
cationic charge (659, 660). Elafin is an important component of the mucosal barrier to
retroviral infection. Elafin blocks viral attachment, entry, and replication in experimental
models (661-664). Commercial sex workers expressing high levels of vaginal elafin are
resistant to HIV infection (662, 665). Although not directly tested, the available
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mechanistic data suggests that immune functions discussed here are largely
independent of the protease inhibitor domain and require the cementonin domain of fulllength elafin.
Imbalance between NE and Elafin
Elafin is a critical component of the epithelial barrier to NE-activity. Imbalance
between NE and its inhibitors is implicated in the pathogenesis of a wide range of
diseases characterized by excessive or chronic inflammation (15). Low levels of elafin
and corresponding high levels of NE are observed in the serum of patients suffering
from acute respiratory distress syndrome (ARDS) (14). A polymorphism in the elafin
gene (Thr34Pro) correlates with a significant reduction in the serum elafin levels and
increases susceptibility to ARDS (666). Compared to healthy individuals, the colon
mucosa of patients with inflammatory bowel disease (both Crohn’s disease and
ulcerative colitis) demonstrates reduced elafin expression and high levels of NE activity
(15, 667). Analysis of bronchoalveolar lavage fluid from patients with acute lung injury
found that elafin levels increased within 48 hours of onset compared to healthy adults.
However, elafin levels decrease over time due to degradation by the 20S proteasome
cooresponding to increased NE activity (16). Elafin levels are also decreased in cases
of bacterial vaginosis and periodontitis (668, 669). Local decrease in elafin expression
within the epidermis enhances pustule formation associated with psoriasis and impetigo
herpetiformis (670-672). In the subset of inflammatory diseases examined, elafin levels
are generally decreased favoring NE.
Consequences of Elafin Overexpression in Mouse Models of Inflammation
Given the important role of NE in regulating inflammation and symptomatic
tissue destruction, the possibility exists that the loss of elafin is a critical factor in the
pathogenesis of inflammatory disease. This hypothesis has been examined in mouse
models of inflammatory disease. Transgenic overexpression or administration of foodgrade bacteria engineered to express elafin protects the colon mucosa from tissue
destruction associated with dextran sodium sulfate induced experimental colitis (667).
Adenoviral deliver of elafin to the lungs of mice significantly reduced acute lung injury
induced by pseudomonas aeruginosa infection (20). Transgenic mice overexpressing
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elafin in the cardiovascular system demonstrate reduced NE-activity, lower levels of
MMPs, and reduced pulmonary hypertension following chronic hypoxia (19). These
mice demonstrate reduced mortality, decreased inflammation, and improved heart
function after viral myocarditis (18) or myocardial infarction (17). Mice pre-treated with
wild-type elafin were resistant to NE-induced tissue destruction and neutrophil aveolisis
in an experimental model of emphysema. However, mice pretreated with mutant elafin
lacking protease inhibitory function was unable to attenuate the pathogenesis of
experimental emphesyma (636). These results indicate that elafin is a critical
counterbalance against NE-activity. Permutations in epithelial elafin expression affect
the integrity of the anti-protease shield and dramatically alter the pathogenesis of
inflammatory disease.
The anti-inflammatory capacity of elafin may extend beyond its anti-protease
activity. Elafin directly reduces NF-κB activation in monocytes exposed to LPS through
a protease-independent, but otherwise undefined effect on the ubiquitantion of IκB
(673). The contributions of these protease independent properties to the antiinflammatory role of elafin have not been sufficiently examined. Elafin is currently being
tested in clinical trials aimed at determining the ability of elafin to modulate postoperative inflammation (674)
Deregulated NE activity drives vascular cell proliferation and intimal thickening
following vascular injury. Transgenic overexpression of elafin in the cardiovascular
system of mice prevents the proliferation of smooth muscle cells and the accumulation
of inflammatory cells following vascular injury (675). Deregulated NE activity may also
play a role in proliferation skin lesions associated with the inflammatory disease
psoriasis. Treatment of the mouse epidermis with NE results in epidermal thickening,
whereas application of elafin can prevent epidermal proliferation(676).
Deregulation of Elafin in Tumorigenesis
Several studies suggest that elafin is downregulated in poorly differentiated
squamous cell carcinomas of the skin, head/neck, and esophagus compared to welldifferentiated tumors, suggesting a role for elafin downregulation in the development of
a poorly differentiated and aggressive tumor phenotype (21, 22, 677). Elafin expression
is absent from the majority of breast tumor derived cell lines when compared to normal
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HMECs (23). The bZIP transcription factor, C/EBP β, is required for elafin expression in
normal HMECs. C/EBP β is expressed as full-length transcriptional activators, termed
liver-enriched activating protein 1 and 2 (LAP1 and LAP2), and a truncated repressor,
termed liver-enriched inhibitory protein (LIP). C/EBP β, a transcription factor required for
mammary gland development and differentiation In the majority of breast cancer cell
lines, elafin is transcriptionally downregulated due to overexpression of a C/EBP β
dominant negative isoform. Dominant negative C/EBP β is predominately expressed (as
a ratio to full-length, activating isoforms) in a large proportion of breast tumors (24).
Recent studies indicate that elafin induces growth arrest and/or apoptosis upon reexpression in cancer cell lines; suggesting that elafin possesses tumor suppressive
activity (678, 679). In breast cancer xenograft models the introduction of elafin, by
intratumoral injection of elafin expressing adenovirus, greatly decreases tumor growth
and progression (25).
In HMECs, the expression of elafin is regulated by C/EBP β transcriptional
elements. C/EBP β is frequently deregulated in breast cancer patients due to
accumulation of the truncated, inhibitory isoform of C/EBP β (24).
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Chapter 2: Imbalance between Neutrophil Elastase and Elafin Promotes Breast
Cancer Progression

INTRODUCTION
NE, a potent serine protease, is normally synthesized in the bone marrow during
myeloid-differentiation and sequestered within the azurophilic granules of neutrophils
(504). NE has broad substrate specificity, preferentially cleaving peptide bonds adjacent
to small hydrophobic amino acids (506). The major physiological function of NE is the
intracellular destruction of pathogens following phagocytosis at sites of infection (500).
Activated neutrophils also secrete NE into the extracellular environment through
exocytosis of azurophilic granules. In this context NE has important roles in the antimicrobial, inflammatory, and wound healing responses. Following normal inflammation,
serine protease inhibitors rapidly quench NE activity and inflammation resolves (506).
Imbalance between NE and its inhibitors is implicated in the pathogenesis of a wide
range of diseases characterized by excessive or chronic inflammation (680).
Pharmacological inhibitors of NE are under development for the treatment of
symptomatic tissue destruction in chronic inflammatory lung diseases (11).
The conventionally understood role of NE in tumor progression is promotion of
cell invasion and metastasis through extracellular matrix degradation and the cleavage
of adhesion molecules (610). However, several recent reports demonstrate a role of NE
in the activation of intracellular signaling pathways during early tumorigenesis. NE was
shown to enhance phosphoinositide 3-kinase (PI3K) activity following the degradation of
insulin receptor substrate-1. In the loxP-Stop-loxP K-rasG12D mouse model of lung
cancer, NE knockout reduces PI3K activity and severely limits tumor growth (542). NE
has also been implicated in cleavage of cyclin E into low-molecular weight isoforms
capable of hyperactivating cyclin-dependent kinase 2 and inducing tumor formation in
mouse models (541, 624). NE activates intracellular signaling through cell surface
receptors, including toll-like receptor 4 (TLR4) (590), proteinase-activated receptor 2
(PAR2) (521), and epidermal growth factor receptor (EGFR) (681), either directly
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through proteolysis of the extracellular domain or indirectly through the
liberation/activation of latent ligands (506).
Elafin is an endogenous inhibitor of NE and the highly related serine protease
proteinase 3. Epithelial cells express elafin either constitutively or in response to
inflammatory cytokines (13, 647). Imbalance between NE and elafin has been observed
in many diseases, including acute respiratory distress syndrome (14), inflammatory
bowel disease (15), and acute lung injury (16). In mouse models, overexpression of
elafin diminishes tissue destruction associated with experimental colitis (15), protects
against acute lung injury (20), reduces pulmonary hypertension following chronic
hypoxia (19), and improves heart function after viral myocarditis (18) or myocardial
infarction (17). Permutations in epithelial elafin expression affect the integrity of the
antiprotease shield and dramatically alter the pathogenesis of inflammatory disease.
Compelling evidence suggests that disequilibrium between NE and its inhibitors
is a critical component in the pathogenesis inflammatory diseases. Inflammation and
the presence of leukocytes in the tumor microenvironment are regarded as essential
components of malignant progression (9). Tumor-associated neutrophils (TAN) are the
major source of NE in the tumor microenvironment. In breast cancer patients, high
levels of NE are prognostic of poor overall (OS), metastasis-free, and disease-specific
survival (12).
Several studies suggest that loss of elafin-mediated control of NE activity may
also be a feature of malignant growth. Elafin is downregulated in poorly differentiated
squamous cell carcinomas of the skin, head/neck, and esophagus compared to welldifferentiated tumors (21, 22). Subtractive cDNA hybridization identified elafin
downregulation in breast cancer cell lines compared to HMECs (23). The transcription
factor, C/EBP β, is required for elafin expression in normal HMECs. C/EBP β has critical
roles in the regulation of cell proliferation and mammary gland development (24, 682684). In the majority of breast cancer cell lines, elafin is transcriptionally downregulated
due to overexpression of a C/EBP β dominant negative isoform. Dominant negative
C/EBP β is predominately expressed (as a ratio to full-length, activating isoforms) in a
large proportion of breast tumors, suggesting that elafin is downregulated in these
breast tumors (24). However, no published study has comprehensively investigated the
expression of elafin during breast tumor progression.
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HMECs as an In Vitro Model System
No direct homolog of elafin exists within the mouse genome. Therefore, we
utilized primary and immortalized HMECs as a model system to interrogate the role of
elafin in the mammary epithelium (685, 686). HMECs are derived from freshly
disassociated reduction mammoplasty or mastectomy tissue specimens. In some
cases, HMEC cell lines have been generated from epithelial cells shed into human
breast milk. Primary HMEC cultures contain a heterogeneous population of cells;
including luminal epithelial cells, myoepithelial cells, stem/progenitor cells, and
fibroblasts (687, 688). In culture, purified HMECs stop proliferating and become
senescent after several passages. Early experiments found that HMECs could be
immortalized by exposure to mutagenic insult, such as benzo(a)-pyrene and γ-radiation,
however the frequency of immortalization was extremely low and the permissive genetic
alterations were unknown (689).
A refined model of HMEC growth and arrest in culture, following their derivation
from human tissue explants, has lead to the creation of systems for the evaluation of
normal breast epithelial cell behavior and carcinogenesis. The study of HMECs has
enhanced understanding of the barriers to oncogenesis and the mechanisms by which
these barriers are circumvented during tumorigenesis. Primary HMEC cultures exhibit
an initial exponential growth phase of between fifteen and twenty population doublings
before transiently growth arresting. This stress associated proliferative arrest, termed
M0, can be overcome by genetic/epigenetic downregulation of p16 expression. The
expression of the viral oncoproteins human papillomavirus (HPV) E7 and SV40-large TAntigen (SV40-Tag) result in Rb degradation and allow cells to circumvent M0-arrest
(689-692).
HMECs bypassing M0 cells are not immortalized and are eventually subject to
irreversible replicative senescence (M1), characterized by cell enlargement, cell
flattening, increased vacuolization, senescence-associated β-galactosidase activity, low
proliferation index, and low apoptotic index (693-695). Telomere attrition causes
HMECs to undergo senescence at M1. The finite replicative limit of normal cells is
termed the Hayflick limit (694, 696). Inactivation of the p53 pathway can overcome
replicative senescence in HMECs, this can be experimentally induced by expression of
HPV-E6 or SV40 large T antigen oncoprotein (697, 698). Populations of HMECs
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emerging from M1 undergo another 30-60 population doublings eventually reach a state
of cell crisis, termed M2. HMECs at M2 are characterized by critically short to nonexisting telomeres, have a high proliferation index, an equally high apoptotic index,
display polyploidy, and chromosomal abnormalities (695). Somatic cells lack the
telomerase enzyme (TERT), which is required for the telomere maintenance (696). The
expression of TERT in HMECs that have bypassed M0, allows bypass of both M1and
M2 (694, 696, 699)
The immortalization of HMECs requires disruption of the Rb pathway (M0),
downregulation of p53 activity (M1), and activation of TERT (M1 and M2). Immortalized
HMECs have the capacity for infinite cell division, a hallmark of cancer (10), however
they are not capable of transformed, anchorage-independent growth and cannot form
tumors in immunocompromised mice. Fully immortalized HMECs can be transformed by
the introduction of a single oncogene, such as oncogenic H-Ras (315, 700).
HMECs express high levels of elafin in comparison to breast tumor cells. In cell
cycle synchronization experiments, elafin mRNA expression is downregulated in Sphase-enriched cell fractions, indicating a potential role in the regulation of cell
proliferation (23). HMECs provide an ideal system to explore the role of endogenous
elafin expression in normal epithelial cells.
Hypothesis and Central Findings
The hypothesis tested in this chapter is that imbalance between NE and elafin
promotes loss of growth control and is a feature of breast tumorigenesis. In support of
this hypothesis, immunohistochemical analysis revealed progressive loss of elafin
expression during breast and ovarian tumorigenesis. In HMECs, we showed that elafin
was required to maintain quiescence (G0) by opposing the mitogenic effect of NE.
Mechanistically, NE-induces activation of the ERK signaling pathway in a TLR4dependent manner. Our results suggest that imbalance between NE and its
endogenous inhibitor, elafin, promotes tumor growth through the mitogenic activation of
TLR4. A therapeutic approach designed to correct the imbalance between NE and its
endogenous inhibitor, elafin, could limit tumor growth and progression.
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MATERIALS AND METHODS
Antibodies
Antibodies Primary antibodies used for immunohistochemistry (IHC), western
blot (WB), immunofluorescence (IF), and ELISA were:
Antibody
Elafin
Elafin
Elafin
Phospho-Rb
site Ser780
Total-Rb
p53
phosphop44/42 MAPK
(Erk1/2) site
Thr202/Tyr204
p44/42 MAPK
(ERK1/2)
KI-67
TLR4
Actin

Species
Mouse
monoclonal
Mouse
monoclonal
Rabbit
polyclonal
Rabbit
polyclonal
Mouse
monoclonal
Mouse
monoclonal
Rabbit
monoclonal
Mouse
monoclonal
Mouse
monoclonal
Rabbit
Polyclonal
Mouse
monoclonal

Clone

Company

TRAB/2F

Hycult

TRAB/2O

Hycult

IHC, WB

Hycult

ELISA

G3-245

Cell Signaling
Technology
BD
Biosciences

Application
IHC, WB, IF,
ELISA

Notes
Epitope: 57 Cterminal amino acids
Epitope:
Transglutaminase
linking domain at the
N-terminus

WB
WB

DO-1

Calbiochem

WB

D13.14.4E

Cell Signaling
Technology

WB

L34F12

Cell Signaling
Technology

WB

MIB-1

Dako

IF

Santa Cruz
Biotechnology

WB

H-80

Chemicon

WB

Used at 1:5000 (WB)

C4,
MAB1501

Used at 1:2000 (WB)

Immunohistochemistry
Breast cancer samples were obtained from 793 patients diagnosed with
pathologic stage I or II breast cancer (American Joint Committee on Cancer) between
1985 and 2000 and treated by surgical resection at The University of Texas M.D.
Anderson Cancer Center (UT MDACC) (701). Samples of normal breast tissue were
obtained from reduction mammoplasty and samples of DCIS were also obtained from
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surgical resections both performed at UT MDACC. Normal breast and DCIS cases were
also obtained from the NIH Cancer Diagnosis Program (progression TMA case sets 3,
5, and 7). Ovarian carcinoma samples were obtained from 213 patients diagnosed with
ovarian carcinoma between 1990 and 2007 and treated by surgical resection at UT
MDACC. Samples of ovarian cystadenoma, borderline tumors, and normal fallopian
tube tissue were also obtained from surgical treatment at UT MDACC. Complete clinical
and follow-up data on patients whose tissue samples were utilized in this study were
obtained by retrospective review of the patients’ files. The Institutional Review Board at
UT MDACC approved the use of patient-derived specimens and data and the authors of
this study strictly followed ethical guidelines of informed consent and appropriate use of
patient data.
The sections were deparaffinized and rehydrated by submerging slides 3 x 5
minutes in Histoclear (National Diagnostics), 1 x 5 minutes in 100% ethanol, 1 x 5
minutes in 90% ethanol, 1 x 5 minutes in 70% ethanol, 1 x 5 minutes in PBS, and 1 x 5
minutes in ddH20. Antigen retrieval was performed for elafin IHC by submerging slides
in Antigen Unmasking Solution (Vector Laboratories) at sub-boiling temperature (95oC)
for 20 minutes, the slides were then cooled to room temperature (20 minutes) in the
solution. The slides were washed 3 x 5 minutes in ddH2O and then submerged in 3%
H2O2 diluted in methanol for 15 minutes at room temperatures to block endogenous
peroxidases. The slides were washed 3 x 5 minutes with 1X PBS and incubated in
normal blocking serum from VECTASTAIN Elite ABC Kit (mouse IgG) diluted in PBS for
one hour, at room temperature, in a humidified chamber. The slides were washed 3 x 5
minutes with PBS and incubated in the primary antibody diluted in VECTASTAIN
blocking serum (antibody concentration = 1:200 for elafin) overnight at 4º in a humidified
chamber. The slides were wash 3 x 5 minutes in PBS + 0.1% Tween-20 and then
incubated with biotinylated anti-mouse IgG from VECTASTAIN Elite ABC kit for 30
minutes at RT. The slides were washed 3 x 5 minutes in PBS + 0.1% Tween-20 and
incubated for 30 minutes with ABC solution from VECTASTAIN Elite ABC kit. The slides
were again washed 3 x 5 minutes in PBS and 2 x 5 minutes in ddH20 and developed
using DAB substrate (Vector Laboratories, following manufactures instructions) for
approximately three minutes until maximum color developed under the microscope
(elafin TMAs contained sections of spleen as positive controls, once maximum color
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developed in these the reaction was stopped by submerging in ddH2O). The slides were
washed in ddH2O and counterstained using Mayer’s hematoxylin (Lillie’s modification)
(DAKO) diluted 1:5 in ddH20 for 10 seconds. The slides were rinsed in tap-water and
dehydrated by submerging 1 x 5 minutes in 70%, 90%, and 100% ethanol followed by 2
x 5 minutes in Histoclear. The slides were coversliped using permount (Fisher
Scientific). Evaluation was performed with a Leica DM LM light microscopy using the
40x optical lens. Image acquisition was performed using SPOT Imaging Solutions
camera and SPOT Advanced software. Image processing was performed using Adobe
Photoshop software (Version 11.0.2).
Cell lines and Culture Conditions
Mortal human mammary epithelial cells (HMECs) 70N, 76N, and 81N were
generated from reduction mammoplasty samples (685). Immortalized derivatives
76NE6, 76NF2V, 76NE7, 81NE6, and 81NE7 were obtained from Dr. V. Band (686).
These cell lines were generated by transfection of mortal 76N and 81N cells, with DNA
from the human papillomavirus (HPV). The 76NE6/81NE6 cell lines were transfected
with the E6 gene of HPV-16 and lack p53 due to E6 directed proteasomal degradation
(702). The 76NF2V cell line were transfected with a mutant E6 gene (F2V) incapable of
degrading p53, but still capable of immortalization (703). The 76NE7/81NE7 cell lines
were generated by transfection of the HPV-16 E7 and are devoid of Rb and related
pocket proteins due to E7 directed proteasomal degradation (704).
HMEC cell lines were cultured in DFCI-1 media, which consists of α-MEM and
Ham's F-12 media (1:1 v/v) (HyClone) supplemented with 1% fetal bovine serum
(Atlanta Biological), 0.01 M HEPES buffer, 2 mM L-glutamine, 12.5 ng/mL of epidermal
growth factor (EGF), 10 nM triiodothyronine, 0.01 mM ascorbic acid, 2 nM estradiol, 1
µg/mL of insulin, 1 mg/mL hydrocortisone, 0.1 mM ethanolamine, 0.1 mM
phosphoethanolamine, 0.01 mg/ml transferrin, 2.5 ng/ml sodium selenite, 0.035 mg/ml
of bovine pituitary extract and 0.01 mg/ml ciprofloxacin. DFCI-3 (growth factor
deprivation) media omits from DFCI-1: bovine pituitary extract, EGF, triiodothyronine,
estradiol, insulin, hydrocortisone and substitutes 1% BSA for fetal bovine serum (685,
686). 293T cells for lentiviral packaging, were cultured in DMEM supplemented with
10% fetal bovine serum (Atlanta Biological), 0.01 M HEPES buffer, 2 mM L-glutamine,
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and 0.01 mg/ml ciprofloxacin. Tumor cell lines were cultured in α-MEM (HyClone)
(HyClone) supplemented with 10% fetal bovine serum (Atlanta Biological), 0.01M
HEPES, 2 mM L-glutamine, 0.1 mM non-essential amino acids,1 mM sodium pyruvate
and 0.1 mg/mL of ciprofloxacin. Prior to stimulation with NE, the tumor cells were
washed three times with PBS and cultured in identically supplemented α-MEM, except
1% BSA was substituted for fetal bovine serum
Cell Synchronization Conditions
Lovastatin (Sigma) was used at a concentration of 10 µM to arrest HMECs in the
G1 phase. Aphidicolin (Sigma) was used at a concentration of 10 µM to arrest HMECs
in early S phase. Nocodazole (Sigma) was used at a concentration of 5 µM to arrest
cells in M-phase.
Lentiviral shRNA Infection
Target

specific

shRNA

was

obtained

in

the

GIPZ

lentiviral

vector

system

(OpenBiosystems) from the MD Anderson shRNA and ORFeome Core Facility. To
generate lentivirus, 70-90% confluent 293T cells in 100 mm3 culture dishes were cotransfected with 3ug of pCMV deltaR8.2, 3 ug of pMD2.G, and 4.5ug of the pGIPZ
shRNA vector, using LipoD293 (SignaGen) transfection reagent (according to
manufactures instructions). pCMV deltaR8.2 and pMD2.G were produced by the Didier
Trono Lab and made available through the Addgene Repository. Twelve hours after
transfection the media was changed to fresh DMEM. The virus containing media was
collected 24 and 48 hours later and filtered through a 0.45 µM PVDF membrane. Target
cells were infected with the virus containing media in the presence of 8 µg/mL
polybrene. The cells were selected in 1ug/ml Puromycin for four to seven days until the
population was 100% GFP positive (indicating integration of the shRNA). The shRNA
sequences used were:
Rb shRNA1 (V3LHS_340829)- TTGCTATCCGTGCACTCCT;
Rb shRNA 2 (V3LHS_340827)- TTATTTCAGTAGATATCGA;
C/EBPβ shRNA1 (V2LHS_48323)- TTATCATTCATCTGTACAC;
C/EBPβ shRNA2 (V3LHS_371448)- TGAACAAGTTCCGCAGGGT;
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Elafin shRNA1 (V2LHS_221931)-TTATCTTGACCTTTAACTG;
Elafin shRNA2 (V3LHS_313908)- TGACCTTTAACTGAAACTT;
TLR shRNA1 (V3LHS_374709)- TACTTTGAATCTTGTTGCT;
TLR4 shRNA2 ( V3LHS_374707)- TCTTTACTAGCTCATTCCT;
EGFR shRNA1 (V3LHS_361964)-TTCAGAATATCCAGTTCCT;
EGFR shRNA2 (V2LHS_200678)- TTCCGTTACACACTTTGCG.
Complementation of Elafin Knockdown Cells
Elafin cDNA was obtained (Incyte PI3 cDNA, LIFESEQ1453048, OpenBiosystems) and
cloned into the gateway pDONR201 via the gateway BP clonase (Invitrogen) using the
following primers:
attB1- Elafin-F:
5'GGGGACAAGTTTGTACAAAAAAGCAGGCTTCatgagggccagcagcttcttgatcgtg-3'
attB2-Elafin-R:
5'-GGGGACCACTTTGTACAAGAAAGCTGGGTCCTActggggaacgaaacaggccatccc-3'
(the

gateway

recombination

sequences

are

in

CAPS

and

the

sequences

complementary to the elafin cDNA are in lower case. The resulting elafin pENTR vector
was verified by DNA sequencing. To create shRNA resistant elafin expression
plasmids, three consecutive codons along the shRNA targeting region were mutated at
the wobble position using the quikchange lightning site-directed mutagenesis kit
(Stratagene) and the following primers:
shRNA1mut- 5'-ggacaagtttcagttaaagtaaagggcaaagtcaaagcgc-3'
shRNA2mut- 5'-cccgttaaaggacaggtctcggttaaaggtcaagataaa-3'.
The M25G mutation to the protease inhibitor domain of elafin was introduced into the
shRNA resistant elafin pENTR vectors again using the quikchange lightning sitedirected mutagenesis kit (Stratagene) and the following primer:
elafinM25G-5’-tagggggattcaaccctgcgcaccggat-3’ (636).
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The shRNA resistant elafin pENTR vectors were then cloned into the plenti CMV Blast
DEST vector (obtained from the addgene repository) (705) using the LR clonase
(invitrogen). The lentiviral particles were packaged using the same method as the
pGIPZ lentivirus, see above. Elafin shRNA cells were infected with elafin containing
plenti CMV vectors and selected in 20 ug/ml Blastacidin and 1 ug/ml Puromycin until
100% cell kill was achieved in elafin shRNA cells uninfected by plenti CMV vectors, 4-7
days.
DNA Content Analysis
Propidium iodide (PI) staining was performed to examine cell cycle distribution.
Following indicated treatments, the cells were harvested by trypsination and washed in
PBS. 2x106 cells were fixed by resuspension in ice-cold 70% ethanol and maintained at
4°C for at least 24 hours. The fixed cells were than washed with PBS, and stained
overnight at 4°C in 0.5 mL of PI staining solution: 10 µg/mL PI (Molecular Probes), 20
µg/mL ribonuclease A (Sigma) in PBS containing 0.5% Tween-20 (Sigma) and 0.5%
BSA (Sigma). The cells were incubated for 30 minutes at 37 °C and filtered through
35µM nylon mesh capped tubes (BD Falcon). PI fluorescence was measured using a
BD FACScalibur flow cytometer and analyzed based on DNA content using FloJo
software (Version 8).
Preparation of Protein Lysates and Western Blot Analysis
Cells were harvested using trypsin, (for measurement of phosphor-ERK using
timepoints less than one hour we harvested cells by scraping them into PBS). The cells
were washed in PBS (tissues were not) and resuspended in protease/phosphatase
inhibition buffer (PPI); 25 g/ml leupeptin, 25 g/ml aprotinin, 10 g/ml pepstatin, 1 mm
benzamidine, 10 g/ml soybean trypsin inhibitor, 0.5 mm PMSF (Phenyl methyl sulfonyl
fluoride), 50 mm sodium fluoride, 0.5 mm sodium orthovanadate. Cells were lysed via
sonication (Sonicator XL; Misonix Inc.) and the lysates were cleared by centrifugation at
125 000 g for 45 min at 4 °C. Protein concentration was determined by Bradford assay
(reagents from Biorad). Protein concentration was normalized by addition of PBS and
mixed with 2x lammeli buffer (4% SDS, 20% glycerol, 120mM Tris-HCL pH 6.8, and
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0.02% bromophenol blue) to a final concentration of 2.5 µg/µl for western blot.
50 µg of protein from each condition being tested was loading into the lanes of a
sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE) gels (15% gels to resolve
elafin, 13% gels for ERK and pERK, 10% gels for all other antibodies) and submitted to
electrophoresis for 300 volt hours. These gels were then transferred to Immobilon P
membrane (Millipore) by electrophoresis for 400 volt hours, at 4°C. The membranes
were blocked for 1 hour in BLOTTO (5% nonfat dry milk in TBST; 20 mM Tris, 137 mM
NaCl, 0.25% Tween, pH 7.6). Following blocking, the membranes were incubated in
primary antibodies typically at a concentration of 0.1 µg/ml in BLOTTO for two hours at
room temperature. Following incubation with primary antibody the membranes were
washed 3 x 20 minutes in TBS-T and then incubated with goat anti-mouse or anti-rabbit
IgG–horseradish peroxidase conjugated secondary antibodies (Pierce) at a dilution of
1:3,000 in BLOTTO for one hour. The membrane was washed 3 x 20 minutes in TBS-T,
and developed with the Renaissance chemiluminescence system (Perkin-Elmer Life
Sciences, Inc.). The membranes were placed in an autoradiography cassette, exposed
to film, and scanned.
Three-Dimensional Culture
The bottom of a six well plate was covered with 500µL of growth factor reduced
matrigel (BD Biosciences). HMECs were plated at a concentration of 5000 cells per well
in DFCI-1 media supplemented with 2% growth factor reduced matrigel (BD). The
media was replaced every three days. The acini were washed once with cold PBS,
scraped, and collected in a 15 mL conical tube. Cell recovery solution (BD Biosciences)
was added to the Matrigel/acini mixture (1:1 v/v) to digest the matrigel. The acini were
washed twice with cold PBS and either embedded in histogel (Thermo) or lysed for
western blot. The acini embedded in histogel were fixed in 10% buffered formalin,
embedded in paraffin, and sectioned for immunoflourescence (IF) analysis. IF was
performed identically to IHC described until after incubation with the primary antibody.
The secondary antibody utilized was Alexa fluor 594-conjugated goat anti-mouse
(Molecular Probes) and the sections were counterstained with 4,6-diamidino-2phenylindole (DAPI) (Sigma) for 15 min at room temperature, mounted with antifade
solution (Molecular Probes), and sealed with clear nail polish (Sally Hansen). An
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Olympus FV300 laser scanning confocal microscope (Olympus America) was used to
obtain 40x magnification images.
Immunofluorescence
To evaluate the intracellular localization of elafin in HMECs; 5,000 cells were
plated on an eight well chamber slide (BD Falcon). Following treatment, slides were
fixed with 2.5% paraformaldehyde in PBS (pH 7.5) for 20 minutes at RT, permeabilized
in PBS + 0.5 Triton X-100 for 10 minutes at RT, and rinsed three times for 15 minutes
each in glycine rinse buffer (130 mM NaCl, 7 mM Na2HPO4, 3.5 mM NaH2PO4, 100mM
glycine). Slides were then blocked in blocking buffer (130 mM NaCl, 7 mM Na2HPO4,
3.5 mM NaH2PO4, 7.7 mM NaN3, 0.1% BSA, 0.2% Triton X-100, 0.05% Tween-20, 10%
goat serum) for one hour. The slides were incubated in the primary antibody, mouse
monoclonal elafin (TRAB/2F; HyCult Biotechnology) and Ki67 antigen (Dako), at a
dilution of 1:200 in blocking buffer, overnight at 4oC. The slides were rinsed three times
for 20 minutes in wash buffer (blocking buffer without the goat serum) and incubated in
secondary anti-body Alexa-Flour 594 conjugated donkey-anti-mouse (Invitrogen). Slides
were again rinsed, nuclei were counterstained with 0.5 µg/mL DAPI in PBS, and slides
were mounted using Prolong Antifade Reagent (Invitrogen). Imaging was performed
using a FV1000 laser confocal microscope (Olympus).
Quantitative PCR Analysis
RNA was extracted from 2 x106 cells using the RNAeasy kit (Qiagen) and subjected to
on column DNase I (NEB) digestion. The RNA was reverse transcribed (1 µg of mRNA
per sample) using the First Strand cDNA Synthesis Kit (Roche). Quantitative PCR was
performed using SYBR Green PCR Master Mix (Applied Biosystems).
Elafin-F-5′-TGGCTCCTGCCCCATTATC-3′
Elafin-R-5′-CAGTATCTTTCAAGCAGCGGTTAG-3’
cFOS-F-5′- TGACTGATACACTCCAAGCGGA -3’
cFOS-R-5′- CAGGTCATCAGGGATCTTGCA-3′
EGR1-F-5′- AGCCCTACGAGCACCTGAC-3′
EGR1-R-5′- GGTTTGGCTGGGGTAACTG -3′
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TLR4-F-5’-AGACCTGTCCCTGAACCCTAT-3’
TLR4-R-5’-CGATGGACTTCTAAACCAGCCA-3’
EGFR-F-5’-GCGTCTCTTGCCGGAATGT-3’ and
EGFR-R-5’-CTTGGCTCACCCTCCAGAAG-3’
C/EBPβ-F-5’-ACCGGGTTTCGGGACTTGA-3’
C/EBPβ-R-5’-GTTTCGATATCACTGGAG-3’
GAPDH-F-5′-TGTACCGTCTAGCATATCTCCGAC-3′
GAPDH-R- 5′-ATGATGTGCTCTAGCTCTGGGTG-3′.
Sandwich ELISA
Immuno MaxiSorp U96 plate (Nunc) were coated with elafin polyclonal antibody
at a concentration of 10 µg/mL diluted in 0.1 M sodium bicarbonate, overnight at 4°C.
The plate was washed two times with PBS containing 0.1% Tween-20 and once with
PBS between each step. The plate was blocked in 1µg/mL BSA (Sigma) in PBS for four
hours at room temperature. 200 µL of conditioned media was added to each well and
incubated for 1 hour at room temperature; serially diluted recombinant elafin
(calbiochem) was used as a control and to derive a formula for concentration
determination. The plate was incubated in mouse monoclonal antibody (TRAF/2O)
diluted to a concentration of 50 ng/mL in 0.1µg/mL BSA in PBS for 30 minutes at room
temperature. The TRAF/2O elafin antibody detects an epitope on the unfolded Nterminus of elafin and provides greater sensitivity in this assay. The plate was incubated
in 50 ng/mL goat anti–mouse IgG HRP conjugated (Thermo) in 0.1µg/mL BSA in PBS
for 30 minutes at room temperature. The ELISA was developed using 1-Step Ultra TMB
(Thermo) until maximum yellow color developed in the controls with maintenance of
linearity, the reaction was quenched with 2M phosphoric acid and absorbance was
measured at 450nM.
Luciferase Assay
HMECs were transiently transfected with firefly-luciferase promoter constructs
containing the 440 bp proximal elafin promoter (pSPL440), the 440 bp proximal elafin
promoter with mutations to the critical C/EBPβ binding sites 4 and 5 (pSPL440m4/5), or
the minimal elafin promoter (pSPL94) (all constructs described in Yokota et. al, 2007)
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using

LipoD293

(SignaGen)

transfection

reagent

(according

to

manufactures

instructions). Cells were co-transfected with CMV-Renilla to control for transfection
efficiency. Firefly and renilla luciferase activity were quantified sequentially according to
manufactures instructions, using the dual-luciferase reporter assay kit (Promega) and
the BD moonlight 3010 luminometer. Firefly luciferase values were normalized to renilla,
Growth Curves
HMECs were plated at a concentration of 2000 cells per well in a 24 well plate.
After 24 hours the cells were washed three-times in sterile PBS and cultured in DFCI-3
growth factor depleted media. At each timepoint examined, the cells were harvested via
trypsinization and cell number was determined using the trypan blue (Fluka) exclusion
test and a standard hemocytometer.
MTT Assay
Cell growth was also measured using the MTT assay in a 96-well plate. HMECs
were plated at a concentration of 1000 cells per well. After 24 hours the cells were
washed three-times in sterile PBS, cultured in DFCI-3 growth factor depleted media,
and treated with NE (Elastin Products) as indicated in the figures. Following treatment,
50 µl of 2.5 mg/mL MTT was added to each well for 4 hours. Following this incubation,
all media was aspirated and 100 µl of solubilization solution (20mL 1N HCL, 50 mL 10%
SDS, 430 mL isopropyl alcohol) was added to the cells. The plates were placed on a
horizontal

shaker

for

one

hour

and

absorbance

was

quantified

using

a

spectrophotometer (Victor3, Perkin-Elmer) at a wavelength of 590 nm.
Microarray
Total RNA was extracted from 2 x106 cells using the RNAeasy kit (Qiagen) and
subjected to on column DNase I (NEB) digestion (all performed according to
manufactures instructions). RNA integrity was confirmed using an Agilent Technologies
Bioanalyzer 2100. The Genomics Core Facility at MD Anderson Cancer Center
performed the cDNA labeling, hybridization to the Illumina HT-12 v4 BeadChip, and
image acquisition. Raw signal intensities were obtained using the Beadstudio analysis
software from Illumina and imported into the lumi Bioconductor package (R version 2.15
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and Bioconductor version 2.11). The lumi package was used to perform quality control,
background correction by RMA method (implemented in affy package), variance
stabilizing

transformation, and

quantile

normalization. To

identify

differentially

expressed mRNAs between the comparative groups, we applied modified two-sample ttests using limma Bioconductor package. The beta-uniform mixture (BUM) model was
used to control false discovery rate (FDR) (706). Differentially expressed genes were
identified using fold change greater than 1.5 and a p-value yielding a FDR of 0.10 as cut
offs.
Statistics
All experiments were performed in triplicates. The results of each experiment
are reported as the mean of experiment replicates. Error-bars represent the standard
deviation from the mean. All pair-wise comparisons were analyzed using the unpaired,
two-sided, t-test assuming a normal distribution of experimental values. A two-tailed
Fisher’s exact test was used for contingency table analysis. For all statistical test, a
p<0.05 was considered significant.

99

RESULTS
Elafin is Downregulated During Breast Cancer Progression.

Several published studies demonstrate that elafin is expressed at the mRNA
level in normal human mammary epithelial cells (HMECs), but not in the majority of
breast cancer cell lines (23, 24). Based on these studies, we utilized patient-derived
tissue specimens to test the hypothesis that elafin is downregulated during breast
cancer progression. Tissue microarrays (TMAs) containing normal breast tissue from
reduction mammoplasty specimens (n=24), ductal carcinoma in situ (DCIS) (n=54), and
invasive breast carcinoma (n=793) were subjected to immunohistochemical analysis
using a monoclonal antibody against elafin (Figure 8, A and B) (707). Despite a
secretion signal near the N-terminus of the elafin peptide sequence (708),
immunohistochemical analysis showed that elafin expression was intracellularly
localized (Figure 8A). In order to quantify the expression of elafin in patient samples, we
employed a scoring system adapted from Allred et al. that considers both the
percentage of positive cells and staining intensity (Figure 9, A and B) (709). Scoring of
elafin immunohistochemistry was performed in collaboration with Dr. Cansu Karakas
M.D., Dr. Jing Zhang M.D. Ph.D., and Dr. Opoku Adjapong M.D.
Representative photomicrographs of elafin expression in normal breast tissue,
DCIS, and invasive breast tissue are presented in Figure 10A. Quantification of elafin
expression reveals that elafin is highly expressed in the epithelium of the normal
mammary gland in comparison to DCIS and invasive breast tumors. Because all
samples of normal breast tissue had an elafin score of 6 (Figure 10B), we defined elafin
downregulation as an elafin score of 0-5. Elafin expression was at or above the level in
normal breast tissue (i.e., the elafin score was 6-8) in 76% of DCIS lesions but only
17% of invasive breast tumors (Figure 10C). Among the invasive breast tumors, tumors
with elafin expression at or above the level in normal breast tissue were more likely than
tumors with elafin downregulation to be estrogen receptor and progesterone receptor
negative and have higher tumor grade (Table 5). Elafin expression was not associated
with trends in recurrence-free survival (Figure 11A) or overall survival (Figure 11B).
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We also examined elafin expression by immunohistochemistry during ovarian
cancer progression (Figure 12A). Elafin was highly expressed in the epithelium of the
normal fallopian tube (n=20), the site of origin for more than half of ovarian carcinomas
(710), but elafin expression in normal fallopian tube demonstrated greater variability
than was observed for elafin expression in normal breast tissue (compare Figure 9B
and Figure 12B). Because most cases of normal fallopian tube had an elafin score of 4
or higher, we defined elafin downregulation as an elafin score of 0-3 (Figure 12B). Elafin
expression was comparable to that in the normal fallopian tube in 67% of preinvasive
ovarian cystadenomas (n=9), 57% of borderline ovarian tumors (low malignant
potential) (n=21), but only 14% of invasive ovarian carcinomas (n=216) (Figure 12C).
The distribution of histological subtypes differed significantly by elafin expression:
ovarian cancer cases with elafin scores of 0-3 were less likely to be of the endometrioid
subtype (Table 6). No association was observed between elafin expression and other
clinicopathological parameters (Table 6), RFS (Figure 13A), or OS (Figure 13B).
Overall, these results demonstrated that elafin expression is lost during both
breast and ovarian cancer progression.
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Figure 8: Antibodies for Elafin Immunohistochemistry

(A) Serial sections of normal breast tissue from reduction mammoplasty specimens (i
and ii are from the same patient, iii and iv are from another patient) were stained with
monoclonal antibodies to the 57 C-terminal amino acids of fully-processed elafin
(Hycult, Clone: TRAB/2F) (i and iii) and to the N-terminal transglutaminase linking
domain of full length elafin (Hycult, Clone: TRAB/2O) (ii and iv). The intracellular
staining pattern was similar for both antibodies. (B) HMECs (76NF2V) were cultured in
either DFCI-1 growth factor containing media (+GFs) or DFCI-3 growth factor deficient
media (-GFs) for 48 hours. Lysates were resolved on a 15% gel in duplicate and
subjected to western blot analysis. One half of the membrane was probed with
TRAB/2F and the other half was probed with TRAB/2O. TRAB/2F appears to be more
specific to elafin than TRAB/2O, which detects several additional proteins of varying
molecular weights presumably with transglutaminase-linking domains.
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Figure 9: Elafin Immunohistochemistry Scoring System.

(A) The scoring system from Allred et al.,1998 (for the quantification of estrogen
receptor positivity in breast tumors) was adapted for elafin IHC scoring. This
system consists of a final score (0-8) that is the sum of a frequency score (0-5)
and an intensity score (0-3). (A) Representative photomicrographs from invasive
breast cancer samples illustrating each frequency score; 0 = 0%, 1 = <1%, 2 =
1-10%, 3 = 10-33%, 4 = 33-66%, and 5 = 66-100%. (B) Representative
photomicrographs from invasive breast cancer samples illustrating each
intensity score; 0 = Negative, 1 = Low, 2 = Medium, and 3 = High.
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Figure 10: Elafin is
Downregulated During Breast
Cancer Progression.

A) Representative
photomicrographs of elafin
immunohistochemical
staining in normal breast
tissue (i and ii), DCIS (iii
and iv), and invasive breast
cancer (v and vi). (B)
Frequency distribution
illustrating the percentage
of cases falling into each
categorical score over the
range 0-8. (C)
Quantification of elafin
downregulation. An elafin
score of 6-8 denotes cases
at or above the elafin
expression level observed
in the normal breast
epithelium, while an elafin
score of 0-5 denotes
downregulation.
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Table 5: Comparison of Breast Cancer Patient and Tumor Characteristics as a Function of Elafin
Expression

The correlation between common clinicopathological characteristics of breast cancer
patients (age, stage, ER, PR, HER2, and Grade) and elafin expression (positive: elafin
score 6-8 and negative: elafin score 0-5) were examined using a fisher-exact test for
correlation with elafin expression.
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Figure 11: Survival Analysis of Breast Cancer Patients.

(A) Kaplan-Meier analysis of recurrence-free survival in elafin positive and negative
breast cancer cases. (C) Kaplan-Meier analysis of overall survival in elafin positive and
negative breast cancer cases.
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Figure 12: Elafin is Downregulated During Ovarian Cancer Progression.

(A) Representative photomicrographs of elafin immunohistochemical staining in normal
fallopian tube (i and ii), nonmalignant ovarian cystadenoma (iii), ovarian borderline
tumor (iv), and invasive ovarian carcinoma (v and vi). (E) Frequency distribution as
described in B. (F) Quantification of elafin downregulation. An elafin score of 4-8
denotes cases at or above the elafin expression level observed in the normal fallopian
tube, while an elafin score of 0-3 denotes downregulation.
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Table 6: Comparison of Ovarian Cancer Patient and Tumor Characteristics as a Function of Elafin
Expression

The correlation between common clinicopathological characteristics of ovarian cancer
(age, histological type, FIGO stage, and Grade) and elafin expression (positive: elafin
score 6-8 and negative: elafin score 0-5) were examined using a fisher-exact test for
correlation with elafin expression.
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Figure 13: Survival Analysis for Ovarian Cancer Patients.

(A) Kaplan-Meier analysis of recurrence-free survival in elafin positive and negative
ovarian cancer cases. (B) Kaplan-Meier analysis of overall survival in elafin positive and
negative ovarian cancer cases
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Elafin is Upregulated in Mortal HMECs Following Growth Factor DeprivationInduced Cell Cycle Exit.

Elafin is highly expressed in HMECs and was previously shown to be cell cycle
regulated at the mRNA level (23). Given the relevance of cell cycle alterations to early
tumor progression, we hypothesized that elafin is required for normal cell cycle control.
Growth factor-deprivation induced G0 arrest of immortalized HMECs results in the
upregulation of elafin compared to the low levels observed in HMECs asynchronously
proliferating in growth factor-containing medium or arrested in the G1, S, or G2/M phase
of the cell cycle (Figure 14).
To further explore the expression of elafin in G0-arrested cells, primary (i.e.
mortal) 81N, 70N, and 76N HMECs were cultured under growth factor-deficient
conditions and harvested at 6-hour intervals for 48 hours. DNA content analysis
revealed that HMECs were progressively arrested in G0/G1 phase, and complete arrest
was seen between 24 and 36 hours of continuous culture (Figure 15A). Western blot
analysis showed upregulation of elafin over the growth factor deprivation time course
(Figure 15B), corresponding to the accumulation of HMECs in G0/G1 phase.
We next performed immunofluorescence analysis of Ki67, a marker of cells
actively progressing through or arrested within the cell cycle, which is downregulated in
G0 cells (Figure 16A). Quantitation of Ki67-positive cells revealed that in growth factorcontaining medium, 70-76% of HMECs expressed Ki67, whereas under growth factor
deprivation, only 6-10% of total HMECs at 24 hours and fewer than 1% of total HMECs
at 48 hours expressed Ki67. This downregulation of Ki67 confirmed that growth factor
deprivation of HMECs induces arrest in G0 and not G1. Elafin expression, examined by
immunofluorescence, dramatically increased in intensity following growth factor
deprivation, and elafin acquired a strongly cytoplasmic localization (Figure 16B).
Quantitative RT-PCR (qPCR) analysis revealed that elafin is highly induced at
the mRNA level under growth factor deprivation conditions, increasing 12- to 178-fold
by 24 hours and 165- to 240-fold by 48 hours compared to the level of elafin mRNA in
HMECs cultured in growth factor-containing medium (Figure 16C). We also examined
elafin levels in the conditioned media of 81N, 70N, and 76N HMECs by ELISA. Fresh
growth factor-deficient medium was added halfway through the 48-hour time period,
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such that all samples of conditioned medium measured in this assay were incubated
with cells for 24 hours. The concentration of elafin in the conditioned media of 81N,
70N, and 76N HMECs cultured in the presence of growth factors was 2.6-2.9 ng/mL,
compared to significantly higher concentrations of elafin in HMECs cultured in growth
factor-deprived medium: 4.0-6.3 ng/mL at 24 hours and 7.1-11.5 ng/mL at 48 hours
(Figure 16D).
Luciferase reporter analysis of the elafin promoter revealed that elafin
upregulation in HMECs was dependent on C/EBPβ sites 4 and 5, as we previously
described (24) (Figure 17A). In the immortalized HMECs 76NF2V, knockdown of
C/EBPβ (Figure 17B) rendered cells incapable of elafin upregulation following growth
factor deprivation (Figure 17C).
These experiments demonstrated that primary HMECs induced to enter G0 by
growth factor deprivation highly upregulate elafin at the mRNA level, resulting in the
intracellular accumulation and secretion of elafin.
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Figure 14: Elafin is Upregulated Following Growth Factor Deprivation

(A) Western blot of phosphorylated Rb (S780) and elafin in 76NE6 and 76NF2V cells
cultured in DFCI-1 medium (asynchronous), DFCI-3 medium (arrested in G0), 10 µM
lovastatin (arrested in G1), 10 µM aphidicolin (arrested in early S phase), and 5 µM
nocodazole (arrested in M phase).
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Figure 15: Elafin is Upregulated in Mortal HMECs Following Growth Factor Deprivation-Induced
Cell Cycle Exit.

(A-B) 81N, 70N, and 76N HMECs were cultured in growth factor depleted DFCI-3 media
and harvested every six hours for 48 hours following growth factor removal (n=3 for
each timepoint). (A) Cell cycle distribution determined by DNA content analysis of
propidium iodide stained cells, measured by flow cytometry. (B) Representative western
blots of elafin expression, actin as a loading control. Elafin western blots were analyzed
by densitometry; values normalized to actin and are represented as a percent of the
maximum elafin expression
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Figure 16: Elafin is Upregulated in Mortal HMECs Following Growth Factor Deprivation-Induced
Cell Cycle Exit.

(A,B) 81N, 70N, and 76N HMECs cultured in either DFCI-1 (+GFs for 24 hours) or
DFCI-3 media (-GFs for 24 and 48 hours) were examined by immunofluorescence
staining for Ki67 (A) and elafin (B) expression. (C) HMECs cultured as in D were
examined by quantitative RT-PCR for elafin expression; values were normalized to
GAPDH expression and are represented relative to control (+GFs condition). (D)
Conditioned media from HMECs treated as in D was examined by sandwich ELISA for
elafin levels, concentrations are reported as ng of elafin per mL of media.
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Figure 17: Elafin Upregulation in Mortal HMECs Following Growth Factor Deprivation-Induced
Cell Cycle Exit is Dependant on C/EBPβ.

(A) 81N, 70N, and 76N cells were co-transfected with the indicated firefly luciferase
elafin promoter construct and CMV-Renilla luciferase and cultured in either DFCI-1
media (+GFs, for 24 hours) or DFCI-3 media (-GFs, for 24 hours). Elafin promoter
activity was normalized to renilla and expressed relative to control (pSPL440 +GFs). (B)
76NF2V cells stably infected with pGIPZ lentiviral vectors containing control or two
unique, C/EBPβ-specific shRNAs were cultured in DFCI-1 (+GFs) or DFCI-3 (-GFs)
media for 24 hours, knockdown was confirmed by qPCR analysis using C/EBPβ specific
primers, values were normalized to GAPDH and represented as a ratio to the control
shRNA level. (C) Lysates from C/EBPβ knockdown and control 76NF2V in B were
subjected to western blot analysis for elafin. Actin, loading control.

115

Rb-Deficient HMECs are Incapable of Entering Quiescence and Fail to Upregulate
Elafin Following Growth Factor Deprivation.

In G0-arrested cells, Rb is required to prevent E2F-induced cell cycle re-entry
(711). Immortalized 76NE6 HMECs, which lack p53, and 76NF2V, which express both
p53 and Rb (686), progressively arrested in the G0/G1 phase when cultured in growth
factor-deficient medium (Figure 18A). However, 76NE7 HMECs, which are deficient in
Rb and related pocket proteins (686), accumulated in the G2 phase of the cell cycle
when cultured in growth factor-deficient medium (Figure 18A). 76NE6, 76NF2V, and
76NE7 HMECs cultured with growth factors were Ki67 positive (76.3-83.5% of cells).
Following growth factor deprivation for 48 hours, only 8.4% of 76NE6 cells and 7.3% of
76NF2V cells were Ki67 positive, while 63.9% of 76NE7 cells remained Ki67 positive
(Figure 18B). Maintenance of Ki67 expression in growth factor-deprived 76NE7 cells
suggests that loss of the Rb checkpoint eliminates the ability of HMECs to arrest in G0.
Western blot analysis of elafin expression over 48 hours of growth factor
deprivation demonstrated elafin upregulation in 76NE6 and 76NF2V cells (Figure 18C).
In contrast, 76NE7 cells did not express Rb and did not demonstrate elafin upregulation
following 48 hours of growth factor deprivation (Figure 18D). This elafin expression
pattern was confirmed by immunofluorescence analysis (Figure 18E). Culture of
HMECs on reconstituted basement membrane (matrigel) generates three-dimensional
structures resembling mammary acini (316, 712, 713). Immunofluorescence analysis
finds the upregulation of elafin in the matrix-deprived, growth-arrested interior of
mammary acini formed from 76NE6 and 76NF2V, but not 76NE7 cells (Figure 19)
Following 48 hours of growth factor deprivation, Rb-deficient 81NE7 HMECs
failed to upregulate elafin compared to Rb-expressing 81NE6 and parental 81N cells
(Figure 20A). 81NE7 could not arrest in G0/G1 phase as indicated by DNA content
analysis (Figure 20B). 76NF2V and 76NE6 cells with Rb knockdown were also unable
to arrest in G0/G1 phase (Figure 20C) and were incapable of elafin upregulation (Figure
20D) following growth factor deprivation.
Taken together, these results showed that Rb is required for G0 arrest and
concomitant elafin upregulation.
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Figure 18: Rb-Deficient HMECs are Incapable of Entering Quiescence and Fail to Upregulate elafin
Following Growth Factor Deprivation.

(A-D) 76NE6, 76NF2V, and 76NE7 immortalized HMECs were growth factor deprived
as in figure 10A. (A) Cell cycle distribution determined by DNA content analysis of
propidium iodide stained cells, measured by flow cytometry. (B) Immunofluorescence
staining for Ki67 at the 0 and 48 hour timepoints. (C) Representative western blots of
elafin expression (only 76NE6 and 76NF2V shown), actin as a loading control. (D)
Densitometry analysis of elafin western blots; values normalized to actin and are
represented as a percent of the maximum elafin expression (E) Western blot of
phosphorylated Rb (S780), total Rb, p53, and elafin in 76NE6, 76NF2V, and 76NE7
cultured in DFCI-1 (+GFs for 24 hours) or DFCI-3 media (-GFs for 24 and hours), actin
as a loading control. (E) 76NE6, 76NF2V, and 76NE7 cells cultured in either DFCI-1
(+GFs for 24 hours) or DFCI-3 media (-GFs for 24 hours) were examined by
immunofluorescence staining for elafin expression.
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Figure 19: Elafin Expression in Mammary Acini.

(A) 76NE6, 76NF2V, and 76NE7 cells were grown on reconstituted basement
membrane (matrigel), acini formed and were harvested at 3, 9, and 15 days; at each
timepoint acini were formalin-fixed, paraffin-embedded, and subjected to
immunofluorescence staining for elafin expression.
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Figure 20: Quiescence and Fail to Upregulate elafin Following Growth Factor Deprivation.

(A,B) 81N, 81NE6, and 81NE7 cells were cultured in either DFCI-1 (+GFs) or DFCI-3
media (-GFs) for 24 hours. 81N cells immortalized by HPV-E6 lack p53 and 81N cells
immortalized by HPV- E7 lack Rb and related pocket proteins. (A) Lysates were
subjected to western blot analysis for elafin. Actin, loading control. (B) Cell cycle
distribution determined by DNA content analysis of propidium iodide stained cells. (C,D)
76NF2V and 76NE6 cells stably infected with pGIPZ lentiviral vectors containing control
and two unique, RB-specific shRNAs were cultured in DFCI-1 (+GFs) or DFCI-3 (-GFs)
media for 24 hours. (C) Western blot of phosphorylated Rb (S780), total Rb, and elafin.
Actin, loading control. (D) Cell cycle distribution was determined DNA content analysis
of propidium iodide stained cells.
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Elafin Knockdown HMECs Circumvent Quiescence and Proliferate in a Growth
Factors Independent Manner.

To examine the role of elafin in maintenance of G0 arrest, we generated 76NE6
(Figure 21A) and 81NE6 HMEC lines with elafin knockdown. Elafin-knockdown and
control cells were cultured in growth factor-deprived medium, and cell number was
assessed at the indicated time points (Figure 21B). Both 76NE6 and 81NE6 elafinknockdown cell lines exhibited modest but significant growth factor-independent
proliferation, with doubling times between 66 and 81 hours, while control cells exhibited
complete growth cessation after only 24 hours in growth factor-depleted medium
(Figure 21C).
To verify the specificity of elafin knockdown and examine the importance of
elafin-mediated protease inhibition in this system, we complemented 76NE6 elafinknockdown cells with wild-type elafin (sensitive to shRNA downregulation), shRNAresistant-elafin, and shRNA-resistant-M25G-elafin (the M25G mutation inactivates the
protease inhibitor domain) (636) (Figures 21D). Elafin-knockdown 76NE6 cells
demonstrated an approximate doubling in cell number compared to controls following
144 hours of growth factor deprivation (Figure 21E). Complementation of elafinknockdown 76NE6 cells with wild-type elafin, but not M25G-elafin, reduced cell number
to the level of controls (Figure 21E).
These experiments revealed a critical role of elafin-mediated protease inhibition
in the maintenance of G0 arrest in long-term growth factor-deprived HMECs.

122

123

Figure 21: Elafin Knockdown HMECs Circumvent Quiescence and Proliferate in a Growth Factors
Independent Manner.

A) Western blot of elafin expression in parental, empty vector, non-targeting shRNA
control, and elafin knockdown (shElafin 1 and shElafin 2) 76NE6 cells cultured with GF
(0 hours) and without GFs for 48 and 96 hours. Actin, loading control. (B) Schematic of
experimental design. 76NE6 cell lines from A were plated at an initial density of 2000
cells/well in 24-well plates and counted at the indicated times after growth factor
removal. (C) Cell counts over time as described in B. Asterisks denote significant
differences (p<0.05) between control and elafin-knockdown groups. (D) 76NE6 cells
expressing elafin shRNA (shRNA1 [S1] and shRNA2 [S2]) were stably transduced with
wild-type elafin (wt), shRNA-resistant elafin (R1, shRNA1-resistant elafin; R2, shRNA2resistant elafin), or shRNA-resistant elafin with a M25G mutation (results for shRNA1
shown). Cell lysates were subjected to western blot analysis for elafin. Actin, loading
control. (E) 76NE6 cells as described in D were cultured in the absence of GFs for 144
hours and counted.
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Elafin Knockdown 76NE6 are Sensitive to the Growth Promoting Effect of NE.

Activated TAN contribute the majority of NE in the tumor microenvironment
(542). Therefore, we assessed the ability of exogenous NE to induce the proliferation of
HMECs. Elafin-knockdown and control 76NE6 cells were growth factor deprived for 24
hours followed by the addition of NE purified from human sputum directly to the media.
Cell density was measured using the MTT assay 48 hours after addition of NE (72
hours after the removal of growth factors) (Figure 22A). Compared to controls, elafinknockdown 76NE6 cells stimulated with NE at concentrations of 1-8 nM demonstrate a
statistically significant increase in cell number (Figure 22B).
The ability of NE to induce proliferation was dose dependent. Elafin-deficient
76NE6 cells were sensitive to the growth-promoting effect of 2 nM NE, whereas elafinexpressing controls were not (Figure 22C). Complementation of elafin-knockdown
76NE6 cells with shRNA-resistant-elafin, but not shRNA-resistant-M25G-elafin,
attenuated proliferation induced by 2 nM NE (Figure 22C). No differences were
observed in this experiment between groups not treated with NE because cell number
was assessed following only 72 hours of growth factor deprivation. [Significant
differences in cell number were not seen in elafin-knockdown HMECs until 120 hours of
growth factor deprivations (Figure 22C).] Pharmacological inhibitors of NE activity
sivelestat and GW311616 inhibited NE-induced proliferation under all tested conditions
(Figure 23, A and B); further evidencing that the mitogenic-effect of NE is dependent on
NE-activity and not contaminates in the NE preparation.
These findings provided evidence that the growth-promoting effect of NE is
dependent on its protease activity.
.
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Figure 22: Elafin Knockdown 76NE6 are Sensitive to the Growth Promoting Effect of Exogenous
NE.

(A) Schematic of experimental design; elafin knockdown and complemented 76NE6
cells described in figure 21 were growth factor deprived in DFCI-3 media for 24 hours,
followed by addition of exogenous NE (purified from human sputum) in DFCI-3 media.
Cell number was determined 48 hours after the addition of NE by either MTT assay or
counting cells using a hemocytometer. (B) Elafin knockdown and control 76NE6 cells,
percent change in cell density in response to 0, 2, 4, 6, and 8 nM NE, measured by
MTT as described in A. (C) Control, elafin knockdown, and elafin complemented 76NE6
cells, cell number following stimulation with 2nM NE as described in A.
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Figure 23: The Growth Promoting Effect
of Exogenous NE is Dependant on its
Proteolytic Activity

(A) Schematic of experimental
design; elafin knockdown and
control 76NE6 cells were growth
factor deprived for 24 hours,
followed by addition of 0, 0.5, 1, 2,
4, 6, and 8 nM NE for 48 hours. NE
inhibitors GW311616 (20µM) and
Sivelestat (100µM) were added twohours prior and 24 hours post NE
addition. (B) 76NE6 control and
shRNA cell lines were treated with
NE in the presence of PBS, DMSO,
GW311616, or Sivelestat as
described in A.
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NE Induces the Deregulated Proliferation of Growth Factor Deprived HMECs
Through TLR4-Dependent activation of ERK Signaling.

We performed microarray analysis to identify the molecular alterations
underlying deregulated proliferation in growth factor-deprived elafin-knockdown
HMECs. Genes differentially expressed between elafin-knockdown and control 76NE6
cells were identified following 0, 48, and 168 hours of growth factor deprivation (Table
6). Upregulation of the immediate early response gene, EGR1, at the 48-hour time point
was of particular interest given the previously identified role of EGR1 in cell cycle reentry of G0-arrested HMECs (714, 715). We validated the upregulation of EGR1 in
76NE6 elafin-knockdown cells by qPCR (Figure 24A). Complementation with shRNAresistant elafin diminished EGR1 mRNA levels (Figure 24A). The ERK signaling
pathway is known to control EGR1 transcription (715). In elafin-knockdown 76NE6 cells,
the MEK inhibitor U0126 (10 µM) abrogated EGR1 upregulation (Figure S24, B and C)
and inhibited proliferation (Figure S19D) following prolonged growth factor deprivation.
We chose to further explore the role of ERK signaling in NE-induced
proliferation. 76NE6 cells were growth factor-deprived for 24 hours and then stimulated
with 10 nM NE. The addition of NE resulted in activation of ERK phosphorylation that
peaked within 15 to 30 minutes (Figure 25A). Upregulation of ERK target genes EGR1
and FOS was observed 3 hours after the addition of NE to growth-arrested 76NE6 cells
(Figure 25B). Addition of U0126 (Figure 25C) to growth factor-deprived elafinknockdown 76NE6 cells prevented proliferation induction by 2 nM NE (Figure 25D).
Sivelestat, a specific NE inhibitor, also prevented proliferation induction by NE (Figure
25D). Given the rapidity of ERK activation following the addition of NE, we hypothesized
that an extracellular receptor mediates the mitogenic effect of NE on HMECs. TLR4
(590), PAR2 (521), and EGFR (681) have all been implicated in NE-induced ERK
activation. Knockdown of TLR4 reproducibly abrogated ERK activation in growth factordeprived 76NE6 and 81NE6 cells (Figure 25E) following the addition of 10 nM NE and
attenuated NE-induced proliferation (Figure 25F).
Both U0126 and MEK1 siRNA effectively inhibited ERK phosphorylation
following the addition of NE to growth-arrested 76NE6 cells (Figure 26A) and
consistently attenuated NE-induced proliferation (Figure 26, B and C). We transduced
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76NE6 HMECs with shRNA specific to PAR2 and EGFR (shown is comparison to TLR4
knockdown). PAR2 was not detected in HMECs (data not shown) and was omitted from
this analysis (Figure 27A). EGFR-knockdown HMECs demonstrated reduced ERK
phosphorylation upon stimulation with 10 nM NE suggesting a role for EGFR in NEinduced ERK activation (Figure 27B). A role for EGR-1 was previously shown in EGFinduced cell cycle re-entry (716). However, knockdown of EGR-1 in 76NE6 cells (Figure
28A) was insufficient to block proliferation induced by NE, EGF, or serum-containing
media (Figure 28B).
These findings suggested that the mitogenic activity of NE in quiescent HMECs
is dependent on TLR4-induced ERK activation.
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Table 7: Microarray Analysis Identifies EGR1 Upregulation in Growth Factor Deprived Elafin
Knockdown 76NE6 HMECs
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Figure 24: The Growth Promoting Effect of Exogenous NE is Dependant on its Proteolytic Activity
and Requires ERK Signaling

(A) Elafin knockdown and complemented 76NE6 cells described in figure 4D were
cultured in growth factor depleted media for 48 hours and analyzed for elafin and EGR1
mRNA expression and normalized to control. (B) Schematic of experimental design;
76NE6 control, shElafin1, and shElafin2 were continuously cultured with 10 µM of the
MEK inhibitor U0196 following growth factor removal. (C) Quantitative RT-PCR of
EGR1 expression in U0196/DMSO treated elafin knockdown 76NE6 48 hours post
growth factor removal, normalized as in B. (D) Cell number of U0196/DMSO treated
elafin knockdown 76NE6 cells 144 hours post growth factor removal.
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Figure 25: NE Induces the Deregulated Proliferation of Growth Factor Deprived HMECs Through
the TLR4/EGFR-Dependant Activation of ERK Signaling

(A) Western blot analysis of pERK and total ERK in parental 76NE6 cells growth factor
(GF) deprived for 24 hours and then stimulated with 10 nM NE. (B) qPCR analysis of
EGR1 and FOS 3 and 6 hours after addition of NE. Values are represented relative to
control (-GFs 24 hr). (C) Schematic of experimental design. Elafin-knockdown 76NE6
cells were GF deprived for 24 hours, and stimulated with 2 nM NE for an additional 48
hours. Two hours before and 24 hours after the addition of NE, DMSO, sivelestat (100
µM), or U0126 (10 µM) was added. (D) Control and elafin-knockdown 76NE6 cells
described in C were counted. (E) Western blot analysis of TLR4, pERK, and total ERK
expression in 76NE6 and 81NE6 TLR4-knockdown cells GF deprived for 24 hours
followed by stimulation with 10 nM NE. Actin, loading control. Par., parental. Cont.,
control. (F) 76NE6 and 81NE6 TLR4-knockdown cells were counted 48 hours after the
addition of 10 nM NE
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Figure 26: The Growth Promoting Effect of Exogenous NE is Dependent on its Proteolytic Activity
and Requires ERK Signaling

(A) 76NE6 cells were transfected with MEK1 or control siRNA, growth factor deprived
for 24 hours, and stimulated with NE (10 nM). Alternatively, 76NE6 cells were growth
factor deprived for 24 hours and treated with DMSO or the MEK inhibitor, U0126 (10
µM), two-hours prior to NE addition. Cells were harvested 15, 30, and 45 minutes after
NE addition and subjected to western blot analysis for phosphorylated (Thr202/Tyr204)and total-ERK expression. (B) Elafin knockdown and control 76NE6 cells were prepared
as above with MEK/control siRNA and stimulated with 0, 0.5, 1, 2, 4, and 8 nM NE for
48 hours, the percent change in cell number was calculated by MTT assay. (C) 76NE6
cells were examined as in B except for the use of U0126/DMSO/PBS (administered 2
hours prior and 24 hours post NE addition) instead of siRNA.
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Figure 27: Knockdown of EGFR and TLR4

(A-D) 76NE6 cells were stably infected with pGIPZ lentiviral vectors containing control
or two unique shRNAs targeting EGFR or TLR4. Knockdown of EGFR (A) and TLR4 (B)
was confirmed by qPCR analysis. Values were normalized to GAPDH and represented
as a ratio to the control shRNA level. PAR2 shRNA was also included; however, we
were unable to detect PAR2 expression in these cells by qPCR. (C) Western blot
analysis of phosphorylated (Thr202/Tyr204) and total ERK expression in 24-hour
growth factor-deprived 76NE6 cells stably transduced with control shRNA or shRNA
targeting PAR2, TLR4, and EGFR following stimulation with 10 nM NE or vehicle alone.
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Figure 28: Knockdown of EGR-1 Fails to Prevent Cell Cycle Reentry Following Addition with NE,
EGF, or Serum Containing Media

(A,B) 76NE6 cells were stably infected with pGIPZ lentiviral vectors containing control
or three unique shRNAs targeting EGR1. The cells were growth factor deprived and
then stimulated with 10 nM NE, 1 nM EGF, 10% serum containing media, or not-treated
(NT). (A) Three hours after treatment the cells were harvested and lysates were
subjected to western blot analysis. Both EGF and NE increased EGR1 levels compared
to NT. EGR1 shRNA1 and shRNA3 abolished EGR1 upregulation. (B) Cells were
counted 48 hours after treatment. NE, EGF, and serum containing media significantly
increased cell number regardless of EGR1 levels.
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DISCUSSION
Immunohistochemical analysis reveals that elafin is highly expressed in the normal
epithelium of the breast and fallopian tube, but is switched off as breast and ovarian
tumors achieve an invasive phenotype. HMECs served as a model system to
understand the role of elafin in the normal mammary epithelium and to discover the
rationale behind elafin downregulation during tumorigenesis.
A model based on the in vitro analysis performed in chapter two is presented in
Figure 29. In this model, elafin is expressed by the normal quiescent epithelium under
the transcriptional control of C/EBPβ, as a shield against neutrophil secreted NE activity
(Figure 29A). During tumorigenesis elafin is downregulated due to deregulation of
C/EBPβ, eliminating a critical counterbalance against the mitogenic effect of NE. We
found that deregulated NE induces proliferation through TLR4-dependant activation of
the ERK signaling pathway (Figure 29B). These results suggest a role for deregulated
NE in promoting ERK-signaling and tumor growth.
Several published studies have observed elafin downregulation in invasive
tumors and tumor-derived cell lines (21, 23, 24, 26). However, contradictory studies
examining elafin expression in ovarian cancer and glioblastoma conclude that elafin
overexpression is a marker of poor prognosis (717, 718). In an experimental
glioblastoma model of anti-angiogenesis therapy, elafin upregulation was observed by
microarray analysis along with CHI3L1, CHI3L2, and IL-1β in avascular when compared
to vascularized tumors. In glioblastoma patient samples, elafin mRNA expression was
associated with higher tumor grade and poor overall patieint survival. IHC examination
of elafin is a small cohort of glioblastoma cases found elafin expression in cells adjacent
to necrotic regions of the tumor (718).
The authors of the ovarian cancer study used a previously unpublished
polyclonal antibody for immunohistochemical detection of elafin and were unable to
detect elafin expression in normal ovarian epithelial cells (717). Aside from
methodological discrepancies, the critical advantage of the immunohistochemical
analysis presented here is the use of a scoring system based on elafin expression in
normal tissue. Using this system, elafin overexpression can be defined as expression
greater than that in the normal epithelium. Elafin overexpression, based on this criteria,
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was observed in only 8% of breast tumors and <2% of ovarian tumors and had no
prognostic significance. The Clauss et al. study scored elafin expression by the
percentage of cells positive only. Tumors demonstrating elafin positivity in less than sixpercent of cells were grouped into the low elafin group (77 of 134 tumor samples) and
tumors demonstrating elafin positivity in greater than six-percent of cells were grouped
into the high elafin group (57 of 134 tumor samples), suggesting that the anti-protease
shield is still diminished in these tumors.
Alternative avenues of elafin transcription may differentiate the outcome of
studies identifying elafin overexpression (717, 718) and downregulation (21-24, 26).
Inducible elafin expression has been described in response to pro-inflammatory
cytokines, especially IL-1β and TNF-α (646, 647), and is dependent NF-κB (717).
C/EBP β sites (24) in the elafin promoter drive the expression of elafin in G0 HMECs
(Figure 17). C/EBP β is essential to the constitutive expression of elafin in the normal
epithelium.
In ovarian tumor cells, elafin expression was NF-κB-dependent (717). In
glioblastoma, focal elafin expression was associated with necrotic tumor areas.
Necrosis is associated with inflammatory cytokine production and NF-κB activation
(718). Elafin immunohistochemical scoring based solely on invasive tumors therefore
reveals an association with inflammation and necrosis, which is known to be associated
with poor prognosis. Consistent with this observation, the relatively small cohort of
breast tumors expressing elafin, at or above the level observed in the normal breast
epithelium, correlates with histopathological markers of aggressive tumor behavior
(Table 5). We hypothesize that inflammation and NF-κB activation results in elafin
reactivation in this subset. Ranking the expression of genes that covariate with elafin in
the TCGA breast cancer (85), Yau et al. 2010 (719), TCGA ovarian (720), and TCGA
glioblastoma (721) cancer datasets finds that elafin expression is highly correlated with
the expression of inflammatory genes, especially secreted factors, cytokines,
chemokines, and proteases (Table 8). The role of elafin in tumors is unclear. Elafin has
never been shown to have oncogenic functions in experimental models. Excessive
inflammation and high levels of NE activity can lead to tissue destruction and apoptotic
cell death (722-724). Elafin expression in aggressive tumors may be meaningless,
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however elafin in these tumors may also function to maintain NE activity within a range
that induces proliferation, but not cell death.
Elafin expression in G0 HMECs requires C/EBP β sites (24) in the elafin
promoter (Figure 17). Alternative splicing results in the expression of C/EBP β as
multiple isoforms, including a truncated transcriptional repressor. The accumulation of
this dominant-negative C/EBP β isoform results in elafin downregulation in HMECs and
tumor cells (24). We also found that Rb is required for elafin expression in HMECs
(Figure 18). Physical interaction with Rb was previously shown to be critical for C/EBP β
DNA-binding (725). In some cell types direct interaction between Rb and C/EBP β leads
to enhanced transcriptional activity of C/EBP β target genes involved in quiescence and
differentiation (726, 727). In fibroblasts, C/EBP β causes cell cycle exit in the presence
of Rb, but accelerates proliferation in the absence of Rb (728). Deregulation of the Rb
(85) and C/EBP β (24) pathways are a frequent event in human cancers and likely
drives elafin downregulation during malignant progression.
Another explanation for the finding that elafin is overexpressed in a subset of
breast and ovarian tumors is amplification of the PI3-gene. Amplification of the
chromosomal region 20q13.2, where elafin resides, is frequently observed in ovarian
cancer, breast, and other tumor types. Several candidate oncogenes have been
identified in the region including NABC1, ZNF217, TPD54, ADRM1, and BTAK,
however no consensus exists on the gene or genes driving amplification. 20q13.2
amplification is consistently associated with poor prognosis across a spectrum of tumortypes including breast and ovarian cancer (729-733). Elafin overexpression may be a
readout on this amplification event.
The preponderate loss of elafin in invasive tumors compared to pre-invasive
lesions suggests that elafin downregulation may play an important role in the transition
to invasive carcinoma. Consistent with a tumor suppressive role for elafin in cancer,
several published studies have observed cytotoxity following elafin re-expression in
tumor cell lines and xenograft tumors (25, 26, 678).
In this study, we concentrated on the stoichiometric relationship (1:1 molar ratio)
between elafin and NE. Under normal culture conditions HMECs do not express NE
(25), however NE expression by epithelial cells has been reported in response to
reactive oxygen species (734). Metabolic stress is a byproduct of growth factor
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deprivation and may be driving inappropriate NE expression in HMECs. However, the
low levels of proliferation observed in elafin KD HMECs following prolonged growth
factor deprivation (Figure 21) likely reflects a low concentration of relevant protease
activity in this system. NE expression has previously been characterized in tumor cell
lines (617, 735), however in the tumor microenvironment the majority of NE is
contributed by activated neutrophils (542, 616). To model this, we added purified NE to
the media of G0 HMECs. The level of cell growth achieved in elafin KD HMECs 48hours after addition of 2 nM NE (Figure 22) is comparable to the level observed
following 144-hours of growth factor deprivation alone (Figure 21).
Several published studies have demonstrated increased proliferation following
addition of exogenous NE (542, 676, 736). The concentrations of NE resulting in a
physiological response in vitro vary between studies; proliferation was induced in airway
smooth muscle cell by addition of 0.35-1.7 nM NE (736), in keratinocytes by addition of
0.1-33 nM NE (676), in lung fibroblasts by addition of 3.5-862 nM NE (681), and in lung
cancer cells be addition of 20-80 nM NE (542). In the present study, the concentrations
of NE utilized ranged from 1-10 nM to induce proliferation in HMECs, which is
comparable to the concentrations used in most published studies. The specific activity
of the purified NE, the intrinsic sensitivity of the cell lines, and the level of anti-proteases
in the culture system are likely important factors in the concentration of NE required to
generate a response. In vivo application of NE results in thickening of the epidermis and
can be attenuated by addition of NE (676)
NE-induced ERK signaling and resultant proliferation is dependent on the TLR4.
Direct cleavage of TLR4 by NE has been reported to induce its activation (737). In both
leukocytes and epithelial cells, NE-induced TLR4 activation has an established role in
the activation of the NF-κB pathway and downstream cytokines expression, such as IL8, TNFα, and IL-6. TLR4 can also activate MAPK pathways including ERK signaling
(590). We observed that knockdown of EGFR in HMECs partially inhibited NE-induced
ERK activation (Figure 27). Stimulation of TLR4 by NE (560) or bacterial ligands (738)
has previously been shown to result in activation of the EGFR, which is responsible for
downstream ERK activation. In a non-small cell lung cancer (NSCLC) cell line, TLR4
ligands promote proliferation in an EGFR-dependent manner (739).
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Figure 29: Proposed Model for NE-Elafin Equilibrium

(A) Elafin is expressed under the control of C/EBPβ and Rb in G0 HMECs. In this
context, elafin blocks the mitogenic effects of secreted NE and maintains G0 arrest. (B)
Loss of elafin expression and the accumulation of TAN-secreted NE in the tumor
microenvironment lead to TLR4/EGFR-dependent activation of the ERK signaling
pathway. The ERK pathway induces an immediate early gene response resulting in the
transcription of growth factors, cell cycle regulatory factors and ultimately cell
proliferation.
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Table 8: Inflammatory Gene Expression Covariates with the Expression of Elafin in Tumors.

Tumor gene expression data from the TCGA breast, ovarian, and gliobastoma projects
and the Yau et al. 2010 breast tumor dataset was examined for correlation with elafin.
All genes were compared to elafin (PI3) and ranked by Pearson product-moment
correlation coefficient (Corr.). P values were calculated based on the t-distribution. The
TCGA breast tumor database was broken down further by intrinsic subtype.
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Chapter 3: The Neutrophil Elastase Inhibitor, Elafin, Triggers Rb-Mediated Growth
Arrest and Caspase-Dependent Apoptosis in Breast Cancer

INTRODUCTION
Endogenous Serine Protease Inhibitors in Tumorigenesis
Maspin is a member of the serpin family of serine protease inhibitors. Similar to
elafin, maspin expression was originally identified as highly expressed in HMECs, but
downregulated in breast tumor derived cells (740, 741). Maspin downregulation has
been observed in several tumor types including melanoma, breast, prostate, and gastric
cancers (742-745). In experimental models, maspin demonstrates tumor suppressor
properties, including reduction of tumor growth, angiogenesis, invasion, and metastasis
(741, 746, 747). Intracellular maspin (esp. nuclear) is a marker of good prognosis in
breast cancer (748, 749). Recent studies suggest that nuclear localization of maspin is
essential to its tumor suppressive activity (750). Intracellular maspin induces apoptosis
in breast cancer cells by associating with the mitochondrial membrane and facilitating
the release of cytochrome c. Maspin also modulates the expression of anti-apoptotic
BCL-2 family members and promotes caspase activation (747, 751-753).
An essential feature of serpin protease inhibition is the exposed reactive center
loop (RCL). The RCL makes contact with the active site of the protease target. Upon
formation of an acyl-enzyme intermediate the serpin undergoes a rapid stressed to
relaxed conformational change, distorting the active site of the target protease, and
disfavoring hydrolysis. Following this reaction the RCL of the serpin remain covalently
bound to the target protease, irreversibly inhibiting protease activity. The RCL of maspin
is short and contains several hydrophobic residues that make it incapable of interacting
with and inhibiting serine proteases (754). Therefore, the tumor suppressive properties
of maspin are not dependent on an ability to inhibit protease activity.
Plasminogen activator inhibitor 1 (PAI-1) is another serpin with a role in
tumorigenesis. PAI-1 is an active inhibitor of urokinase-type plasminogen activator
(uPA), which has an established role in tumor progression. PAI-1 was originally
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hypothesized to have a tumor suppressive role in cancer by opposing the
tumor/metastasis enhancing activities of uPA. Several early studies supported a tumor
suppressive role for PAI-1, however in breast cancer patients the expression of both
uPA and PAI-1 are prognosis of poor prognosis (755-758). Protease independent roles
have since been described for PAI-1 in enhancing tumor growth, angiogenesis, and
metastasis (759).
WAP-domain containing, secretory leukocyte protease inhibitor (SLPI) has also
been shown to have context dependent roles in tumor growth and progression (760,
761). Overexpression of both wild-type or protease inhibitor-dead SLPI enhanced
proliferation, colony formation, survival, and xenograft tumor formation following
overexpression in the HEY-A8 ovarian cancer cell line (760). Overexpression of SLPI
enhances the tumorigenicity and metastatic capacity in the 3LL-S (Lewis Lung
Carcinoma) cell line in a subcutaneous xenograft model. Contrarty to the results
reported in the ovarian cancer cell line HEY-A8, ithe pro-tumorigenic capacity of SLPI n
the 3LL-S cell line was dependnat on its protease inhibitory domain. (762, 763). Tumor
suppressive effects of SLPI overexpression have also been reported. In the F3II BALB/c
murine mammary carcinoma cell line, SLPI overexpression severely limited the ability of
these cells to form tumors in mice (764). Overexpression of SLPI in the metastatic cell
line H-59 reduces the ability of these cells to elicit a pro-inflammatory response in the
liver and to form metastases (765). In a particularly interesting study, SLPI
overexpression was shown to enhance the proliferation and growth of colon xenograft
tumors, but inhibit the growth of mammary xenograft tumors. In vitro SLPI induces
apoptosis in breast tumor cells, but not colon tumor cells (761).
Endogenous

serine

protease

inhibitors

play

important

roles

in

tumor

progression. Interestingly, many studies have identified protease-independent role for
protease inhibitors in tumorigenesis and progression. Protease-independent function
(673) have also been identified for elafin. There is no known role for elafin in
tumorigenesis.
Hypothesis and Central Findings
Several published studies suggest that elafin expression is downregulated
during tumorigenesis including in squamous cell carcinomas of the skin, head/neck, and
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esophagus (21, 22, 677, 766). Data presented in chapter 2 of this dissertation clearly
demonstrates that elafin is downregulated in breast and ovarian cancer patients. The
downregulation of elafin during tumorigenesis suggests that elafin possesses tumor
suppressive properties. The majority of breast tumor derived cell lines demonstrate
transcriptional downregulation of elafin, when compared HMECs (23).
The central hypothesis of this chapter states that elafin has tumor suppressive
activity in breast cancer. The observations presented here suggest that the Rb pathway
governs the anti-tumor properties of elafin. In breast cancer cells with functional Rb, the
expression of elafin triggered Rb-dependent cell cycle arrest. Elafin also exhibited
suppressive activity in breast cancer cell lines lacking Rb, but this was associated with
an induction of caspase-3 dependent. Normal mammary epithelial cells were not
affected by elafin. Collectively, these results argue that elafin mediates tumor
suppressive effects that are cytostatic or cytotoxic depending on Rb status. These
findings suggest that elafin could be engineered as a therapeutic modality to treat
breast cancer without toxicity to normal proliferating cells.

147

MATERIALS AND METHODS
The methodology for DNA content analysis, preparation of protein lysates,
western blot analysis, growth curves, and MTT assay are detailed in chapter two,
additional reagents and protocols are described here.
Antibodies
Primary antibodies used for western blot (WB) or immunoprecipitation (IP):
Antibody

Species

Clone

Company

Application

Rb

Mouse
monoclonal

4H1

Cell Signaling
Technology

WB

Phospho-Rb
site
Ser807/811

Rabbit
Polyclonal

Cell Signaling
Technology

WB

Rabbit
Polyclonal
Rabbit
Polyclonal

Cell Signaling
Technology
Cell Signaling
Technology

Cleaved
Caspase 3
Asp 175

Rabbit
Polyclonal

Cell Signaling
Technology

WB

CDK4

Rabbit
Polyclonal

Santa Cruz
Biotechnology

IP

PARP
Caspase 3

Notes
Detects only
phosphorylated
Rb

WB
WB

Cell Lines and Culture Conditions
All cell lines were maintained in a humidified tissue culture incubator at 37ºC and
6.5% CO2. All tumor derived cell lines (MDA-MB-157, MDA-MB-231, MDA-MB-468,
MCF-7, ZR75.1, and T47D) were obtained from ATCC. Between 18 and 36% of
established cell lines are cross contaminated or incorrectly identified (767), therefore all
cell lines utilized were authenticated by the short tandem repeat method. All cell lines
were also tested for mycoplasma contamination using the MycoAlert kit (Lonza). MDAMB-468 cells were maintained in DMEM (HyClone) supplemented with 10% fetal calf
serum (Atlanta Biological), 0.01M HEPES, 2 mM L-glutamine, and 0.1 mg/mL of
ciprofloxacin. The remaining tumor cell lines were maintained in α-MEM (HyClone)
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supplemented in the same manner as DMEM with the addition of 0.1 mM non-essential
amino acids and 1 mM sodium pyruvate.
The pan-caspase inhibitor zVad-fmk (calbiochem) was solubilized in DMSO at
50 mM and diluted in media at a concentration of 50µM. Cyclohexamide was dissolved
in PBS at a concentration of 1 mg/mL, filtered, and diluted in media to a final
concentration of 100 µg/mL.
Knockdown/Overexpression in Breast Cancer Cell Lines
MDA-MB-231 and MCF-7 cells stably expressing shRNA directed against Rb
were a gift from Dr. E. Knudsen; these cells were maintained in α-MEM supplemented
with 2 ug/mL puromycin (Sigma). MCF-7 cells with reconstituted caspase 3 were a gift
from Dr. B. Fang; these cells were maintained in α-MEM supplemented with 0.1 mg/mL
G418 (Mediatech). MCF-7 RBKD and MCF-7 shRNA control cell lines expressing
caspase 3 or pcDNA3.1 empty vector were generated by transfection of the MCF-7
RBKD and MCF-7 shRNA control cell lines with 6 µg of pcDNA3.1/Casp3 (also from Dr.
B. Fang) or 6 µg of pcDNA3.1 empty vector using Genejuice reagent (Novagen),
according to manufactures instructions. Cells expressing these vectors were selected in
α-MEM containing 0.5 mg/ml G418 (Mediatech) and 2 ug/mL puromycin (Sigma) for four
weeks. Single-cell clones were selected and expanded in culture media supplemented
with 0.1 mg/ml G418 and 2 ug/mL puromycin (Sigma) and screened by western blot
analysis for the expression for Rb and caspase 3.
Production of Adenovirus and Infection of Target Cells
Elafin and Firefly Luciferase transgenes were expressed downstream of a
cytomegalovirus (CMV) promoter in replication incompetent adenovirus type 5. Viruses
were amplified in the packaging cell line AD-293 (Stratagene) and purified in a CsCl
gradient by centrifugation at 176 000 g (Beckman ultracentrifuge) at 4oC for 18 hours.
Multiplicity of Infection (MOI) was calculated based on the number of plaque forming
units (pfu) in AD-293 cells. For infections 2 x 106 cells were plated on a 100mm plate,
after 24 hours cells were washed with sterile PBS and treated with AD-elafin, ADluciferase, or PBS in four mL of media. After two hours of infection the media was
removed and replaced with fresh culture media. All tumor cell lines were optimally
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infected at 1 MOI except for MDA-MB-231, which along with HMEC cell lines were
infected at 2 MOIs. Transgene expression was determined by western blot analysis.
Infection efficiency was monitored using an identically tittered adenovirus expressing
cDNA corresponding to GFP, all cell lines were infected at greater than 90% efficiency.
BrdU incorporation
Cells were plated in a 100 mm3 plate and treated 24 hours later with Ad-Elafin,
Ad-Luc, or PBS. 48 hours post-treatment, cells were pulsed for 1 hour with 10 µM BrdU
(Invitrogen), harvested, washed in PBS, and fixed in ice cold 70% ethanol for at least 24
hours. Following fixation, 2 x 106 cells were aliquoted from each condition and washed
in wash buffer (PBS + 1% BSA). The DNA was slightly denatured in 2M HCL, the cells
were rinsed in wash buffer, residual acid was quenched by addition of 0.1 M sodium
borate, and the rinsed again in wash buffer. Cells were then incubated in the dark for 1
hour on a rocker in 50 uL of dilution buffer (PBS + 0.5% tween-20 + 1%BSA) containing
a 1:10 dilution of FITC-conjugated anti-BrdU monoclonal antibody (BD Bioscience).
Cells were washed in buffer to remove background and resuspended in 0.5 mL of
propidium iodide (PI) (Molecular Probes) staining solution (10 ug/mL PI + 20ug/mL
Ribonuclease A (Sigma) in wash buffer) for 30 minutes at RT. PI and FITC fluorescence
was measured using a BD FACScalibur flow cytometer and analyzed using FloJo
software.
TUNEL Assay
To assess the percentage of cells that had undergone apoptosis, cells were
treated as indicated and harvested 72 hours post treatment. Both the floating and
adherent cells (by trypsin) were collected and 2 x 106 cells were aliquoted per condition
and washed in PBS. Cells were fixed on ice for 20 minutes in 2.5% (w/v)
paraformaldhyde (Sigma) in PBS (pH 7.4) and post-fixed in ice cold 70% ethanol for at
least 24 hours. The TUNEL reaction was performed using the APO-BrdU TUNEL Assay
Kit (Invitrogen) according to manufactures instructions. The included Alexa-Fluor 488
conjugated anti-BrdU antibody was used in all cases except where GFP expression
from stably transfected plasmids (RBKD and control cell line) interfered with detection of
the Alexa-Fluor 488 dye; in this case Alexa-Fluor 647 conjugated Anti-BrdU antibody
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(BD) was substituted.
Immunoprecipitation-Kinase Assay
For determination of CDK4 kinase activity, 1 µl/sample of polyclonal rabbit CDK4
antibody was added to 30 µl/sample of protein A sepharose beads (GE HealthCare) at
a concentration of 0.1 g/mL in lysis buffer (0.5M tris, pH 7.5, 2.5M sodium chloride, 1%
NP-40 (Igepal)) and 36 µl/sample of 10 mM DTT/lysis buffer/PPI and incubated
overnight, at 4oC on a rocker. The following day, 200 µg of protein samples were added
to the mixture and incubated for one hour, at 4oC with rotation. The beads are then
washed in 500 µl of the lysis buffer three times and then washed an additional three
times in 500 µl of kinase wash buffer (10mM MgCl2, 1mM DTT, 0.1 mg/ml BSA, 25mM
Tris HCL pH 7.5, 125mM NaCl). All liquid is then removed from the reaction and the
beads are resuspended in the kinase reaction buffer: 10mM MgCl2, 1 mM DTT, 0.1
mg/ml BSA, 25 mM Tris HCL pH 7.5, 125mM NaCl plus 60mM ATP, 5µ Ci of γ-32P ATP
and 1µg of GST-Rb 769 substrate (Santa Cruz). The reaction was allowed to proceed
for 30 minutes at 37ºC and inactivated by addition of 15µl of sample buffer.

The

samples were resolved on a 10% SDS-PAGE gel, stained in Brilliant Blue (Sigma) for
one hour and de-stained overnight. The gel is then dried onto filter paper, exposed to a
phosphorimager screen, and analysis by a Typhoon scanner (Molecular Dynamics).
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RESULTS
Exogenously Expressed Elafin Induces Apoptosis in HMECs Lacking Functional
Rb.

In Chapter two, we demonstrate that actively proliferating HMECs in growth
factor containing media do not express elafin. However, elafin is highly upregulated in
growth factor deprived, G0-arrest HMECs (Figure 15). In the HMECs, elafin is required
for maintenance of G0-arrest during long-term growth factor deprivation conditions
(Figure 21). To determine if exogenously expressed elafin can affect growth of actively
proliferating HMECs, elafin was overexpressed using an adenoviral vector. Adenoviral
expression of luciferase was used as a control for viral infection. Mock transduced cells
were treated with an equivalent volume of PBS.
Sub-confluent 76NE6, 76NF2V, and 76NE7 cells were treated with adenoviral
elafin, adenoviral luciferase, or PBS. Lysates were subjected to western blot analysis to
demonstrate expression of the elafin transgene in comparison to endogenous elafin
expression in growth factor deprived 76NE6 cells (Figure 30A-compare lane C [control:
76NE6 –GFs 48 hr], to lane E for each cell line). Adenoviral expression of elafin in
proliferating HMECs produces expression levels comparable to growth factor deprived
76NE6 cells (Figure 30A). The overexpression of elafin causes no statistically
significant change in the doubling times of Rb-proficient cell lines 76NE6 (PBS: 16±1.1
hours, luciferase: 15±0.5 hours, and elafin 15±0.3 hours) and 76NF2V (PBS: 18±0.6
hours, luciferase: 18±0.6 hours, and elafin 20.3±0.5 hours), suggesting that elafin
expression alone is insufficient to induce growth arrest. However, overexpression of
elafin in 76NE7 cells, which are devoid of Rb, resulted in a significant decrease in cell
number by 96 hours post-treatment (Figure 30B).
To determine if the decrease in cell number seen in 76NE7 cells (Figure 30B) is
due to adenoviral elafin-induced cell cycle arrest or induction of apoptosis we analyzed
BrdU incorporation (Figure 30C) and TUNEL staining (Figure 30D). There was no
statistically significant change in BrdU incorporation following ectopic expression of
elafin in any of the cell lines tested (76NE6, 76NF2V, or 76NE7) (Figure 30C). There
was a significant increase in TUNEL positive cells in adenoviral elafin treated 76NE7
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cells compared to adenoviral luciferase treated 76NE7 or adenoviral elafin treated
76NE6 or 76NF2V cells (Figure 30D). The TUNEL assay measures DNA fragmentation,
a result of apoptotic cell death.
These results suggest that elafin induces apoptosis preferentially in Rb deficient
HMECs (76NE7) compared to Rb-expressing HMECs (76NE6 and 76NF2V).
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Figure 30: Exogenously Expressed Elafin Induces Apoptosis in HMECs Lacking Functional Rb.

(A-D) 76NE6, 76NF2V, and 76NE7 cells were treated with PBS, adenoviral luciferase
(Ad-L), or adenoviral elafin (Ad-E). (A) Cells were harvested 48 hours post-treatment
and subjected to western blot analysis for elafin expression. Actin, loading control. (B)
Growth was monitored by trypan blue exclusion test every 24 hours for 96 hours.
Asterisk indicates statistical significant. (C) Proliferation was assessed 48 hours posttreatment by measuring BrdU incorporation. (D) Apoptosis was assessed 72 hours
post-treatment by TUNEL assay.
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Expression of Elafin in Rb Negative Breast Cancer Cells Results in Apoptosis.

Based on the finding that elafin induces apoptosis in Rb deficient HMECs, we
hypothesized that Rb deficient breast cancer cell lines are susceptibility to elafininduced apoptosis. We examined elafin re-expression in three breast cancer cell lines
with functional/wild-type Rb (MCF-7, ZR75.1, and T47D) and three cell lines deficient in
Rb (MDA-MB-157, MDA-MB-468 and MDA-MB-436). All six cell lines were treated with
adenoviral elafin, adenoviral luciferase, or PBS and were examined for growth kinetics,
BrdU incorporation, and TUNEL positivity (Figure 31). Western blot analysis of
adenoviral transduced cells reveals restoration of elafin expression in breast cancer cell
lines comparable to control (76NE6 cells growth factor deprived for 48 hours),
suggesting that elafin is being expressed at physiologically relevant levels (Figure 31A).
Treatment of Rb positive breast cancer cell lines with adenoviral elafin resulted in a
modest growth inhibition, whereas treatment of Rb negative cell lines with adenoviral
elafin resulted in a precipitous decline in cell number (Figure 31B).
All three of the Rb expressing cell lines demonstrated a significant reduction in
BrdU incorporation, while the Rb deficient cell lines demonstrated no significant change
in BrdU incorporation (Figure 32A). Examination of TUNEL positivity fails to identify an
increase in apoptotic cell death in Rb positive cell lines in response to adenoviral elafin.
However, all three Rb negative cell lines underwent significant levels of apoptosis in
response to elafin expression (Figure 32B).

The percent TUNEL positivity ranged

between 22-30% of all Rb negative cells treated with adenoviral elafin, compared to 15% of cells treated with adenoviral luciferase (p<0.01).
These results suggest that elafin overexpression results in growth inhibition in
Rb positive cells and apoptosis in Rb negative breast cancer cells.

155

Figure 31: Expression of Elafin in Rb Negative Breast Cancer Cells Results in Apoptosis.

(A,B) MCF-7, ZR75.1, T47D, MDA-MB-157, MDA-MB-436, and MDA-MB-468 cells
were treated with PBS, adenoviral luciferase, or adenoviral elafin. (A) Cells were
harvested 48 hours post-treatment and subjected to western blot analysis for elafin
expression. Actin, loading control. (B) Growth was monitored by trypan blue exclusion
test every 24 hours for 96 hours. Asterisks indicate a statistically significant change in
cell number, elafin treated compared to controls.
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Figure 32: Expression of Elafin in Rb Negative Breast Cancer Cells Results in Apoptosis.

(A,B) MCF-7, ZR75.1, T47D, MDA-MB-157, MDA-MB-436, and MDA-MB-468 cells
were treated with PBS, adenoviral luciferase, or adenoviral elafin. (A) Proliferation was
assessed 48 hours post-treatment by measuring BrdU incorporation. (B) Apoptosis was
assessed 72 hours post-treatment by TUNEL assay.
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Inhibition of Caspase Activity Leads to Attenuation of Elafin-Mediated Apoptosis.

Caspase activation is essential to apoptotic cell death. Caspase 3 is a
component of both the intrinsic and extrinsic (death receptor) apoptotic pathways.
Cleavage of caspase 3 and caspase 3 target PARP are specific indicators of apoptotic
cell death (Figure 33). To determine if caspase activity is increased by adenoviral elafin
expression in the Rb negative cells we examined caspase 3 and PARP cleavage by
western blot analysis. Treatment of the Rb deficient cell line MDA-MB-468 with
adenoviral elafin dramatically increased cleavage of PARP and caspase 3, suggesting
activation of caspase-dependent apoptosis (Figure 33A). To determine if adenoviral
elafin-induced cell death is caspase-dependent, MDA-MB-468 and MDA-MB-157 cells
were treated with adenoviral elafin in the presence of the pan-caspase inhibitor zVadfmk. Treatment with zVad-fmk significantly reduced elafin-mediated cell death,
indicating a requirement for caspase activation in elafin-induced cell death (Figure 33B).
These results suggest that elafin induces caspase-dependent, apoptosis in Rb deficient
breast cancer cells and not another form of cell death.
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Figure 33: Inhibition of Caspase Activity Leads to Attenuation of Elafin-Mediated Apoptosis.

(A) MDA-MB-468 cells were treated with PBS, adenoviral luciferase, or adenoviral elafin
for 48, 72, and 96 hours. Cells were harvested and lysates were subjected to western
blot analysis for full length caspase 3, cleaved caspase 3 (Asp175), PARP, and elafin.
Actin, loading control. (B) MDA-MB-468 and MDA-MB-157 cells were treated with PBS,
adenoviral luciferase, or adenoviral elafin in the presence of 50 µM zVad-fmk, DMSO,
or PBS. Viability was measure by MTT assay every 24 hours for 120 hours. Eight
replicates from two independent experiments were combined and expressed as a
percentage of the PBS control. Statistical significance was calculated by the t-test for no
treatment vs. elafin-alone (1), luciferase alone vs. elafin alone (2), and elafin + DMSO
vs. elafin + zVad-fmk (3): displayed as a table.
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MDA-MB-231 Rb Knockdown Cells are Sensitive to Elafin-Induced Apoptosis.

We next examined if Rb directly mediates the sensitivity of breast cancer cell
lines to elafin-induced cytotoxicity. MDA-MB-231 cells expressing Rb shRNA (RBKD)
cells were evaluated by western blot analysis. In these cells Rb is efficiently
downregulated (Figure 34A; left panel). Adenoviral expression of the elafin transgene
was approximately equivalent in the MDA-MB-231 RBKD and controls cell lines and
similar to the level expressed by 76NE6 cells growth factor deprived for 48 hours
(control) (Figure 34A; right panel). MDA-MB-231 RBKD cells demonstrate enhanced
growth kinetics compared to control and parental cells (Figure 34B). MDA-MB-231
RBKD cells also demonstrate enhanced sensitivity to the adenoviral elafin-induced
cytotoxicity (Figure 34B). Treatment of the MDA-MB-231 RBKD cells with adenoviral
elafin resulted in a significant reduction in cell number 72 and 96 hours post-treatment
when compared to MDA-MB-231 parental or shRNA control cells (Figure 34C). To
validate that the decrease in cell number was due to adenoviral elafin induced
apoptosis, TUNEL staining was performed. A significant increase in TUNEL positivity
was detected in MDA-MB-231 RBKD cells compared to control cell lines (Figure 34D).
These results illustrate a direct role for Rb deficiency in sensitizing breast cancer cells
to elafin-induced apoptosis.
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Figure 34: Knockdown of Rb in MDA-MB-231 Cells Increases Sensitivity to Elafin-Induced
Apoptosis.

(A-D) MDA-MB-231 parental, shRNA control, and RBKD cell lines were treated with
PBS, adenoviral luciferase, or adenoviral elafin (A) Lysates were collected at 48 hours
and subjected to western blot analysis. PBS treated lysates were examined by western
for Rb expression, left panel. All lysates were examined for elafin expression, right
panel. Actin, loading control. (B) Growth was monitored by trypan blue exclusion test
every 24 hours for 96 hours. Asterisks indicate a statistically significant difference in
cell number comparing elafin treated to luciferase and PBS treated cells. (C) Cell
number at 96 hours was compared between MDA-MB-231 parental, control, and RBKD
cells; cell viability was calculated as a percentage of the PBS control. (D) Apoptosis was
assessed 72 hours post-treatment by TUNEL assay.
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Rb is Required for Elafin Induced G0/G1 Arrest in MCF-7 Cells.
Treatment of Rb positive breast cancer cell lines with adenoviral elafin causes
them to undergo proliferative arrest not apoptosis (Figure 32). To further characterize
cell cycle arrest in Rb positive breast cancer cells we performed DNA content analysis.
Treatment of MCF-7 (Rb positive) cells with adenoviral elafin results in the accumulation
of cells in the in the G1 phase of the cell cycle (Figure 35A). Rb is a critical component
of the G1 checkpoint control, therefore we examined if elafin overexpression modulates
CDK4 kinase activity and Rb phosphorylation in MCF-7 breast cancer cells. For these
experiments MCF-7 cells were treated with PBS, adenoviral luciferase, or adenoviral
elafin for the 24, 48, and 72 hours. Lysates were subjected to western blot analysis and
a CDK4 immunoprecipitation kinase assays (Figure 35). Elafin treatment resulted in a
decrease in the phosphorylation of Rb using phospho-specific antibodies, directed
against serine 807/811, serine 780, and total phosphorylated Rb (Figure 35B). The
CDK4 kinase activity was measured using GST-Rb as a substrate. CDK4 kinase activity
was profoundly decreased following overexpression of elafin (Figure 35C). These
results suggest that the expression of elafin in MCF-7 cells causes a G1 arrest
characterized by a decreased in Rb phosphorylation, in part due to attenuation of CDK4 kinase activity.
Next, we set out to examine if Rb downregulation in MCF-7 cells is sufficient to
convert cell fate from growth arrest to apoptosis following elafin expression (as was the
case in the RBKD MDA-MB-231 cells [Figure 34]). To accomplish this we treated MCF7 cells stably expressing an shRNA vector targeting Rb with PBS, adenoviral luciferase,
or adenoviral elafin and examined cell viability (Figure 36). Efficient downregulation of
Rb was observed by western blot analysis in MCF-7 RBKD cells compared to control
and parental MCF-7 cells (Figure 36A; left panel). Consistent expression of the elafin
transgene was confirmed by western blot analysis for MCF-7 RBKD and control cells
(Figure 36A; right panel). Elafin expression achieved in MCF-7 RBKD and controls was
equivalent to levels observed in 76NE6 cells growth factor deprived for 48 hours (Figure
36A; right panel). MCF-7 shRNA control cells treated with adenoviral elafin
demonstrated a moderate reduction in cell number at 96 hours when compared to
luciferase control (Figure 36B), similar to the pattern seen in the MCF-7 parental cell
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line (Figure 31A). MCF-7 RBKD cells showed no significant change in growth kinetics
following treatment with adenoviral elafin or adenoviral luciferase (Figure 36C). MCF-7
RBKD cells demonstrate enhanced growth kinetics compared to controls (Figure 36C)
Direct comparison of the parental, shRNA control, and RBKD cell lines (normalized to
PBS control) illustrates failure of RBKD cells to arrest following administration of
adenoviral elafin, compared to control and parental cells. MCF-7 RBKD cells
demonstrate significantly less sensitivity to elafin-induced cell cycle arrest, as measured
by BrdU incorporation (Figure 36D). This indicates that knockdown of Rb in MCF-7 cells
does not sensitize cells to apoptosis, but is sufficient to attenuate cell cycle arrest.
Collectively, these results show that elafin induced growth arrest in breast
cancer cells is Rb-dependent.
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Figure 35: Expression of Elafin in MCF-7 Cells Causes a G0/G1 arrest.

(A) MCF-7 cells were infected with adenoviral luciferase or adenoviral elafin. Cells were
collected every six-hours for 72-hours and subjected to DNA content analysis. (B-C)
MCF-7 cells were treated with PBS, adenoviral luciferase, or adenoviral elafin. (B)
Lysates were subjected to western blot analysis and probed for pRb S807/811, pRb
S780, total pRb, and elafin. (C) CDK-4 was immunoprecipitated from 250 µg of protein
lysates, the immunocomplex was then subjected to in vitro kinase assay using GST-Rb
as a substrate.
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Figure 36: Rb is Required for Eafin-Induced G0/G1 Arrest in MCF-7 Cells.

(A-D) MCF-7 parental, shRNA control, and RBKD cell lines were treated with PBS,
adenoviral luciferase, or adenoviral elafin (A) Lysates were collected at 48 hours and
subjected to western blot analysis. PBS treated samples were examined for Rb
expression, left panel. All lysates were examined for elafin expression, right panel.
Actin, loading control. (B) Growth was monitored by the trypan blue exclusion test every
24 hours for 96 hours. Asterisk denotes statistical significance. (C) Cell number was
compared 96 hours post-treatment between MCF-7 parental, shRNA control, and RBKD
cell lines as a percentage of the PBS controls. (D) Proliferation was assessed 48 hours
post-treatment by measuring BrdU incorporation. Values are expressed as percent
inhibition of BrdU incorporation; values normalized to PBS and then subtracted from
100.
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Overexpression of Elafin Causes Apoptosis in MCF-7 Cells Only After
Knockdown of Rb and Restoration of Caspase 3.

Downregulation of Rb was shown to sensitize MDA-MB-231 cells to elafin
induced apoptosis; however downregulation of Rb in MCF-7 cells failed to replicate
these results. MCF-7 cells lack endogenously expressed caspase 3. Therefore we
hypothesized that loss of Rb and presence of caspase 3 are both required for elafininduced apoptosis. To address this hypothesis, we first confirmed that elafin expression
fails to induce apoptosis following reconstitution of caspase 3 alone. Western blot
confirmed the expression of caspase 3 in stably transfected MCF-7 cells (Figure 37A,
left panel). MCF-7 caspase 3 reconstituted cells were treated with PBS, adenoviral
luciferase, or adenoviral elafin. Western blot analysis confirms equivalent expression of
elafin (Figure 37A). No significant increase in apoptotic cell death, measured by TUNEL
assay, was seen in MCF-7 caspase 3 or MCF-7 RBKD cells in response to adenoviral
elafin (Figure 37B).
To directly examine if Rb downregulation and presence of caspase 3 are corequirements for apoptosis in MCF-7 cells following elafin expression, we established
clones of MCF-7 RBKD and MCF-7 shRNA control cell lines expressing either
pcDNA3.1-empty vector or pcDNA3.1-caspase 3. Knockdown of Rb, stable expression
of caspase 3, and expression of the elafin transgene were verified by western blot
analysis (Figure 37C,D). Treatment of MCF-7 RBKD cells expressing caspase 3 with
adenoviral elafin caused a severe reduction in cell viability (Figure 38A). The same
experiment was performed in MCF-7 shRNA control cells line, however in these cells
reconstitution of caspase 3 did not lead to a significant decrease in viability compared to
controls. Comparison of cell viability at 120 hours post treatment demonstrates that
elafin mediated loss of cell viability in MCF-7 RBKD clones expressing caspase 3 is
significantly different from all other MCF-7 cell lines examined (Figure 38B). TUNEL
assay reveals a significant increase in the percentage of cells undergoing apoptosis in
MCF-7 RBKD expressing caspase 3 versus controls (PCDNA + Ad-luc, PCDNA+AdElafin or CASP 3 + Ad-Luc) (Figure 38C).
These results indicate that loss of Rb and the reconstitution of caspase 3 are
both required for elafin-induced apoptosis in the MCF-7 cell line.
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Figure 37: Adenoviral Elafin does not Induce Apoptosis in MCF-7 Rb Knockdown Cells.

(A) Lysates from MCF-7 pcDNA3.1 empty vector and pcDNA3.1-caspase 3 stable
clones were subjected to western blot analysis for caspase 3. Actin, loading control (left
panel). Lysates from MCF-7 pcDNA3.1 empty vector and pcDNA3.1-caspase 3 were
subjected to western blot analysis for elafin 48 hours after treatment with PBS,
adenovirus luciferase, or adenovirus elafin. Actin, loading control (right panels). (B)
MCF-7 pcDNA3.1 empty vector, pcDNA3.1-caspase 3, RbKD, and shRNA control cells
were treated with PBS, adenovirus luciferase, or adenovirus elafin. Apoptosis was
assessed by TUNEL assay. (B) MCF-7 RBKD cells were transected with either
pcDNA3.1 empty vector or pcDNA3.1-caspase 3 and selected in puromycin. Cells were
treated with adenoviral elafin. Lysates were subjected to western blot analysis.
Untreated cells were used to assess the levels of Rb and caspase 3, reproducibility of
transgene expression was assessed by western blot for elafin.
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Figure 38: Overexpression of Elafin Causes Apoptosis in MCF-7 Cells Only After Knockdown of Rb
and Restoration of Caspase 3.

(A) Cell viability was measured by MTT assay every 24 hours for 120 hours and
calculated at each time point by normalizing values from luciferase and elafin treated
cells to PBS control then plotting the difference between the viability of elafin and
luciferase (i.e. elafin effect – viral effect). (B,C) MCF-7 control shRNA background cells
expressing either pcDNA3.1 empty vector or pcDNA3.1-caspase 3. These cells were
assayed in the same manner as panels B and C. (C) The viabilities measured at 120
hours in the cell lines generated from the MCF-7 RBKD and MCF-7 control shRNA as
well as the parental cell lines were pooled and statistically compared. (C) Apoptosis was
measured by TUNEL assay.
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DISCUSSION
Elafin is expressed in HMECs, but it is transcriptionally downregulated in tumor
derived cell lines (24). In chapter 2, the data presented demonstrated that elafin was
highly upregulated in growth factor deprived, G0-HMECs (Figure 15) and is required for
maintenance of G0-arrest (Figure 21). In the absence of Rb, growth factor deprived
HMECs failed to arrest in G0 and did not express elafin at levels comparable to Rbexpressing HMECs (Figure 18). In this chapter, adenoviral-mediated expression of
elafin was used to determine if elafin expression alone is sufficient to induce growth
arrest in normally proliferating Rb-expressing HMECs (76NE6 and 76NF2V) and Rbdeficient (76NE7) HMECs. In this experiment, adenoviral-elafin failed to induce growth
arrest in Rb-expressing HMECs. However, in HMECs lacking Rb, adenoviral-elafin
surprisingly caused apoptotic cell death (Figure 30). This Rb-dependent apoptotic effect
led to the hypothesis that tumor cells with a deregulated Rb pathway could also be
forced to undergo apoptosis following elafin expression. Indeed, we observed that the
expression of elafin could induce apoptosis in Rb-negative cells (Figure 32). We also
found that Rb-positive breast cancer cells are growth inhibited in response to elafin
expression (Figure 32). In these cells, elafin expression led to the downregulation of
CDK4 activity and a reduction in Rb phosphorylation (Figure 35). Critically, Rb-positive
MDA-MB-231 cells, which are insensitive to adenoviral elafin-induced apoptosis, could
be converted to a sensitive phenotype by downregulation of Rb alone (Figure 34).
Of note, the Rb-negative cell lines used in this work were all of the basal-like
subtype and the Rb-positive cell lines were all of the luminal subtype. Rb-loss is rare in
the luminal subtypes of breast cancer (Figures 4 and 5), however it occurs with greater
frequency in the basal-like subtype of breast cancer (Figure 7). To exclude the
possibility that adenoviral elafin-induced cytotoxicity is exclusive to the basal-like
subtype, MCF-7 (luminal subtype) cells were converted to an elafin-sensitive phenotype
(Figure 38). MCF-7 cells were not sensitized to the apoptotic effect of adenoviral elafin
following Rb knockdown alone (Figure 37), as was the case with MDA-MB-231 cells
(Figure 34). Caspase activity is required for adenoviral elafin induced apoptosis (Figure
33). MCF-7 cells lack caspase 3 (Figure 37). Restoration of caspase 3 in MCF-7 Rb
knockdown cells was sufficient to sensitize these cells to adenoviral elafin induced
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apoptotic cell death, suggesting that the activity of elafin in breast cancer cell lines is not
dictated by breast cancer subtype. Rb-status and an intact caspase-dependent
apoptotic cascade are major determinate of sensitivity to elafin-induced apoptosis
versus growth arrest. Taken together, the results presented here clearly indicate that
elafin has tumor suppressive properties in breast cancer cell lines similar to results
reported for the serine protease inhibitors SLPI and maspin (747, 751-753, 761).
Following publication of the work presented here (678), adenoviral elafin was
shown to have therapeutic efficacy following intratumoral injection of MDA-MB-468
xenograft tumors (25). Adenoviral elafin treated MDA-MB-468 xenograft tumors
demonstrate a significant growth delay compared to adenoviral luciferase or PBS
treated tumors. The survival of adenoviral elafin treated, tumor-bearing mice was
significantly extended. Approximately 20% of the tumors were completely eradicated by
adenoviral elafin treatment (25).
Elafin downregulation has also been observed in melanoma. Elafin reexpression using a tet-inducible system resulted in apoptotic cell death in melanoma
cells, but not normal melanocytes. In this system p53 was required for the elafininduced cell death (27). In the work presented here, apoptotic cell death is p53
independent since all of the breast tumor cell lines (MDA-MB-468, MDA-MB-157, MDAMB-436) sensitive to elafin-induced apoptosis express mutant p53. Induction of elafin
expression in melanoma xenograft tumors significantly reduced tumor size (27).
The majority of breast tumors demonstrate elafin downregulation (Figure 10).
Approximately one-quarter of all breast tumors exhibit homologous loss or mutation of
Rb (768, 769). Rb loss is associated with aggressive breast cancer subtypes, especially
basal-like tumors (Figure 7) (770, 771). The basal-like subtype of breast cancer are
resistant to currently available targeted therapies (i.e. anti-estrogens and anti-HER2)
(427, 772). A therapy capable of specifically targeting breast tumors with Rb loss may
have significant clinical utility in highly aggressive breast tumors. Elafin represents a
candidate therapeutic capable of specifically targeting tumor cells with disruption of the
G1 checkpoint with no toxicity in normally dividing cells.
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Chapter 4: Neutrophil Elastase in Basal-like Breast Cancer Progression

INTRODUCTION
TAN and Tumorigenesis
Inflammatory signaling and the presence of leukocytes within the tumor
microenvironment are critical components of tumor progression (9, 10). Early tumor
microenvironment studies largely ignored the neutrophil component of the inflammatory
infiltrate due to doubts that such a short-lived cell type could dramatically impact
tumorigenesis (423).Tumor-derived chemokines drive the constant replenishment of
neutrophils in the tumor microenvironment. Chemokines are produced directly by tumor
cells as a consequence of oncogene-induced (e.g. K-Ras and Myc) NF-κB pathway
activation

(368,

407)

and

by

activated

fibroblasts

subjected

to

hypoxia,

chemotherapeutics, and other cellular stresses (373, 375).
Relatively few studies have examined tumor-associated neutrophils (TAN) in
human cancer. In renal cell carcinoma, TAN (CD66b-positive) were prognostic of short
recurrence-free survival (RFS). In the presence of TAN, patients demonstrated a fiveyear RFS of 53%, however in the absence of TAN patients had a five-year RFS of 87%.
In multivariate analysis, TAN were an independent prognostic marker of diseasespecific survival (DSS) and overall survival (OS) (410). In human gliomas, the
concentration of TAN (CD15-positive and myeloperoxidase-positive) correlate with high
tumor grade (411). High levels of neutrophils (scored based on H&E) in the
bronchoalveolar lavage fluid from patients with bronchioloalveolar carcinoma were
associated with high levels of IL-8, NE, and poor DSS (407). Although not commonly
observed in pancreatic tumors, TAN (scored based on H&E staining) were associated
with the aggressive micropapillary and undifferentiated subtypes (412). High neutrophil
levels in the peripheral blood were associated with poor outcome in metastatic
melanoma and renal cell carcinoma patients (408, 409).
TAN contribute growth factors (i.e. HGF), cytokines (i.e. Oncostatin M, TNFα,
IL1-β, IL-6, and IL-12), reactive oxygen species (ROS), and proteases (i.e. NE, PR3,
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CG, MMP-8, and MMP-9) to the tumor microenvironment (345, 418-421). In mouse
models, neutrophil depletion using Gr-1 (LY-6G) antibodies or blockade of neutrophil
recruitment using antibodies against Cxcr2, profoundly inhibited tumor growth,
angiogenesis, and metastasis in mouse tumor models (415-417). These studies
suggest a pro-tumorigenic role for TAN in human cancer. TGF-β blockade forced TAN
to assume an anti-tumor phenotype, however little evidence exists of a role for TAN in
anti-tumor immunity in the absence of therapeutic manipulation (422, 423).
NE and Tumorigenesis
Several groups demonstrated that high levels of NE (measured by ELISA) were
independently prognostic of OS, metastasis-free survival, DSS, and RFS in multivariate
analysis of breast cancer patients (12, 599-601). High NE expression demonstrated a
negative correlation with tumor ER and PR status. In ER-positive tumors the mean level
of NE was 5.8 ng/mg of tissue compared to 14.9 ng/mg in ER-negative tumors. In PRpositive tumors the mean level of NE was 6.0 ng/mg compared to 9.1 ng/mg in PRnegative tumors (12). Triple-receptor negative breast cancer (TNBC) highly expresses
chemokines critical to the recruitment and activation of TAN (773-776), indicating that
the recruitment of neutrophils is highest in TNBC and that these are the tumors with the
greatest concentration of NE. However, NE may also play a role in the outcome of
patients with ER-positive tumors. High levels of NE are associated with a poor response
rate to tamoxifen, shorter progression-free survival, and poor post-relapse free survival.
In multivariate analysis, NE is an independent predictive marker of response to
tamoxifen (599).
Sivelestat, a pharmacological inhibitor of NE, was able to reduce the
proliferation, motility, and chemotaxis of the pancreatic cancer cell line Capan-1 in vitro
(603). In a mouse xenograft model of non-small cell lung cancer using the EBC-1 and
PC-1 cell lines, sivelestat attenuates tumor proliferation (606). Sivelestat also inhibited
spontaneous metastasis of EBC-1 xenograft tumors (607). Beige mice are deficient in
NE (608). Cohorts of NE-deficient and control mice were created for the study of NE in
tumorigenesis by crossing beige mice with SKH 1 hairless mice. Following ultraviolet
irradiation, NE-expressing control mice developed an average of 10 tumors per mouse
after 20-weeks, while NE-deficient mice developed an average of only 0.4 tumors per
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mouse over the same period. In the same system, benzopyrene exposure resulted in
the formation an average of 7 tumors per control mouse and an average of only 0.2
tumors

per

NE-deficient

mouse.

Pharmacological

inhibitors

of

NE,

2,4,6-

trinitrochlorobenzene and oxazolone were able to attenuate the development of skin
tumors following ultraviolet irradiation of SKH 1 mice (609). NE knockout mice were
developed to understand the normal role of NE in immunity and inflammation (500). NE
knockout in the transgenic loxP-Stop-loxP K-rasG12D mouse model of lung cancer
dramatically reduced tumor burden compared to control. NE knockout significantly
extended survival in loxP-Stop-loxP K-rasG12D mice. Over a 30 weeks period following
administration of adenoviral Cre all of the NE+/+ genotype mice had reached the limit of
tumor burden, however none of the NE-/- mice has reached the same limit. NE
knockout dramatically reduced tumor growth. NE-mediated degradation of IRS-1
resulted in the activation of the PI3K-Akt pathway and may be responsible for enhanced
tumor growth (542).
Hypothesis and Central Findings
The hypothesis tested in this chapter states that NE is essential to the growth
and progression of breast cancer. Immunohistochemical analysis of NE in breast
tumors revealed that high levels of NE-expressing, TAN are associated with TNBC and
are prognostic of poor recurrence-free survival (RFS). ERK-catalyzed phosphorylation
of p90RSK (T359/S363) and Rb phosphorylation (S807/811) were significantly enriched
in NE-positive tumors. We generated C3(1)TAg x NE-/- mice to directly examine the
role of NE in TNBC development. Compared to C3(1)TAg x NE+/+ littermates, the
C3(1)TAg NE-/- mice showed decreased tumor growth and proliferation. Although NE is
implicated in inflammation, no statistically significant difference in the expression of
inflammatory cytokines, neutrophil, or macrophage infiltration was observed.
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MATERIALS AND METHODS
The methodology for preparation of protein lysates, western blot analysis,
growth curves, and immunohistochemistry are detailed in chapter two, modifications,
additional reagents, and additional protocols are described here.
Antibodies
Primary antibodies used for western blot (WB) and immunohistochemistry (IHC):
Antibody
Neutrophil
Elastase
Egr-1
Phosphop90RSK site
Thr359/Ser363
BrdU
Ly6G (Gr-1)
F4/80
Irs-1
Phospho-Akt
IκB
PhosphoGSK3β site
Ser9
SV40 large Tantigen

Species
Mouse
monoclonal
Rabbit
polyclonal

Clone

Company

Application

NP57

DAKO

IHC

Santa Cruz
Biotechnology

WB

Cell Signaling
Technology

WB

AbD Serotec

IHC

Rabbit
polyclonal
Rat
monoclonal
Rat
monoclonal
Rat
monoclonal
Mouse
monoclonal
Rabbit
monoclonal
Rabbit
monoclonal

BU1/75
(ICR1)
clone 1A8
6A545
4.2.2
D9E
44D4

BD
Biosciences
Santa Cruz
Biotechnology
Millipore
Cell Signaling
Technology
Cell Signaling
Technology

IHC
IHC
WB
WB
WB

Rabbit
polyclonal

Cell Signaling
Technology

WB

Rabbit
polyclonal

Santa Cruz
Biotechnology

WB

Immunohistochemistry
IHC analysis was performed as described in chapter two. The antigen retrieval
was omitted for NE-IHC because it destroys the epitope recognized by the antibody. For
IHC detection of BrdU, Ly6G, and F4/80 antibodies the biotin conjugated rabbit anti-rat
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secondary antibody (Abcam) was substituted for the secondary goat anti-mouse
antibody included on the Vectastain kit (Vector).
Patient Samples
For analysis of NE in breast tumors, 306 patients with stage I-III breast cancer
were enrolled in a prospective study between January 2000 and June 2010 (MD
Anderson lab protocol 00222). Fresh frozen tumor tissue and formalin-fixed, paraffinembedded tissue blocks were obtained from eligible participants. The median age of the
patient population was 56 years (range: 26-92 years) and median follow up was 6.2
years. Complete clinical and follow-up data was obtained by review of the patients’ files.
The MD Anderson Institutional Review Board approved the use of all patient derived
tissues.
Reverse Phase Protein Array (RPPA)
Tumor tissue was thawed and homogenized using a micromincer (BioSpec) and
prepared using the same protocol as western blot analysis described in chapter two.
RPPA analysis performed by the Functional Proteomics core facility at UT MDACC has
been previously described (777). Patient tumors were homogenized, lysed via
sonication, and cleared by ultracentrifugation; as previously described for western blot
analysis (678). Protein concentration was determined by Bradford assay and the lysates
were aliquoted in SDS containing sample buffer at a concentration of 1µg/µL. Protein
samples were serially diluted and arrayed on nitrocellulose coated slides (Grace Biolab)
using an Aushon 2470 Arrayer (Aushon BioSystems). The slides are probed with
different primary antibodies, followed by the appropriate biotin-conjugated secondary
antibody. The signal was amplified using the Catalyzed Signal Amplification System
(DAKO) and detected using DAB (DAKO). The slides were scanned with ImageQuant
(Molecular Dynamics) and spot intensity was determined by MicroVigene software
(VigeneTech Inc.). Protein abundance was defined by supercurve fitting, a logistic
model developed by the Dept. of Bioinformatics and Computaional Biology UT MDACC
for the relative quantification of each sample, and normalized for protein loading.

177

RPPA Antibodies

14-3-3 ζ
14-3-3 β
4EBP1
4EBP1 pS65
4EBP1 pT37
A-Raf pS299
αTubulin
αβ-Crystallin
ACC pS79
ACC1
AIB1
AKT
AKT pS473
AKT pT308
AMPK pT172
AMPK
Annexin
ARV
ATM
ATM pS198
ATR pS423
ATRIP
Beta-Catenin
Beta-catenin
pS33
B-RAF
BAD pS112
BAK
BAX
BClX
BClXL
BCl2
BCl2
BCl2 pS70
BID
BIM
BRCA1
BRCA2
cJun pS73
cKIT
cMyc
cMyc pT58

cRAF
Caspase 7
cleaved
Caspase 3
cleaved
Caveolin
CD20
CD31
CD86
CHK1
CHK1 pS345
CHK2
Collagenase VI
Cyclin B1
Cyclin D1
Cyclin E1
Cyclin E2
ECadherin
EGFR
EGFR pY1173
EGFR pY992
eIF4E
ELK1 pS383
ER pS167
ERα pS118
ERK2
ETV6
FAKC
FGFR1
FGFR2
Fibronectin
Fortilin
FOXM1
FOXO3a
FOXO3a pS318
GATA3
GSK pS9
GSK3 αβ
GSK3 αβ pS21
GYS1
GYS1 pS640
HER2

HLA-E
HSP27
HSP70
IGFBP2
IGFRb
IRS1
IRS1 p307
JNK pT183
KU80
MAPK pT202V
MEK1
MEK1/2 pS217
MGMTV
MMECD10
MRE11
MSH2
mTOR
N-Cadherin
NFκB p65
pS536
p21
p27
p38
p38_pT180
p53
p70S6K
p70S6K pS371
p70S6K pT389
p90RSK
p90RSK T359
PAI1
PARP cleaved
PAX2
PCNA
PDK1
PDK1 pS241
PI3K p110α
PKCE pT40
PKCα
PKCα pS657
PKCδ pS644
PLCR2 pY759

178

PLK1
PR
PTCH
PTEN
Rab25
RAD51
Rb
Rb pS807/811
S6
S6 pS235
S6 pS240
SHC pY317
SMAD1
SMAD3
SMAD3 pS423
SMAD4
SMAD6
SRC
SRC pY527
STAT3
STAT3 pS727
STAT3 pY705
STAT5
STAT5 pY694
STAT6 pY641
STAT6 pY641
Stathmin
SYK
TAU
TAZ
TAZ pS89
Telomerase
TSC2
TSC2 pT1462
VASP
VEGFR2
XRCC1
YAP
YAP pY127
YBI
YBI pS112
YKL40

Mice
The generation of C3(1)Tag (778) and NE knockout (500) mice were previously
described. Both were maintained in the FVB/N background. Experimental cohorts of
C3(1)Tag x NE-/- and C3(1)Tag x NE+/+ virgin female mice were monitored for tumor
development by biweekly palpation. Tumor growth rate was analyzed by bi-weekly
measurement of two orthogonal tumor diameters with a Vernier caliper. Mice were
sacrificed when tumor reached the 1.5 cm along greatest axis according to institutional
guidelines. Several mice were sacrificed at two months of age to assess tumor
progression. Two hours prior to sacrifice the mice were injected intraperitoneally with
100 mg BrdU/kg body weight. The contralateral mammary gland was fixed in formalin
and paraffin embedding for IHC analysis. The tumor was excised, half was fixed in
formalin and paraffin embedding for IHC analysis and the other half was snap frozen in
liquid nitrogen for protein and mRNA extraction.
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RESULTS
NE-Positive TAN Predict Recurrence in Breast Cancer Patients and Correlate with
the Phosphorylation of Erk-Effector p90RSK and Rb.

To understand the role of NE in patients with invasive breast cancer, the
correlation between NE expression, patient outcome, clinicopathological parameters,
and intracellular signaling pathways was examined in breast tumor samples. For this
study, we performed immunohistochemical staining for NE and elafin on 305 breast
tumors prospectively collected from patients at The University of Texas MD Anderson
Cancer Center for the examination of predictive markers. This patient cohort had
advantages compared to the TMA cohort presented in Chapter 2. First, full tumor blocks
were available, allowing our pathologists to examine representative areas of tumor
epithelium and include the peritumoral area, where TAN often localize. Second, fresh
frozen tissue was available from the majority (276/305) of patients, allowing us to
perform RPPA analysis.
We first validated the finding presented in Chapter 2 that elafin is downregulated
in invasive breast tumors. As in Chapter 2, elafin expression was classified as at or
above the expression level in normal breast epithelium (elafin score 6-8) or
downregulated compared to the expression level in normal breast epithelium (elafin
score 0-5) (Figure 39A). This analysis revealed that the percentage of tumors with elafin
downregulation in this patient cohort was almost identical to the percentage of tumors
with elafin downregulation in the TMA cohort presented in Chapter 2 (Figure 39B).
Immunohistochemical analysis of NE (Figure 40A) revealed the presence of
TAN in 118 of 305 (39%) tumors examined. Positivity was defined as greater than 5
TAN per high-power field; only NE-positive neutrophils within the tumor area were
counted. Breast cancer patients with high levels of TAN, defined as greater than 15
TAN per high-power field, were present in 45 of 305 tumors (15%) and correlated with a
significantly poorer RFS than tumors with low levels of TAN or no TAN (Figure 40B).
High levels of TAN were significantly associated with TNBC, high tumor grade, and
recurrence on univariate analysis (Table 9). Cox proportional hazards analysis revealed
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that high levels of TAN were independently prognostic of RFS and were associated with
a hazard ratio of 2.4 (95% CI, 1.1-5.5) for RFS (Table 10).
The correlation between the NE-positive infiltrate and cancer cell signaling
pathways was examined by subjecting tumor lysates from the 276 patients who had
fresh frozen tissue available for RPPA analysis (Figure 41). Comparison of breast
tumors positive for TAN (107/276) and breast tumors negative for TAN (169/276) using
the Mann-Whitney U-test revealed differences in the abundance of several signaling
intermediates (Table 11). High levels of p90RSK phosphorylated at threonine
359/serine 363 (phosphorylation catalyzed by ERK) and Rb phosphorylated at serine
807/811 were strongly associated with the presence of NE-positive TAN (Figure 42A).
To determine if NE can induce phosphorylation of p90RSK and Rb, 76NE6 cells
and the breast cancer cell lines MDA-MB-231 and MDA-MB-157 were cultured in the
absence of growth factors for 24 hours and stimulated with 10 nM NE. We observed
dose-dependent increases in cell proliferation in both tumor cell lines and 76NE6
HMECs 48 hours after addition of NE (Figure 42B). MDA-MB-231, MDA-MB-157, and
76NE6 cells were also harvested 30 and 120 minutes after NE addition. Western blot
analysis revealed increased phosphorylation of p90RSK T359/S363 and Rb S807/811,
especially in MDA-MB-157 and 76NE6 cells (Figure 42C). NE stimulation also
enhanced phosphorylation of ERK and resulted in EGR1 upregulation in these cell lines
(Figure 36C). Both ERK and Rb phosphorylation were largely saturated in MDA-MB-231
cells; however, addition of NE modestly enhanced phosphorylation of p90RSK and still
resulted in upregulation of EGR1 (Figure 42C).
NE-positive TAN were prognostic of poor RFS, associated with an aggressive
tumor phenotype, and correlated with the phosphorylation of p90RSK and Rb.
Exogenous NE activates the ERK signaling pathway in immortalized HMECs and breast
cancer cell lines.
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Figure 39: Comparison of Elafin Expression between Breast Cancer Patient Cohorts.

(A,B) Elafin expression was examined by IHC in the TMA breast cancer patient cohort
presented in chapter 2 (Cohort 1) and in the non-TMA breast cancer patient cohort
described in this chapter (Cohort 2). (A) Frequency distribution illustrating the
percentage of cases falling into each categorical score over the range 0-8 for breast
cancer patient cohorts. (B) Quantification of elafin downregulation in the two breast
cancer patient cohorts. An elafin score of 6-8 denotes cases at or above the elafin
expression level observed in the normal breast epithelium, while an elafin score of 0-5
denotes downregulation.
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Figure 40: NE-Positive TAN Predict Recurrence in Breast Cancer Patients

(A) Representative photomicrographs of NE immunohistochemical staining of invasive
breast carcinoma with negative (i), low (ii), and high (iii and iv) levels of TAN. (B)
Kaplan-Meier plot of RFS in breast cancer patients segregated by expression of TAN,
low/negative versus high.
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Table 9: Univariate Analysis of Patient and Tumor Characteristic in Breast Cancer Patients with
and without Tumor Associated Neutrophils.

Tumors with high TAN were compared to tumors with low/negative TAN for their
relationship to clinicopathological factors in breast cancer. The p-value was calculated
by Fisher’s exact test, unknowns were excluded from the analysis.
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Table 10: Multivariate Cox Proportional Hazards Analysis of Clinicopathologic Variables’
Influence on Breast Cancer Recurrence-free Survival.

Multivariate analysis was performed using the whole cohort (n=305) on all
clinicopathological except for ER, PR and tumor grade since those variables were
highly associated with TAN in univaritate analysis.
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Figure 41: Hierarchical Clustering of RPPA data.

RPPA analysis was performed on 276 breast tumor lysates. Hierarchical clustering was
performed on the log2-median centered values by Pearson correlation (centered) using
the Cluster 3.0 software (Eisen Lab) and visualized as a heatmap using treeview (Eisen
Lab). Tumors were segregated into three clusters, however these clusters did not
correlate with ER, PR, or HER status and did not segregate NE positive and negative
tumors. A possible explanation is the neo-adjuvant treatment of these patients.
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Table 11: Statistically Significant Events Correlating with TAN-Positivity in RPPA Analysis.

Relative abundance of critical nodes in cell signaling pathways was examined using
RPPA with 174 validated antibodies. Statistical comparison of TAN-positive and TANnegative cohorts was performed using the Mann-Whitney U-test. The mean of the
normalized, linear RPPA values are reported for each group.
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Figure 42: NE-Positive TAN Correlate with the Phosphorylation of ERK-Effector p90RSK and Rb
in Breast Tumors.

(A) Relative abundance of pp90RSK T359/S363 and pRb S807/811, according to RPPA
analysis. Values represent log2-median centered values. The p-value was calculated by
Mann-Whitney U-Test. (B) Change in cell number determined by MTT assay for 76NE6,
MDA-MB-231, and MDA-MB-157 treated with 0, 2, 4 nM NE for 48 hours (C) 76NE6,
MDA-MB-231, and MDA-MB-157 cell were treated with 10µM NE and subjected to
western blot for pRb, pERK, pp90RSK, and EGR-1. Actin, loading control.
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NE Knockout Reduces Tumor Growth and Proliferation in the C3(1)TAg Model of
TNBC
Genetically engineered mouse models can recapitulate the progression of
human breast cancer. Many molecular, histological, and genetic similarities exist,
however mouse models fail to completely reproduce the molecular heterogeneity of
human breast tumors (779-781). Based on the relatively high concentration of NE in
NE-positive TAN observed in human TNBC patients, a mouse model of TNBC was
considered ideal to test the hypothesis that NE plays a role in breast tumorigenesis.
Relatively few mouse models of TNBC exist, due in part to the use of hormone
responsive promoters to target oncogenes to the mammary epithelium.
The C3(1)TAg mouse model has been shown to give rise to TNBC and is
molecularly similar to basal-like breast cancer in humans (778, 779, 782, 783). In this
model, the expression of SV40 large tumor antigen is directed to the mammary gland by
the promoter of rat prostatic binding protein C3 (1) (Pbpc3). This results in the
downregulation of p53 and Rb tumor suppressor pathways in the mammary epithelium.
Atypia of the mammary ductal epithelium develops at about eight weeks of age, which
progress to mammary intraepithelial neoplasia (resembling DCIS) at about twelve
weeks of age. Invasive carcinomas develop at about sixteen weeks of age in onehundred-percent of female mice (male mice get prostate cancer). Lung metastasis
develop in ten to fifteen-percent of tumor bearing mice. C3(1)TAg mice are a useful and
predictable model of TNBC development (778, 782).
C3(1)TAg mice were crossed with the previously established NE knockout mice
(500). C3(1)TAg x NE+/+ and C3(1)TAg x NE-/- cohorts were followed for tumor
development for approximately 6 months, at which point all mice had developed tumors
(Figure 43A). No statistically significant difference was found in tumor incidence
between the C3(1)TAg x NE+/+ and C3(1)TAg x NE-/- cohorts (Figure 43A).
Following tumor initiation, growth was followed until the tumor exceeded the
maximal allowable size of 1.5 cm along the greatest tumor axis (Figure 43B). Doubling
time was calculated by application of an exponential growth model. C3(1)TAg x NE-/tumors demonstrated a significantly slower tumor growth rate compared to C3(1)TAg x
NE+/+ mice (Figure 43C). To determine if the difference in tumor growth rate was due
to altered proliferation, tumors were subjected to immunohistochemical analysis of BrdU
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incorporation (mice were injected with 100 mg BrdU/kg body weight two hours prior to
sacrifice) (Figure 44A). Quantification reveals significantly less proliferation in C3(1)TAg
x NE-/- compared to C3(1)TAg x NE+/+ tumors (Figure 44B). To determine if
differences in apoptotic cell death contribute to the observed difference in tumor growth
between genotypes, the tumors were subjected to immunohistochemical analysis for
cleaved caspase 3 (Figure 45A). No statistically significant difference in the number of
cleaved caspase 3 positive cells was observed between genotypes following
quantification (Figure 45B).
The mammary glands of C3(1)TAg x NE-/- and C3(1)TAg x NE+/+ genotype
mice sacrificed at two months of age were subjected to immunohistochemical analysis
of BrdU incorporation (Figure 46A). No statistically significant difference in the
percentage of BrdU positive cells was observed (Figure 46B). Immunohistochemical
analysis of BrdU incorporation was also preformed in the contralateral mammary gland
of tumor bearing mice (Figure 46C). Quantification reveals significantly lower levels of
proliferation in the contralateral mammary glands of C3(1)TAg x NE-/- compared to
C3(1)TAg x NE+/+ (Figure 46D). These results suggest that NE activity may be an
important factor in the growth of pre-invasive lesion in the mammary gland.
NE is a component of the inflammatory response. Deregulated NE activity is
known to promote inflammatory gene expression. Deregulated inflammatory signalling
is a critical driver of tumor proliferation, therefore we examined the expression of
inflammatory gene expression in C3(1)TAg x NE-/- and C3(1)TAg x NE+/+ tumors
(Figure 47). Proliferation-associated genes, Melk and Mki67, were significantly
downregulated in C3(1)TAg x NE-/- compared to C3(1)TAg x NE+/+ when evaluated by
quantitative RT-PCR (Figure 47). However, evaluation of inflammatory-associated
genes, Tnf, Il1b, Il6, Csf2, Cxcl1, Ccl3, Mmp9, and Ccl2 does not reveal a statistically
significant difference between C3(1)TAg x NE-/- and C3(1)TAg x NE+/+ genotypes
(Figure 47). Hierarchical clustering of inflammatory gene expression identifies a cluster
of C3(1)TAg tumors with relatively high levels of inflammatory gene expression and a
cluster of C3(1)TAg tumors with relatively low inflammatory gene expression. However,
clustering based on these failed to differentiate tumors based on the NE-/- or NE+/+
genotype (Figure 48). Taken together these results suggest that NE may have a

190

specific role in promoting breast tumor cell growth, but not in the inflammatory
microenvironment.
To assure that decreased proliferation in C3(1)TAg x NE-/- was not due to a
decrease in the infiltration of neutrophils, immunohistochemical analysis of Ly6G (Gr-1)
was performed (Figure 49A). Quantification of Ly6G positive neutrophils revealed no
statistically significant difference between C3(1)TAg x NE-/- and C3(1)TAg x NE+/+
groups (Figure 49B). Macrophages are an abundant inflammatory component of the
tumor microenvironment. Immunohistochemical analysis of F4/80 was performed to
assess the concentration of macrophages within the tumor stroma where macrophages
predominately localized (Figure 49C). Quantification of peritumoral macrophages
reveals no statistically significant difference between the C3(1)TAg x NE-/- and
C3(1)TAg x NE+/+ genotypes (Figure 49D).
Western blot analysis was preformed on lysates from twelve tumors from both
the C3(1)TAg NE+/+ and C3(1)TAg NE-/- genotypes. Several tumors from NE knockout
mice demonstrated slightly higher levels of the NE substrate Irs-1, however the levels
were not consistently different between genotypes and no correlation was seen with the
phosphorylation of Akt (Ser473) or the Akt substrate GSK3β (Ser9), as previously
reported in a lung cancer model (542). Phosphorylated Erk (Thr202/Try204), Erk
catalyzed phosphorylation of p90RSK (Thr359/Ser363), and the Erk regulated
transcription factor Egr-1 demonstrated no consistent difference in expression between
the C3(1)TAg NE+/+ and C3(1)TAg NE-/- tumors. Tlr4, an extracellular receptor
activated by NE, was consistently expressed in all samples independent of tumor
genotype. The NF-κB pathway inhibitor IκB was not differentially expressed in C3(1)TAg
NE+/+ and C3(1)TAg NE-/- tumors. SV40 large T-antigen was expressed at equal
levels in both tumor genotypes suggesting that the absence of NE did not compromise
the integrity of the C3(1)TAg model (Figure 50).
Taken together the results presented here suggest that NE contributes to tumor
growth and proliferation, but is not dependent on upregulation of inflammatory
mediators.
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Figure 43: Tumor Incidence and Growth in C3(1)TAg x NE+/+ and C3(1)TAg x NE-/- Genotype
Mice.

(A) Kaplan-Meier analysis of tumor incidence in C3(1)TAg NE+/+ and C3(1)TAg NE-/cohorts. (B) Growth kinetics for individual C3(1)TAg NE+/+ (left panel) and C3(1)TAg
NE-/- (right panel). (C) Doubling time was calculated for all C3(1)TAg NE+/+ and
C3(1)TAg NE-/- tumors by fitting an exponential growth model.
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Figure 44: BrdU Incorporation in C3(1)TAg x NE+/+ and C3(1)TAg x NE-/- Genotype Tumors.

(A) C3(1)TAg NE+/+ and C3(1)TAg NE-/- tumors were subjected to
immunohistochemical analysis of BrdU incorporation. (B) BrdU positive cells were
counted as a percentage of total cells in three representative high magnification fields
per tumor, a total of six tumors were examined per group.
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Figure 45: Cleaved Caspase 3 in C3(1)TAg x NE+/+ and C3(1)TAg x NE-/- Genotype Tumors.

(A) C3(1)TAg NE+/+ and C3(1)TAg NE-/- tumors were subjected to
immunohistochemical analysis of cleaved caspase 3. (B) Cleaved caspase 3 positive
cells were counted in six representative high magnification fields per tumor, a total of six
tumors were examined per group
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Figure 46: BrdU Incorporation in C3(1)TAg x NE+/+ and C3(1)TAg x NE-/- Genotype Mammary
Glands.

(A) C3(1)TAg NE+/+ and C3(1)TAg NE-/- mammary gland from two month old mice
were subjected to immunohistochemical analysis of BrdU incorporation. (B) BrdU
positive cells were counted as a percentage of total cells in ten representative high
magnification fields per section, a total of six sections were examined per group. (C)
C3(1)TAg NE+/+ and C3(1)TAg NE-/- mammary gland contralateral to the tumors
examined in Figure 39A were subjected to immunohistochemical analysis of BrdU
incorporation. (D) BrdU positive cells were counted as a percentage of total cells in ten
representative high magnification fields per section, a total of six sections were
examined per group.
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Figure 47: Quantitative PCR of Proliferation and Inflammatory Gene Expression in C3(1)TAg x
NE+/+ and C3(1)TAg x NE-/- Genotype Tumors.

(A) Quantitative RT-PCR was used to evaluated the levels of proliferation and
inflammation-associated gene expression in C3(1)TAg NE+/+ and C3(1)TAg NE-/tumors; twelve tumors were examined per group. Values were normalized to Actin
expression and are represented relative to mean C3(1)TAg NE+/+ expression.
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Figure 48: Inflammatory qRT-PCR Gene Signature in C3(1) TAg Tumors

Quantitative RT-PCR was used to evaluated the levels of inflammation associated gene
expression in C3(1)TAg NE+/+ and C3(1)TAg NE-/- tumors (some presented in Figure
47). Hierarchical clustering was performed on the log2-median centered values by
Pearson correlation (centered) using the Cluster 3.0 software (Eisen Lab) and
visualized as a heatmap using treeview (Eisen Lab).
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Figure 49: Neutrophil and Macrophage Infiltration in C3(1)TAg x NE+/+ and C3(1)TAg x NE-/Genotype Tumors.

(A) C3(1)TAg NE+/+ and C3(1)TAg NE-/- tumors were subjected to
immunohistochemical analysis of Ly6G a specific marker of neutrophils. (B) Ly6G
positive cells were counted in ten representative high magnification fields per tumor, a
total of six tumors were examined per group. (C) C3(1)TAg NE+/+ and C3(1)TAg NE-/tumors were subjected to immunohistochemical analysis of F4/80, a specific marker of
macrophages. (D) F4/80 positive cells were counted in ten representative high
magnification fields per tumor, a total of six tumors were examined per group.
Macrophages accumulate in the peritumoral stroma, therefore representative fields
were choose directly adjacent to the tumor epithelium.
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Figure 50: Western Blot Analysis of Signaling Pathways Implicated in NE-Induced Proliferation in
C3(1)TAg x NE+/+ and C3(1)TAg x NE-/- Genotype Tumors.

Whole tumor lysates from 12 C3(1)TAg NE+/+ and 12 C3(1)TAg NE-/- genotype mice
were subjected to western blot analysis for Irs-1, pAkt (Ser473), pGSK3β (Ser9), pERK
(Thr202/Try204), Egr-1, p90RSK (Thr359/Ser363), Tlr4, IκB, SV40 large T-antigen.
Actin, loading control.
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DISCUSSION
NE expression is restricted to the myeloid lineage. In normal blood, NE
immunohistochemistry strongly stains neutrophils and only very weakly stains a
subpopulation of monocytes. NE immunohistochemistry also stains neutrophil
precursors in the bone marrow and can be used to identify acute myeloid leukemia cells
(784). Tumor-promoting myeloid derived suppressor cells, a heterogeneous population
of undifferentiated granulocytes often observed in the tumor microenvironment, have
been reported to express NE at the mRNA level (785) and may be detected by NE
immunohistochemistry performed on tumor sections
Downregulation of elafin in breast tumors suggests increased sensitivity to the
growth promoting effect of NE. NE is largely contributed by TAN within the tumor
microenvironment (616). The ability of tumor cells to recruit and manipulate
nonmalignant cell types, including fibroblasts, endothelial cells, and leukocytes, governs
their malignant growth potential (786). Immunohistochemical analysis of NE in a breast
tumor specimens revealed that high levels of NE-expressing TAN (Figure 40A). High
levels of NE-expressing TAN were prognostic of poor RFS, high tumor grade, and a
TNBC phenotype (Figure 40B). These results are consistent with previous studies that
found a correlation between high levels of NE measured by ELISA and poor patient
survival (12, 599-601). The expression of the endogenous NE inhibitor elafin was also
evaluated by immunohistochemistry in this patient cohort. Using the cutoffs established
in Chapter Two (Figure 10) elafin expression was found to be downregulated in the
majority of invasive breast tumors, validating these results (Figure 39). Therefore,
deregulated NE-activity in breast tumors is likely multifactorial, resulting from both the
downregulation of endogenous protease inhibitors and the increased concentration of
NE secreted by TAN during tumor progression.
RPPA analysis of cancer cell signaling pathways revealed the enrichment of
ERK catalyzed phosphorylation of p90RSK at T359/S363 (787) and phosphorylation of
Rb at S807/811 in tumors with TAN (NE-positive) compared to tumors without TAN
(NE-negative) (Figure 42A). In Chapter two, TLR4-dependent ERK activation and
proliferation was observed following the addition of exogenous NE to G0-arrested
HMECs. Treatment of breast cancer cell lines and immortalized HMECs with NE is
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capable of inducing phosphorylation of p90RSK at T359/S363 and phosphorylation of
Rb at S807/811 (Figure 42C), indicating that NE is a TAN-secreted factor capable of
enhancing the phosphorylation of these proteins. TAN secrete an array of growth
factors, proteases, cytokines, and ROS into the tumor microenvironment
In our analysis, we used a cut-off of 15 TAN per high-magnification field, which
is higher than the cut-off used to interrogate the correlation with cell signaling pathways
by RPPA (5 TAN per high-power field). Chronic inflammation is known to be an
important contributing factor to breast cancer recurrence (367). Use of the higher cut-off
to identify the prognostic significance of NE-expressing TAN may identify a group of
highly inflammatory tumors. NE-induced TLR4 activation has been shown to induce the
expression of pro-inflammatory cytokines/chemokines (590, 737) and may have a role
in amplifying the inflammatory response within this subset of breast tumors.
NE-positive TAN were shown to be enriched in TNBC and high-grade tumors
(Table 9). NE levels (measure by ELISA) have previously been shown to correlate with
ER and PR negative status (12). TNBC highly expresses chemokines critical to the
recruitment of TAN, especially IL-8, which may account for the increased number of
TAN in these tumors (773-776).
The C3(1)TAg mouse model has been shown to give rise to TNBC tumors that
are molecularly similar to basal-like breast cancer in humans (778, 779, 782, 783).
Therefore we utilized the C3(1)Tag model of TNBC to test the mitogenic role of NE in
vivo. No direct homolog of elafin exists within the mouse genome (639), therefore the
contribution of elafin downregulation to breast tumorigenesis could not be directly tested
in vivo. NE knockout were previously generated to study the role of NE in immunity and
inflammation (500). NE knockout was shown to limit tumor growth and progression in
the loxP-Stop-loxP K-rasG12D mouse model of lung cancer (542). We found that NE
knockout does not slow the kinetics of tumor progression in the C3(1)TAg model (Figure
43A), however NE knockout does reduce tumor growth (Figure 38C) and proliferation
(Figure 39A,B).
C3(1)TAg tumors in NE knockout mice demonstrated significantly reduced tumor
growth (Figure 43) and proliferation (Figure 44) compared to NE expressing controls.
No difference in the level of TAN (Figure 49 A, B), tumor-associated macrophages
(Figure S49 C, D), or inflammatory gene expression (Figure 47) was observed between
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C3(1)TAg-induced tumors in NE+/+ and NE-/- genotype mice. In this model system, NE
has a specific role in the proliferation of tumor cells, but does not appear to alter
inflammatory signaling or the recruitment of leukocytes. A study comparing NE
knockout and NE/PR3 dual knockout mice found that the ability of NE to cleave the antiinflammatory factor progranulin and enhance the inflammatory response could be
compensated for by PR3 (538). In humans, elafin inhibits both NE and PR3 (13),
therefore downregulation of elafin may more broadly sensitize tumors to changes in
inflammatory signaling.
The data presented here and elsewhere (508, 542) demonstrate a role of
deregulated NE activity in tumor growth and progression, suggesting that NE is an
important therapeutic target in cancer
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Chapter 5: General Discussion

Elafin is Downregulated During Breast Cancer Progression
Inducible and Systemic Protease Inhibitors
Elafin is an endogenous inhibitor of the serine proteases NE and PR3. Epithelial
cells are known to express high levels of elafin in response to pro-inflammatory
cytokines (i.e IL-1β and TNF-α) (13, 647). The p38 MAPK, c-JUN, and NF-κB pathways
are essential to inducible elafin expression (646, 648, 649). In contrast, systemic serine
protease inhibitors, such as α1-antitrypsin and α1-antichymotrypsin, are constitutively
expressed by the liver and diffuse into tissues from the circulatory system. Systemic
protease inhibitors provide essential baseline control of NE activity; however, they are
insufficient to control the high concentrations of neutrophil-secreted NE at sites of
inflammation. In this context, elafin is an essential barrier against the deleterious effects
of excessive NE activity and necessary for the normal resolution of inflammation (645,
646).
Elafin Expression in Human Tissue Under Normal and Disease Conditions
The normal epidermis does not express elafin (647), however inflammation
associated with the hyperproliferative disease psoriasis or experimental wounding was
found to enhance elafin expression (650-653). Elafin expression can be detected in
bronchial secretions and is hypothesized to be a biomarker of inflammatory lung
disease (788, 789). Elafin may also be a biomarker of autoimmune graft versus host
disease based on the expression of elafin in the skin rash characteristic of the disease
(790). In the endometrium, elafin is highly upregulated during menstruation, suggesting
that elafin has a role in physiological tissue remodeling (655). Constitutive elafin
expression has been observed at mucosal surfaces, including the tongue, tonsils,
gingiva, epiglottis, esophagus, vagina, and pharynx (647). In addition to its protease
inhibitory capacity, elafin also has anti-microbial and immune functions, which likely
underlies its constitutive expression at mucosal surfaces. Immunohistochemical
analysis of elafin expression was performed on several normal human tissues, in
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parallel with specimens of normal breast tissue, DCIS, and invasive breast presented in
figure 10. This analysis revealed that elafin was expressed by the normal endometrium,
kidney, spleen, colon, and mammary gland, but not the prostate (Figure 51).
Inadequate expression or absence of elafin has been observed in disease states
characterized by chronic or excessive inflammation, including acute respiratory distress
syndrome (14), inflammatory bowel disease (15), and acute lung injury (16). These
studies suggest that deregulated NE plays an important role in the pathogenesis of
inflammatory disease. NE has been shown to participate in tissue destruction and
fibrosis associated with several inflammatory diseases. In COPD and emphysema, NE
is viewed as a critical therapeutic target in preventing tissue destruction in inflammatory
lung diseases(791).
The tumor microenvironment is characterized by extensive recruitment of
inflammatory cells and altered production of inflammatory mediators. The inflammatory
components of the tumor microenvironment are indispensible to tumor progression(9).
Several studies suggest that loss of elafin-mediated control of NE-activity is a feature of
malignant growth. Elafin is downregulated in poorly differentiated squamous cell
carcinomas of the skin, head/neck, and esophagus compared to well-differentiated
tumors (21, 22). In the majority of melanoma and breast cancer cell lines elafin is
downregulated compared to normal HMECs and melanocytes (23, 26). These studies
served as the rationale to examine elafin expression in human tumors
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Figure 51: Immunohistochemical Analaysis of Elafin in Normal Human Tissues.

Elafin expression was evaluated by immunohistochemistry in the normal endometrium
(A), kidney (B), prostate (C), spleen (D), colon (E), and mammary gland (F).
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Immunohistochemical Analysis of Elafin Expression During Breast and Ovarian
Cancer Progression
As a first step in establishing a role for elafin in tumorigenesis,
immunohistochemical analysis of elafin was performed on normal breast tissue from
reduction mammoplasty, DCIS, and invasive breast carcinoma specimens (701). This
analysis revealed that elafin is highly expressed in the normal mammary epithelium, but
downregulated in the majority of invasive tumors and a subset of DCIS (Figure 10). To
determine if elafin downregulation is a generalizable event during tumorigenesis, elafin
immunohistochemical analysis was performed on normal fallopian tube, ovarian
cystadenomas, borderline tumors, and invasive ovarian carcinoma specimens (792).
The majority of ovarian cystadenomas and borderline tumors examined maintained
elafin expression at levels similar to the normal epithelium, however elafin expression
was downregulated in the majority of invasive ovarian tumors (Figure 12).
Elafin loss in the majority of invasive breast tumors compared to pre-invasive
tumors suggests that elafin is specifically switched off as tumors achieve a malignant
phenotype. This expression pattern suggests that elafin has tumor suppressive
properties early during breast cancer development. Maspin, a member of the serpin
family of serine protease inhibitors, was previously reported to have tumor suppressive
properties in breast cancer (741, 746, 747). Similar to elafin, maspin expression was
originally identified as highly expressed in HMECs, but downregulated in breast tumor
cell lines (740, 741). Immunohistochemical studies observed mapsin downregulation in
melanoma, breast, prostate, and gastric cancers (742-745). Continued research is
necessary to determine if elafin has a bona fide tumor suppressive role in breast
tumorigenesis similar to maspin.
Future Direction: Evaluating Elafin as a Prognostic Biomarker in DCIS
In this study elafin expression was not prognostic of survival in breast or ovarian
cancer patients (Figure 11 and 13). However, given the preponderant loss of elafin in
invasive compared to pre-invasive tumors, elafin downregulation may identify early
neoplasias likely to progress to invasive carcinoma. We were unable to evaluate the
prognostic significance of elafin in pre-invasive lesions using the patient cohorts
presented due to insufficient statistical power and inadequate follow-up. Elafin
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downregulation as a prognostic marker of progression in pre-invasive breast DCIS is a
particularly interesting hypothesis to be tested if an adequate patient cohort becomes
available.
Over the last several decades, increased mammographic screening has
contemporaneously led to an increased frequency of DCIS diagnosis. The risk of a
subsequent invasive tumor event, following diagnosis of DCIS, is not associated with
patient age, race, menopausal status, or a family history of breast cancer. Detection of
DCIS by palpation rather than mammography is associated with an increased risk of
developing invasive breast cancer. Large tumor size (greater than 10 mm), positive
margins, high/intermediate nuclear grade, and the extent or type (comedo) of necrosis
are also associated with an increased risk of developing invasive breast cancer. There
are currently no reliable molecular biomarkers capable of identifying women diagnosed
with DCIS at high risk of developing subsequent invasive carcinoma. Such a prognostic
marker could be utilized to better stratify DCIS patients into a cohort requiring extensive
therapy and a cohort better served by limited intervention (793).
Following lumpectomy alone approximately 8% of women diagnosed with DCIS
will develop ipsilateral invasive breast cancer within 5-years. The addition of radiation
therapy reduces the rate of a subsequent invasive event to approximately 3% (794).
The low rate of progression limits the ability to develop a sufficiently powered cohort of
DCIS patients for the identification of prognostic markers. Very few studies have
overcome this barrier to the study of prognostic markers in DCIS. A recently published
exception examined a cohort of 1162 women diagnosed (between 1983 and 1994) with
DCIS and treated by lumpectomy alone. Specimens from these patients were subjected
to immunohistochemical analysis for ER, PR, Ki67, p53, p16, HER2, and COX-2. This
study reveals differences in the prognostic factors that are associated with DCIS
recurrence and progression to invasive disease. High Ki67, p16, and COX-2 were
shown to be associated (independently and together) with increased risk of invasive
breast cancer (793).
Elafin may have prognostic significance in DCIS patients that could be evaluated
through by immunohistochemical evaluation of elafin downregulation in a large cohort of
DCIS patients with sufficient follow-up.
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Future Direction: Evaluating the Impact of Polymorphism in the PI3 (Elafin) and
ELA2 (NE) Genes on Breast Cancer Incidence
The majority of hereditary breast cancer risk is dependent on the combinatorial
effect of several moderate and low penetrance gene variants. Polymorphisms in the PI3
and ELA2 genes have never been examined in a cohort of breast cancer patients
versus controls. The hypothesis that an association exists between polymorphisms in
these genes and breast cancer incidence could be tested to evaluate an etiological role
for deregulated NE activity in breast cancer
Variants in the PI3 gene encoding elafin are associated with the incidence of
acute respiratory distress syndrome (ARDS), an disease of excessive lung
inflammation. Comparing 449 ARDS patients with 1031 controls a significant
association between ARDS and rs2664581 (resulting in an amino acid substitution,
elafin T34P). The rs2664581 polymorphism in PI3 was associated with a lower serum
concentration of elafin (666).
Polymorphisms in the promoter region of the ELA2 gene encoding NE are
associated with lung cancer incidence. Comparing 348 lung cancer patients and 299
controls identified an association between lung cancer and two polymorphisms in the
ELA2 promoter -903T/G and -741G/A. A genotype of -903TT was associated with a 2.3
fold greater risk of developing lung cancer, while the -741GG genotype was associated
with a 1.4 fold higher risk. Luciferase reporter analysis of both polymorphisms found
that they substantially increase ELA2 promoter activity (604). A subsequent study
confirmed this association and identified additional polymorphisms in the ELA2
promoter, including -832G/T and -789C/T, that are associated with lung cancer
development(795). Another study found no association between polymorphism in the
ELA2 gene/promoter and either lung cancer or COPD (796). Polymorphisms in the
ELA2 have also been identified as associated with coronary heart disease (797).
A Novel Role for Elafin in Growth Control by Opposing Deregulated NE-Activity
Conventionally Understood Role of Elafin in Inflammatory Disease
Mouse models of elafin overexpression are protected from tissue destruction
associated with experimental colitis (667), resistant to acute lung injury (20),
demonstrate reduced pulmonary hypertension following chronic hypoxia (19), and
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improved heart function after viral myocarditis (18) or myocardial infarction (17). The
protease inhibitory capacity of elafin is essential to its anti-inflammatory role in mouse
models of emphysema (636). Elafin also has anti-inflammatory properties independent
of its anti-protease activity. Elafin directly reduces NF-κB activation in monocytes
exposed to LPS through a protease-independent effect on the ubiquitination of NF-κB
pathway inhibitor IκB (673). Inducible elafin expression is critical to attenuation of
inflammation, prevention of tissue destruction, and preservation of organ function.
Inflammation in the Normal Mammary Gland and Tumorigenesis
Inflammatory signaling networks and cell types play essential roles in the
growth, development, and function of the mammary gland. The NF-κB pathway is
essential to lobuloaveolar proliferation and differentiation (232). Csf-1 knockout mice
are deficient in macrophages and demonstrate impaired branching morphogenesis
(217). Mmp-2 knockout mice are incapable of invasion at TEBs and Mmp-3 knockout
mice are deficient in lateral side branching (186). Cytokine signaling through Stat3
initiates involution of the mammary epithelium, a process characterized by the
infiltration of macrophages and neutrophils (244, 798).
Perturbations in inflammatory signaling and the integrity of ECM are involved in
mammary tumorigenesis (8). In mouse models, inflammatory cells are recruited to early
adenomas and non-invasive mammary intraductal neoplasia (799) and are detected
throughout tumor progression (800). The recruitment of leukocytes is essential to early
breast tumorigenesis, growth, and progression (344, 386, 398, 801). Sub-clinical,
chronic inflammation is a significant risk factor for the development of human breast
cancer (127, 128). Examination of normal breast tissue obtained from reduction
mammoplasty confirms that neutrophils (CD15+CD11b+CD49d-) are abundantly present
even in the absence of neoplasia (802). High levels of NE in breast tumors correlates
with poor patient outcome and resistance to therapy (12, 599-601). Studies examining
the presence of neutrophils within normal breast tissue and during breast cancer
progression are limited. However, the available evidence suggests that neutrophils
localize to the mammary gland and are present throughout breast tumorigenesis. The
role of neutrophils in the normal mammary gland and during breast tumorigenesis is
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poorly understood. A role for the NE activity has never been considered in breast
tumorigenesis.
A Role for Elafin in Growth Control
Immunohistochemical analysis revealed that elafin was highly expressed in the
normal mammary epithelium. Corroborating this result, HMECs were previously found
to express high levels of elafin in cell culture experiments (23). Elafin is downregulated
during breast tumorigenesis. To understand the role of elafin in the mammary
epithelium and the impetus for its downregulation during tumorigenesis we employed
HMECs as a model system.
Elafin is highly expressed by growth factor deprived G0 HMECs compared to
HMECs proliferating in growth factor containing media or arrested within the cell cycle
(Figure 14 and 15). This result suggests a previously unrecognized role for elafin in
growth control. Elimination of G1/G0 checkpoint control by downregulation of the Rb
tumor suppressor results eliminates the ability of HMECs to enter G0 and upregulate
elafin (Figure 18 and 20). C/EBP β sites (24) in the elafin promoter are also necessary
for expression of elafin in G0 HMECs (Figure 17). The integrity of the Rb and C/EBP β
pathways are likely essential to the constitutive expression of elafin in the normal breast
epithelium. Dominant negative C/EBP β is predominately expressed (as a ratio to fulllength, activating isoforms) in a large proportion of breast tumors (24). The Rb tumor
suppressor is inactivated by directly by mutation and allelic loss and indirectly by
alteration in proteins controlling Rb levels and activity(85).
Elafin knockdown HMECs fail to maintain G0-arrest during long-term growth
factor deprivation. The elafin protease inhibitory domain is essential to its anti-mitogenic
capacity (Figure 21). Elafin knockdown HMECs demonstrate increased sensitivity to the
growth promoting effect of exogenous NE (Figure 22). Several published studies have
demonstrated increased proliferation following addition of exogenous NE (542, 676,
736). In vivo the application of NE to the mouse epidermis results in proliferation,
whereas application of elafin can prevent epidermal proliferation (676). Mechanistically,
TLR4 dependent ERK activation is essential to the growth promoting effect of NE
(Figure 25). Overall, these results suggest that elafin is an essential component of
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epithelial growth control as a critical counterbalance against mitogenic effect of NE in
normal epithelial cells.
Future Direction: In Vivo Role of Protease Inhibitors in Breast Tumorigenesis
Mice do not have a direct elafin homolog. However, secretory leukocyte
peptidase inhibitor (Slpi) shares structural similarity with the elafin WAP domain and has
the capacity to inhibit NE. Unlike elafin, Slpi is incapable of inhibiting Pr3 and can inhibit
trypsin, chymotrypsin, and cathepsin G.
Experimental evidence from mouse models of inflammatory disease suggests
that Slpi is a critical counterbalance against deregulated NE activity. The colonic
epithelium of thymic stromal lymphopoetin (Tslp) knockout mice orally administered
dextran sodium sulfate (DSS) failed to upregulate Slpi, demonstrated high NE activity,
and were unable to recover from colitis compared to controls. Administration of
recombinant Slpi or the NE inhibitor sivelestat enhanced recovery from DSS-induced
colitis in Tslp knockout mice (803). Slpi knockout mice demonstrate impaired healing
following cutaneous wounding. Wounding healing in Slpi knockout mice was
characterized by increased inflammation, excessive production of Tgfβ, and high NE
activity (804). Progranulin (also known as proepithelin) is a critical growth and
regulatory factor in the wound healing response. NE cleaves progranulin into a form that
is detrimental to normal wound healing. Addition of full-length progranulin to the wounds
of Slpi knockout mice restores the wound healing response (539). Roles for Slpi in
inflammation and immunity have also been identified independent of its anti-protease
capacity (805, 806).
Studies investigating the role of SLPI in cancer have often arrived at seemingly
incompatible conclusions. SLPI has been shown to have tumor promoting (760-763)
and tumor suppressive effects (761, 764, 765) in xenograft mouse models. In these
experiments, SLPI was overexpressed in tumor-derived cell types prior to ortotopic or
sub-cutaneous injection. The pro-tumor effects of SLPI overexpression appear to be
independent of its anti-protease activity (760) and highly dependent on the tumor type
being examined (761). Anti-tumor effects were exclusively observed in mammary tumor
xenografts (761).
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A more complete understanding of Slpi-mediated protease inhibition could be
obtained by crossing the Slpi knockout mouse with transgenic breast tumor models.
This experiment would test the hypothesis that disequilibrium between NE and its
inhibitor Slpi promotes breast tumorigenesis and progression in vivo. The contribution of
inflammatory processes to breast tumorigenesis has previously been examined in the
MMTV-PyMT transgenic mouse model. MMTV-PyMT tumors demonstrate abundant
infiltration of neutrophils (presumably expressing NE). The progression of MMTV-PyMT
tumors has been carefully delineated making it possible to examine the effects of
changes in NE activity throughout tumor progression (800). MMTV-PyMT tumors are
also highly metastatic, making this transgenic model ideal for the study of deregulated
NE in metastatic breast cancer. In chapter 4, the C3(1)TAg model was utilized to
understand the role of NE in TNBC. In this model, NE knockout significantly reduced the
level of proliferation (Figure 44). Knockout of Slpi in these mice may enhance
proliferation in tumors and pre-invasive lesion. C3(1)TAg are not highly metastatic, a
major drawback to this model.
Future Direction: The Role of TLR4 in Breast Tumorigenesis
TLRs recognize molecules derived from invading microbes, termed pathogenassociated molecular patterns, and are essential to the innate immune response. TLR4
specifically recognizes lipopolysaccharide (LPS). Activation of TLR4 by LPS requires
several auxiliary proteins, including LBP and CD14, and the co-receptor MD-2.
Stimulation of TLR4 by LPS results in the intracellular recruitment of adaptor proteins
MyD88 and TRIF, which activates of the NF-κB, ERK, and JNK pathways leading to the
expression of pro-inflammatory cytokines and interferons (807). Treatment of murine
macrophages with NE resulted in the upregulation of cytokines Tnfa, Il1b, Cxcl1, and
Il6, while Tlr4 knockout macrophages are incapable of upregulating these cytokines
upon NE stimulation (597). In bronchial epithelial cells NE induced IL-8 expression
through TLR4 activation (590). Direct proteolysis of TLR4 by NE has been reported
(737). However, the NE cleavage sites on TLR4 have not been identified. Mapping the
cleavage of TLR4 by mass spectrometry or another biochemical technique is important
to the development of a complete understanding of NE-induced TLR4 activation. The
effect of NE-mediated cleavage on the recruitment of auxiliary proteins and the
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activation of downstream signaling must also be resolved by biochemical analysis. The
relevance of NE-mediated cleavage of TLR4 to human breast tumorigenesis is an
important question. Antibodies that identify cleaved and uncleaved TLR4 could facilitate
detection of truncated forms in tumors (737).
Tumor cells have been shown to express TLR4, however the expression of
TLR4 is highest in macrophages, dendritic cells, and other immune cell types within the
tumor microenvironment (808, 809). TLR4 activation can result in the activation of
iNOS, IL-6, uPA, IL-10, IL-8, TGFβ, and VEGF (809, 810), factors with known roles in
tumor growth and progression suggesting that TLR4 has pro-tumorigenic properties. In
chronic liver disease, intestinal bacterial infiltrate the liver and result in the activation of
TLR4. Activation of TLR4 in the liver is critical to the development and progression of
heptacellular carcinoma in mouse models (811). In experimental models of breast and
ovarian cancer, downregulation of TLR4 has been shown to reduce the growth and
progression of xenograft tumors (812, 813).
Microbial-derived TLR4 ligands are not found at many sites of tumor initiation,
including breast and ovarian cancer (808). Endogenous ligands of TLR4 are believed to
play an important role in the activation of TLR4 in these tumors. High-mobility group
box-1 (HMGB1) has been identified as an endogenous ligand of TLR4 (809). HMGB1 is
a nuclear protein that is secreted by necrotic cells (814, 815). NE may be an important
instigator of TLR4 activation during inflammatory conditions (590, 597).
TLR4 can also play a role in anti-tumor immunity. In breast cancer patients
treated with chemotherapy or radiotherapy, HMGB1 released by dying cells activates
TLR4 expressing dendritic cells resulting in an anti-tumor immune response. Patients
with a TLR4 loss of function allele relapse earlier following chemotherapy or
radiotherapy compared to patients with fully functional TLR4 indicating that initiation of
an innate immune response is an indispensible component of cancer therapy (816).
The available evidence suggests that TLR4 activation can dramatically enhance
pro-tumorigenic cytokine and growth factor signaling or initiate anti-tumor immunity
depending on context and the cell type affected. Mice bearing a point mutation to the
third exon of Tlr4 (resulting in a proline to histidine substitution at position 712) have
been developed. These mice demonstrated defective Tlr4 activation following LPS
stimulation and extreme susceptibility to bacterial sepsis (817). To test the hypothesis
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that epithelial Tlr4 promotes tumorigenesis, the mammary epithelium from mice
transgenic for MMTV-PyMT and mutant TLR4 can be transplanted into the cleared
mammary fat pad of wild type. To test the hypothesis that Tlr4 in the stromal
compartment accelerates tumorigenesis the MMTV-PyMT transgenic mammary gland
expressing wild type Tlr4 can be transplanted into the cleared mammary fat pad of Tlr4
mutant mice. Adoptive transfer of TLR4 mutant bone marrow into MMTV-PyMT
transgenic mice could be used to test the hypothesis that Tlr4 activation leukocytes
promotes tumorigenesis. Alternatively, to test the hypothesis that leukocyte Tlr4 is
essential to the anti-tumor response these mice could be treated by irradiation or
chemotherapy and evaluation of tumor regression.
Conditional TLR4 knockout mice have been recently developed (818) providing an
alternative model to specifically eliminate TLR4 expression from the mammary
epithelium and specific cell types within the bone marrow or stromal compartments.
Elafin has Tumor Suppressive Properties
Published studies have observed downregulation of elafin in breast tumor
derived cell lines compared to HMECs (23, 24). To test the hypothesis that elafin has
tumor suppressive properties, elafin was expressed in breast tumor-derived cell lines
using an adenoviral vector. Elafin expression caused cell cycle arrest in breast cancer
cell lines expressing the Rb tumor suppressor. However, in breast cancer cell lines
lacking Rb, elafin expression induces apoptotic cell death (Figure 31). Elafin expression
does not affect HMECs, which endogenously express elafin. However, HMECs with a
compromised Rb-dependent, G1-checkpoint fail to express endogenous elafin and are
sensitive to the adenoviral elafin-induced apoptotic cell death (Figure 30). Overall, the
expression of elafin causes cell cycle arrest or apoptosis in breast tumor derived cell
lines depending on Rb status, but does not affect normal HMECs with an intact G1
checkpoint Elafin represents a candidate therapeutic capable of specifically targeting
tumor cells with disruption of the G1 checkpoint with no toxicity in normally dividing
cells.
Since the publication of this work (678), intratumoral injection of adenoviral elafin
into MDA-MB-468 xenograft tumors was shown to reduce tumor burden and prolong the
survival of mice (25). Elafin re-expression using a tet-inducible system resulted in
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apoptotic cell death in melanoma cells, but not normal melanocyte. In melanoma
xenografts, expression of elafin significantly reduced tumor size (27).
Future Direction: Identification of the Mechanism by which Elafin Induces
Apoptotic Cell Death
The work presented here and elsewhere (25-27), reporting the ability of elafin to
induce apoptosis in breast and melanoma cell lines, does not address if the apoptotic
effect of elafin is protease dependent or independent. NE expression has previously
been characterized in tumor cell lines (25, 617, 735). In experimental models,
pharmacological NE inhibitors were able to attenuate the development of skin tumors,
reduce

growth

and

metastasis

in

a

lung

xenograft

model,

and

inhibit

proliferation/chemotaxis of pancreatic cells (603, 606, 607, 609). Knockdown of NE has
been shown to decrease migration and growth of breast tumor cell lines (25, 617). In
these experiments no effect was observed on cell survival, however MDA-MB-231 cells
were the predominately utilized model system. In Figure 34, MDA-MB-231 cells were
not sensitive to the apoptotic effect of elafin unless Rb was experimentally
downregulated. To address the hypothesis that the apoptotic effect of elafin on breast
cancer is protease dependent, previously reported mutations to the protease inhibitor
domain of elafin that inactivate its anti-protease activity should be utilized (636).
Inducible expression of these mutants elafin M25G and elafin M25K should be
evaluated by TUNEL and BrdU incorporation in the panel of cell lines that are sensitive
to elafin-induced growth arrest (MCF-7, ZR75-1, and T47D) and apoptosis (MDA-MB157, MDA-MB-436, and MDA-MB-468).
Future Direction: Therapeutic Reactivation of Elafin in Breast Tumors
In xenograft models, adenovirus was directly injected into tumors (25), while this
is an excellent proof of principle it is unlikely to be a viable clinical strategy given the
clinical restraints on gene therapy. However, a pharmacologically active compound
capable of inducing elafin re-expression in tumor cells could be a clinically translatable.
In melanoma cell lines, normally lacking elafin expression, treatment with a DNA
methyltransferase inhibitor induced the expression of elafin. The elafin promoter was
not directly methylated in melanoma cells. Demethylation of the FOXA2 promoter
resulted in restoration of FOXA2 levels and elafin transcripiton. In these experiments,
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elafin knockdown melanoma cells demonstrate reduced sensitivity to apoptotic cell
death induced by DNA methyltranferase inhibitor (26). This experiment suggest that
elafin reactivation by therapeutics may be an important determinate of cytotoxicity.
Oltipraz is a chemopreventative agent that has been shown to induce C/EBP β
DNA binding and activation of gene transcription both in vivo and in vitro (819-824).
Oltipraz has been used in clinical trials as both a chemopreventative agent (825) and in
the treatment of patients with liver fibrosis and cirrhosis (821), however the results of
these studies are inconclusive. C/EBP β is essential to the expression of elafin in
HMECs and deregulation of C/EBP β is responsible for elafin downregulation in breast
cancer cell lines (24). Therefore, oltipraz may be capable of enhancing the transcription
of elafin in breast tumor cells and may be a promising anti-cancer agent.
The ability of oltipraz to induce elafin expression should be examined,
particularly in Rb-negative breast cancer cell lines. To determine if oltipraz can induce
apoptotic cell death through elafin upregulation, Rb-negative breast cancer cell lines
expressing elafin shRNA can be treated with the oltipraz. If these experiments, prove
successful, pre-clinical models combining elafin-inducing oltipraz with traditional
chemotherapy or targeted therapies could be tested.
More specific elafin-inducing drugs could be identified using the previously
established elafin luciferase reporter system (24). This system consists of a fireflyluciferase promoter constructs containing the 440 bp proximal elafin promoter
(pSPL440) and the 440 bp proximal elafin promoter with mutations to C/EBPβ binding
sites 4 and 5 (pSPL440m4/5), which are critical to elafin transcription. Breast cancer cell
lines stably incorporating these plasmids could be used to screen for drugs that potently
induce elafin expression specifically through C/EBPβ. NF-κB-dependent (717)
expression of elafin has been described in response to pro-inflammatory cytokines,
especially IL-1β and TNF-α (646, 647). Avoiding drugs that induce elafin through this
pathway is important given the tumor promoting effect of NF-κB.
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Neutrophil Elastase Promotes Breast Cancer Growth In Vivo
Conventionally Understood Role of NE in Inflammation and Tumorigenesis
NE is normally sequestered within the azurophilic granules of neutrophils and is
essential to the intracellular destruction of pathogens following phagocytosis at sites of
infection (500). Activated neutrophils secrete NE into the extracellular environment.
Extracellular NE activity is associated with degradation of the ECM and disruption of cell
adhesion, which plays a role in tumor invasion and metastasis. NE has also been
implicated in the alteration of cytokine and chemokine signaling resulting in increased
infiltration and activation of pro-inflammatory cell types. The conventionally understood
role of NE in tumor progression emphasizes the importance of NE in cell invasion and
metastasis, through ECM degradation and the cleavage of adhesion molecules (610).
Role of NE in Intracellular Signaling
Several groups have demonstrated a role for NE in intracellular signaling. NE
activates cell surface receptors, including TLR4 (590), proteinase-activated receptor 2
(PAR2) (521), and epidermal growth factor receptor (EGFR) (681), either directly
through

proteolysis

of

the

extracellular

domain

or

indirectly

through

the

liberation/activation of latent ligands within the ECM (506). These pathways have never
been studied in tumorigenesis and are largely known from examining the role of NE in
inflammatory lung disease. Tumor cells demonstrate the capacity to endocytos NE from
the

extracellular

microenvironment.

Intracellular

NE

was

shown

to

enhance

phosphoinositide 3-kinase (PI3K) activity following the degradation of insulin receptor
substrate-1 (542). NE has also been implicated in cleavage of cyclin E into lowmolecular weight isoforms capable of hyperactivating cyclin-dependent kinase 2 and
inducing tumor formation in mouse models (541, 624).
Tumor Associated Neutrophils and NE in Tumorigenesis and Progression
Tumor-infiltrating neutrophils (TAN) are recruited by cancer cell-derived
chemokines (368) and are prognostic of poor patient outcome in several tumor types
(410, 826). Depletion of neutrophils or disruption of neutrophil chemotaxis inhibits tumor
growth, angiogenesis, and metastasis in mouse models of tumor progression (415-417).
NE knockout in the loxP-Stop-loxP K-rasG12D mouse model of lung cancer severely
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limits tumor growth and proliferation, providing direct in vivo evidence of a role for NE in
lung tumorigenesis (542). NE-mutant mice ware protected from skin carcinogenesis
following ultraviolet irradiation and benzopyrene exposure (609).
The evaluation of NE by immunohistochemistry reveals that high levels of NEexpressing, tumor-associated neutrophils were prognostic of poor recurrence-free
survival and correlate with intracellular signaling events. This observation is consistent
with several previous studies that measure NE in breast tumors by ELISA, which found
a strong correlation between high levels of NE and poor patient outcome (12, 599-601).
Reverse phase protein array (RPPA) analysis of critical signaling pathways
revealed a correlation between NE-expressing neutrophils and phosphorylation
p90RSK (ERK-dependent) and Rb. In chapter 2, TLR4 dependent ERK activation was
found to be essential to the growth promoting effect of NE. Previously published studies
have also observed that NE can induce ERK signaling. (681). An enrichment of ERKspecific phosphorylation of p90RSK in NE-positive tumors suggests that this
observation is an important downstream effector of TAN capable of inducing ERK
signaling and cell proliferation.
NE-positive TAN were associated with TNBC and high-grade tumors. High NE
expression (determined by ELISA) was previously shown to negatively correlate with
tumor ER and PR status (12). TNBC highly expresses chemokines critical to the
recruitment and activation of TAN, including IL-8 and IL-6 (773-776). Based on the high
concentration of NE-positive TAN in TNBC we chose to examine the role of NE in a
mouse model of TNBC. The C3(1)TAg mouse model has been shown to give rise to
TNBC tumors (778, 779, 782, 783). NE knockout does not slow the kinetics of tumor
progression in the C3(1)TAg model (Figure 43A), however NE knockout does reduce
tumor growth (Figure 38C) and proliferation (Figure 39 A, B).
By extending the role of NE beyond tumor cell invasion, our results argue that the
application of therapeutic modalities targeting NE activity could inhibit multiple elements
of tumor growth and progression. NE inhibitors are currently under development for the
treatment of chronic inflammatory lung diseases. This study positively contributes to the
rationale for examination of these inhibitors as anti-cancer agents. Many studies
suggest that the recruitment of non-malignant cell types is an essential component of
breast tumor progression. Targeting essential crosstalk between the tumor epithelial
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compartment and the stromal microenvironment is a promising approach to anti-cancer
therapy.
The NE inhibitor sivelestat, was able to reduce the proliferation, motility, and
chemotaxis of the pancreatic cancer cell line Capan-1 in vitro (603). In a mouse
xenograft model of non-small cell lung cancer using the EBC-1 and PC-1 cell lines,
sivelestat attenuates proliferation and metastasis (606). Sivelestat also inhibited
spontaneous metastasis of EBC-1 xenograft tumors (607). Beige mice are deficient in
NE (608). Pharmacological inhibitors of NE, 2,4,6-trinitrochlorobenzene and oxazolone
were able to attenuate the development of skin tumors following ultraviolet irradiation
(609).
Future Directions: Alternatives to the C3(1)TAg Model to Determine a Role for NE
in Metastatic Breast Cancer
C3(1)TAg tumors were poorly metastatic. The lungs of C3(1)TAg tumor bearing
mice were inflated with formalin, fixed, paraffin-embedded, and sectioned for
immunohistochemical analysis. Following staining with an antibody specific to SV40
large T-Antigen (data not shown) only 4 out of 49 mice had metastatic lesions (two were
of the NE+/+ genotype and two of the NE-/- genotype). Interestingly, the NE+/+ mice
with metastatic lung lesions had a greater number of foci and larger lesion size than
NE-/- mice, however no conclusions could can be drawn about the influence of NE on
metastasis in this model. The MMTV-Wnt1 mouse models and the BRCAfl/flp53+/- also
generate tumors with a TNBC phenotype, however they are also poorly metastatic (827,
828). To test a role for NE in metastatic breast cancer the NE knockout could be
examined in the MMTV-PyMT transgenic model, which is highly metastatic (404, 779).
Alternatively, in vivo passaging of the C3(1)TAg tumors could be performed to create
transplantable mouse tumors with increased metastatic proclivity and then injected into
the mammary fat pads of NE+/+ and NE-/-.
Future Directions: Development of Pre-Clinical Models of NE-Inhibition in Breast
Cancer.
AZD9668, a pharmacological NE inhibitor, was well tolerated by healthy
individuals and was found to possess favorable pharmacokinetics in phase I clinical
trials (829). In phase II clinical trials, AZD9668 did not alleviate the symptoms of COPD
patients (598, 830) and had limited benefit in patients with bronchiectasis and cystic
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fibrosis (831, 832). AZD9668 diminished levels of pro-inflammatory biomarkers in the
bloodstream and levels of NE specific elastin catabolites, desmosine and isodesmosine
in the urine (831, 832). Collectively, these studies suggest that AZD9668 is not an
effective therapy in inflammatory lung disease. However, these studies were relatively
short term (less than one month) and the results of future long term clinical trials should
be considered.
AZD9668 is capable of inhibiting NE-activity in human patients (831, 832) and
patient derived neutrophils (833). Oral administration of AZD9668 to rats or mice
prevented NE-induced lung injury and reduced inflammation following exposure to
cigarette smoke (833). AZD9668 may be an effective inhibitor of NE in tumor models.
NE knockout reduces tumor growth (Figure 38C) and proliferation (Figure
39A,B) in the C3(1)TAg of TNBC. The MMTV-PyMT breast tumor model has been
suggested throughout this discussion as a possible alternative to examine the role of
NE in metastatic breast cancer largely based on the abundant infiltration of neutrophils
in MMTV-PyMT (800). To testing the efficacy of AZD9668 in breast cancer, C3(1)TAg
and MMTV-PyMT transgenic mice could be orally administered AZD9668 following
tumor initiation at approximately 4 months, proliferation, absolute growth delay, and
metastasis as primary endpoints. As a preventative therapy AZD9668 could be
administered beginning at four weeks of age with tumor-free survival as the primary end
point.
Chemotherapeutic agents activate tumor fibroblast resulting the production of
inflammatory cytokines and chemokines resulting in a robust inflammatory resoponse
and the recruitment of neutrophils and macrophages (348, 834). TAN in the tumor
microenvironment likely contribute NE, which may have a role in chemoresistance and
recurrence based on the results presented within this dissertation. Therefore
combination of cytotoxic chemotherapy with AZD9668 may be an effective anti-tumor
strategy. This hypothesis could be tested in traditional cell line xenograft models of
breast cancer or in patient specimen derived explant models which are more
representative of human tumors. In these models, tumor regression, survival, and
recurrence could be examined following co-administration of AZD9668 and cytotoxic
chemotherapeutics, such as doxorubincin.
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Conclusions
The interdependency of tumor cells and the microenvironment in which they
evolve (7) provides a strong rationale for the therapeutic targeting of essential crosstalk.
The cellular constituents of the tumor microenvironment are not susceptible to the
selective pressures driving therapeutic resistance in tumor cells; therefore, therapeutic
modalities targeting critical microenvironmental factors may yield durable antitumor
responses.
The data presented here suggests that NE is an important downstream effector
of TAN capable of inducing ERK signaling and cell proliferation. The absence of elafin
in the majority of breast tumor enhances sensitivity to the mitogenic effects of NE. Elafin
has tumor suppressive properties in vitro. The absence of NE significantly decreased
tumor growth and proliferation in vivo. A therapeutic approach directed specifically at
controlling deregulated NE-activity may therefore be an effective therapy in breast
cancer. Effective inhibitors of NE have been developed for the treatment of
inflammatory lung disease (11).
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with his father, the son has always gone by his middle name, Tony, to avoid confusion
and having his name affixed with a detestable suffix “Joe Jr.” or even worst a prefix
“Little Joe.” Tony has a twin sister, Andria Marie Caruso, who is now a medical intern
specializing in ear, nose, and throat at the Walter Reed National Military Medical Center
in Bethesda Maryland. Clearly, higher education is a priority in the Caruso family. The
elder Joseph is a computer engineer at the Naval Surface Warfare Center Dahlgren
Division and Rosemary is a distinguished professor of biology and former Dean at the
University of Mary Washington. After graduating from Stafford Senior High School in
2003, Tony attended Villanova University to study Biology. He completed a senior
honors thesis under the mentorship of Dr. Louise Russo Ph.D. Tony graduated from
Villanova University in May of 2007 with a B.S. in Biology. Following graduation, Tony
enrolled in the University of Texas Graduate School of Biomedical Sciences to pursue a
Ph.D. under the mentorship of Dr. Khandan Keyomarsi Ph.D. On a personal note, Tony
is the proud owner of two beagles, Nelson and Gracie Caruso, who are loyal and
adorable. He is the president of the HTOWN men's lacrosse club, which competes
throughout Texas in the southwest lacrosse association (SWLA).
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